UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant      Filed by a Party other than the Registrant  

Check the appropriate box:

 

 

Preliminary Proxy Statement

 

☐ 

Confidential, For Use of the Commission Only (as permitted by Rule14a-6(e)(2))

 

 

Definitive Proxy Statement

 

☐ 

Definitive Additional Materials

 

☐ 

Soliciting Material Pursuant to§240.14a-12

PERRIGO COMPANY PLC

 

 

(Name of Registrant as Specified in Its Charter)

N/A

 

 

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

☒ 

No fee required.

 

☐ 

Fee computed on table below per Exchange Act Rules14a-6(i)(1) and0-11.

 

 (1) 

Title of each class of securities to which transaction applies:

 

  

 

 (2) 

Aggregate number of securities to which transaction applies:

 

  

 

 (3) 

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule0-11. (set forth the amount on which the filing fee is calculated and state how it was determined):

 

  

 

 (4) 

Proposed maximum aggregate value of transaction:

 

  

 

 (5) 

Total fee paid:

 

  

 

 

☐ 

Fee paid previously with preliminary materials.

 

☐ 

Check box if any part of the fee is offset as provided by Exchange Act Rule0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

 (1) 

Amount Previously Paid:

 

  

 

 (2) 

Form, Schedule or Registration Statement No.:

 

  

 

 (3) 

Filing Party:

 

  

 

 (4) 

Date Filed:

 

  

 


LOGOLOGO

NOTICE OF 20192021 ANNUAL GENERAL MEETING

Friday, April 26, 2019Virtual Meeting Only – No Physical Meeting Location

Wednesday, May 12, 2021

8:0030 a.m. (GMT)(EDT)

The 20192021 Annual General Meeting (the “AGM”) of Shareholders of Perrigo Company plc (“the Company” or “Perrigo”) will be held virtually on Friday, April 26, 2019Wednesday, May 12, 2021 at 8:0030 a.m. (GMT)(EDT) (1:30 p.m. (Irish Time)) via a live webcast. Please visit www.proxydocs.com/PRGO for more details.

Given the ongoing public-health crisis caused by the coronavirus (COVID-19) pandemic, related governmental and private sector actions, and the importance of safeguarding the health and well-being of our employees and shareholders; we will be conducting this year’s AGM in a virtual format only, via live webcast over the internet. We have designed the virtual AGM to provide the same rights and opportunities to participate as shareholders would have at The Westin Dublin, College Green, Westmoreland Street, Dublin 2, Ireland, The Guinea Room, to:an in-person meeting, including the right to vote and ask questions through the virtual meeting platform. You may virtually join the AGM and vote and submit your questions during the meeting by visiting www.proxydocs.com/PRGO and following the instructions.

Meeting Agenda:

 

 1.

Elect,To elect, by separate resolutions, teneleven director nominees to serve until the 20202022 Annual General Meeting of Shareholders;

 2.

Ratify,To ratify, in anon-binding advisory vote, the appointment of Ernst & Young LLP as the Company’s independent auditor, and authorize, in a binding vote, the Board of Directors, acting through the Audit Committee, to fix the remuneration of the auditor;

 3.

ProvideTo provide advisory approval of the Company’s executive compensation;

 4.

Renew and restate the Company’s Long-Term Incentive Plan;

5.

Approve the creation of distributable reserves by reducing some or all of the Company’s share premium;

6.

RenewTo renew the Board’s authority to issue shares under Irish law;

 7.5.

RenewTo renew the Board’s authority toopt-out of statutorypre-emption rights under Irish law; and

 8.6.

TransactTo transact any other business that may properly come before the meeting.

Proposals 1 – 4 and 6 are ordinary resolutions requiring the approval of a simple majority of the votes cast at the meeting. ProposalsProposal 5 and 7 areis a special resolutionsresolution requiring the approval of not less than 75% of the votes cast. All proposals are more fully described in this Proxy Statement.

In addition to the above proposals, the business of the AGM shall include the consideration of the Company’s Irish Statutory Financial Statements for the fiscal year ended December 31, 2018,2020, along with the related directors’ and auditor’s reports and a review of the Company’s affairs.

If you plan on attendingwish to join the meeting,virtual AGM, you may obtain admission tickets atmust be a shareholder as of the registration desk immediately record date, March 15, 2021. To participate in the AGM virtually via the Internet, please visit www.proxydocs.com/PRGO and register in advance prior to the deadline of May 10, 2021 at 5:00 p.m. (U. S. Eastern Time). Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you access to the virtual meeting and to submit questions during the virtual meeting. Shareholders whoseYou may vote and will be able to ask questions and hear responses to questions during the AGM by following the instructions available on the


meeting website during the meeting. If you hold your shares are registered in the name ofthrough a broker, bank or other nominee should bring proofin “street name” (instead of as a registered holder) and you wish to participate and vote during the AGM, you will receive instructions from your broker, bank or certificate of ownershipother nominee that you must follow to the meeting.

While all shareholders are invitedparticipate and for your shares to attend the meeting, onlybe voted. Only shareholders of record on February 26, 2019March 15, 2021 may vote on the matters to be acted upon at the meeting. Instructions on how to attend and participate online, including how to demonstrate proof of stock ownership are available at www.proxydocs.com/PRGO.

Your vote is important. Please consider the issues presented in this Proxy Statement and vote your shares as soon as possible. To do so, you should promptly sign, date and return the enclosed proxy card or proxy voting instruction form or vote by telephone or Internet following the instructions on the proxy card or instruction form.

A shareholder entitled to attend and vote at the virtual AGM is entitled, using the form provided (or the form in section 184 of the Irish Companies Act 2014), to appoint one or more proxies to attend, speakask questions and vote instead of him or her at the virtual AGM. A proxy need not be a shareholder of record.

By order of the Board of Directors

Todd W. Kingma

Executive Vice President, General Counsel

and Company Secretary

March 14, 2019[April    , 2021]


We are once again pleased to take advantage of the Securities and Exchange Commission rule allowing companies to furnish proxy materials to their shareholders over the Internet. Thise-proxy process expedites shareholders’ receipt of proxy materials while reducing the costs and the environmental impact of our annual meeting. On or about March 14, 2019,[April , 2021], we mailed to our beneficial owners and consenting shareholders of record a notice of internet availability of proxy materials containing instructions on how to access our proxy statement, and Annual Report and Irish Statutory Financial Statements and how to vote online. All other shareholders will receive a paper copy of the proxy statement, proxy card, and Annual Report and Irish Statutory Financial Statements by mail unless otherwise notified by us or our transfer agent. The notice of internet availability contains instructions on how you can (i) receive a paper copy of the proxy statement, proxy card, and Annual Report and Irish Statutory Financial Statements if you only received a notice by mail or (ii) elect to receive your proxy statement, and Annual Report and Irish Statutory Financial Statements over the Internet if you received them by mail this year.

This Proxy Statement, the Annual Report on Form10-K and Irish Statutory Financial Statements for the fiscal year ended December 31, 2018,2020, are available at http://www.viewproxy.com/perrigo/2019.www.proxydocs.com/PRGO.


Perrigo Company plc

Proxy Statement

Table of Contents

 

Page
Proxy Summaryii
Corporate Governance1
Environmental, Social & Governance5
Board of Directors and Committees12
Certain Relationships and Related-Party Transactions16
Director Compensation17
                Page

Proxy Summary

i

Corporate Governance

1

Board of Directors and Committees

5

Certain Relationships and Related-Party Transactions

9

Director Compensation

10

Ownership of Perrigo Ordinary Shares

   11

Section 16(a) Beneficial Ownership Reporting Compliance

19
   14

Executive CompensationDelinquent Section 16(a) Reports

   1421 

Executive Compensation22
Potential Payments Upon Termination or Change in Control

36

Remuneration Committee Report

   43 

Equity Compensation Plan Information

   44 

CEO Pay RatioRemuneration Committee Report

   4450 

Audit Committee Report

45

Proposals to be Voted on:

  
Equity Compensation Plan Information50
CEO Pay Ratio51
Audit Committee Report52
Proposals to be Voted on:

(1) Election of Directors

   4653 

(2) Ratification of the appointment of Ernst  & Young LLP as the independent auditor of the Company and the authorization to fix the remuneration of the auditor

   5261 

(3) Advisory vote on the Company’s executive compensation

   54

(4) Renew and restate the Company’s Long-Term Incentive Plan

62
   55

(5) Approve the creation of distributable reserves

    65

(6)(4) Renew the Board’s authority to issue shares under Irish law

63

(5) Renew the Board’s authority to opt-out of statutory pre-emption rights under Irish law

64
Presentation of Irish Statutory Financial Statements66
Annual Report on Form 10-K   67 

(7) Renew the Board’s authority toopt-out of statutorypre-emption rights under Irish lawQuestions and Answers and Voting Information

   68 

Presentation of Irish Statutory Financial StatementsExhibit A

   69

Annual Report on Form10-K

1
   70

Questions and Answers and Voting Information

    71

Exhibit A

  77

Annex A

  79

The proxy statement, form of proxy and voting instructions are being mailed to shareholders starting on or about March 14, 2019.[April , 2021].

 

i  2021 Proxy Statement


Proxy Summary

Proxy Summary

Here are highlights of important information you will find in this proxy statement. As this is only a summary, we encourage you to review the complete proxy statement before you vote.

Our Virtual Annual Meeting

Logistics

 

Date and Time

April 26, 2019 May 12, 2021
at 8:0030 a.m. (GMT)(EDT)

(1:30 p.m. (Irish Time))

  The Westin Dublin, College Green, Westmoreland Street, Dublin 2, Ireland, The Guinea Room

Virtual Meeting Site:

Please visit
www.proxydocs.com/PRGO
for more details

Record Date

February 26, 2019March 15, 2021

  

Shareholders on the close of business on the record date may vote on all matters.

Proposals

 

Resolutions Proposed for Shareholder Vote 

Board Vote


Recommendation

  

Page Reference
for

Additional
Details

1.  Election of directors

 FOR each nominee  4653

2.  Ratify, in anon-binding advisory vote, the appointment of Ernst  & Young LLP as the Company’s independent auditor, and authorize, in a binding vote, the Board of Directors, acting through the Audit Committee, to fix the remuneration of the auditor

FOR

61

3.  Advisory vote on executive compensation

 FOR  5262

3.  Advisory vote on executive compensation

FOR54

4.  Renew and restate the Company’s Long-Term Incentive Plan

FOR55

5.  Approve the creation of distributable reserves by reducing some or all of the Company’s share premium

FOR65

6.  Renew the Board’s authority to issue shares under Irish law

 FOR  6763

7.5.  Renew the Board’s authority toopt-out of statutorypre-emption rights under Irish law

 FOR  6864

Governance

 

·  Annual director elections

  Annual director elections

·  Separate independent Chair and CEO roles

9

·  10 of 1011 director nominees are independent

  

·  Annual Board and committee assessments

·All committee members are independent

  

·  Robust stock ownership guidelines

·Board of Directors is diverse in gender, ethnicity, experience and skills

  

·  

Regular Board refreshment
Majority voting for directors

·  No shareholder rights plan

·  Regular Board refreshment

  

·  Board level risk oversight

·Independent directors regularly meet in executive session

  

·  

Separate independent Chair and CEO roles
·Annual Board and committee assessments
·Robust stock ownership guidelines
·Majority voting for directors
·No shareholder rights plan
·Board level risk oversight
·Anti-hedging and anti-pledging policies

·  

Regular shareholder engagement

i


Board Refreshment

 

 ·  

Geoffrey M. Parker and Theodore R. Samuels wereErica L. Mann was appointed to the Board in 2016, with Mr. Samuels beginning his service on January 4, 2017.

·

Bradley A. Alford, Rolf A. Classon, Adriana Karaboutis, Jeffrey B. Kindler and Jeffrey C. Smith were appointed to the Board in 2017.

·

Erica Mann is being recommended for election at this year’s AGM, and after fifteen years of distinguished service, Laurie Brlas and Gary Cohen are coming off the Board.

·

Average tenure: approximately 1.8 years as of the date of the AGM.

Executive Transition/Succession Planning

The Board appointed Murray S. Kessler as President and Chief Executive Officer and a member of our Board in October 2018, following the resignation of Uwe Roehrhoff, who had served in those roles since January 2018, following the retirement of John T. Hendrickson.

2018 Performance Update1

·

Fiscal year 2018 was a year of transition as management and the Board of Directors took decisive action to improve our performance. Specifically, we:

Announced the appointment of Uwe Roehrhoff as President and CEO to evaluate the corporate portfolio;

Announced the appointment of Ronald L. Winowiecki as CFO, from acting CFO;

Announced the appointment of Rolf A. Classon as Chairman of the Board;

Announced that the Board of Directors unanimously approved the separation of the Rx business, pivoting Perrigo back to its consumer focus;

Expanded our growth strategy withRx-to-OTC switches through a licensing deal for the OTC version of Nasonex®;

Announced the appointment of Murray S. Kessler as President and CEO to design and implement the strategy to transform the Company to a consumer-focused strategy and the evolution from a healthcare company to a self-care company; Mr. Kessler has over 30 years of experience in growing consumer products companies and managing businesses in regulated environments; and

Enhanced leadership with the addition of innovation and business intelligence leaders.2019.

 

 ·  

Delivered net sales of $4.7 billion and adjusted operating profit of $0.9 billion.Katherine C. Doyle was appointed to the board in July 2020

 ·  

Increased investmentsOrlando D. Ashford was appointed to the board in research and development (“R&D”) to enhance our new product pipelineDecember 2020

·

Average tenure: approximately 3.36 years as well as in advertising and promotion to driveof the date of the AGM.

LOGOii


Proxy Summary

Executive Transition/Succession Planning

Richard Sorota was appointed Executive Vice President, President, Consumer Health Care Americas in March 2020, following the announced retirement of Jeffrey R. Needham.

2020 Performance Update1

In fiscal year 2020, management and the Board of Directors took decisive action and made significant progress in its three-year plan to transform Perrigo into a consumer Self-Care market leader. Some of our highlights include:

·

Delivered consolidated reported net sales which were up nearly 5% year-over-year; additional investments were made to address supply constraints.of $5.1 billion, reported operating income of $0.1 billion, and adjusted operating income of $0.8 billion.

·

Grew consolidated adjusted net sales by 5.0%2, net sales excluding divested businesses and currency by 6.4%3 and organic net sales by 1.9%4, despite the negative 1.4 percentage point impact from the extraordinary weak cough/cold/flu season.

 ·  

Consumer Healthcare International improved itsSelf-Care Americas adjusted operating marginnet sales grew 9.0% to an annuala record $2.7 billion; excluding the impact of 16% through new productscurrency and better selling, general & administrative (“SG&A”) efficiencies.divestitures, net sales grew 10.3%, with organic net sales growing 3.4%.

 ·  

Consumer Healthcare Americas deliveredSelf-Care International adjusted net sales growth of 1.4% year-over-year2 driven by new productsincreased 0.8% to $1.4 billion; excluding divested businesses and currency, net sales in the analgesics and dermatological categories.grew 3.6%.

 ·  

Prescription Pharmaceuticals reported net sales increased R&D investments by 18% as0.8%.

Advanced the consumer self-care growth strategy with the acquisitions of:

·

The assets of Steripod®, a leading toothbrush accessory brand and innovator in the team continued to identify attractive opportunities for new products.toothbrush protector market;

 

1 ·

See Exhibit A for reconciliationThe oral care assets of AdjustedHigh Ridge Brands, which strengthens Perrigo’s oral self-care leadership position as the #1 fastest growing value brand player in the children’s oral care category; and

(non-GAAP)· to Reported (GAAP)

Three Eastern European OTC skincare and hair loss treatment brands, expanding Consumer Self-Care International’s robust dermatology platform into growing geographies with market-leading, margin accretive brands.

·

Entered the cannabidiol (“CBD”) market through a strategic investment in and long-term supply agreement with Kazmira LLC, a leading supplier of hemp-based CBD products free of tetrahydrocannabinol (“THC”).

2 ·

OnReconfigured our portfolio by divesting the U.K.-based Rosemont Pharmaceuticals business, a constant currency basisgeneric prescription pharmaceuticals manufacturer focused on liquid medicines, for approximately $195 million; and excluding animal health.completed our portfolio reconfiguration after announcing on March 1, 2021 an

 

ii1 See Exhibit A for reconciliation of Adjusted (non-GAAP) to Reported (GAAP).

2 Adjusted net sales excludes the 2019 net sales from the divested animal health business when the business was classified as held-for-sale and reverses certain product returns relating to the voluntary global market withdrawal of ranitidine in the third quarter of 2019.

3 Net sales growth excluding currency and divested businesses excludes the 2019 net sales from the divested animal health business when the business was classified as held-for-sale, reverses certain product returns relating to the voluntary global market withdrawal of ranitidine in the third quarter of 2019, excludes 2019 net sales from the divested animal health business before the business was classified as held-for-sale, excludes 2019 net sales from the Rosemont Pharmaceuticals business, excludes 2019 net sales from the Canoderm prescription product, and are on a constant currency basis.

4 Organic net sales growth excludes net sales from the 2020 acquisition of the Oral Care Assets purchased from High Ridge Brands from CSCA and CSCI, excludes net sales from the 2020 Eastern European Brands acquisition from CSCI, and Ranir net sales through the second quarter of 2020 from CSCA and CSCI.

iii  2021 Proxy Statement


Proxy Summary

agreement to sell the Rx Pharmaceutical business for $1.5 billion in cash and more than $50 million in other considerations, establishing Perrigo as a pure-play global consumer self-care company positioned to significantly enhance shareholder value.

 ·  

Achieved 102% operating cash flow conversion to adjusted net income and cash from operations of $643 million.3more than $300 million in new product sales.

 ·  

Used balance sheet strength to repurchaseGrew our e-commerce sales by more than 100%.

·

Improved customer service levels while successfully managing through the COVID-19 pandemic without missing a single shift at any of our global facilities.

·

Invested in repeatable growth platforms through a centralized R&D team that added and replenished approximately 5.1 million shares and pay approximately $105$500 million in dividends.future new product pipeline potential.

·

Increased our dividend for the 18th consecutive year; issued $750 million in new debt at an attractive rate, repurchased $164 million of our stock, committed more than $300 million to capacity improvements and ended the year with $642 million of cash on the balance sheet.

·

ESG – strong progress in support of Perrigo’s commitment to environmental, social and governance matters, as described in detail on pages 5-11, including:

·

Adoption of the United Nations Sustainable Development Goals;

·

Quantifiable goals to reduce carbon emissions, reduce water usage, and increase recycle ready packaging; and

·

Strong focus and support of diversity and inclusion and human capital management.

Compensation

Executive Compensation Principles

 

 ·  

Perrigo’s executive compensation program is designed to attract, motivate and retain our executives,executive leadership team, including our named executive officers, who are criticalleading Perrigo’s transformation and are key contributors to our long-term success, andsuccess. We also aim to ensure that all employees’ pay is significantly performance-based.

·

Highlights:linked to performance (both on an individual and operational basis).

 

LOGO

What We Do  What We Do Not Do

LOGO   Place a significant emphasis on variable,at-risk, performance-based performance-based pay

 

LOGO   Permit hedging or pledging of
Perrigo stock

LOGO   Provide significant perquisites

LOGO   Reprice options

LOGO   Provide “single trigger” change in control cash severance benefits

LOGO   Directly align total rewardexecutive compensation with shareholder returns through long-term operational, financial, and share price performance

LOGO   Include clawback provisions in our incentive agreements

LOGO   Have rigorous stock ownership guidelines

 

LOGO   Use an independent compensation consultant

LOGO   Conduct independent annual risk assessments

 

LOGOiv


Proxy Summary

Program Design

 

 ·  

PrimaryThe primary elements includeof executive compensation consist of base salary, annual cash incentive and long-term equity incentive compensation.

 ·  

A substantial portionThe vast majority (greater than 70%75%, on average) of our executive compensation is performance-based andand/or at-risk.at-risk (i.e. not guaranteed).

 ·  

ProgramCompensation is weighted toward long-term equity awards rather than short-term cash compensation to furtherdirectly align the interests of executivesexecutive leadership and our shareholders.

 

LOGO

LOGO

3

Cash flow conversion to adjusted net income and cash from operations excludes a $50 million payment for Nasonex® OTC.

iii


20182020 Compensation

 

 ·  

For 2018,2020, base salaries for all named executive officers were increased at the same overall rates as our broader employee population – 3%, except for the first time since 2016, following a solid financial performanceMr. Sorota, whose increase reflected his promotion in 2017.March 2020.

 ·  

While the performance of the CompanyThe Annual Incentive Plan paid out above-target in 2018 was disappointing and not where we expected it to be,connection with delivering above-target results while making significant progress in ourpay-for-performance model reflected that reality – both our annual incentive bonus and long-term incentive payouts were below target and well below historic levels: three-year Self-Care transformation.

 

 · 

Consistent with ourpay-for-performance model, and aligned withThe three-year cumulative payout for the performance of the Company in 2018, the Corporate bonus formulaic payout2018-2020 ROTC-PSUs was at 64.7%92% of target.

 · 

Based on our 2018 ROTC of 33.7%, the 2018 tranche of ROTC performance-based equity compensation vested at 0% of target. The ROTC-PSUs are operating as intended and, aligned with the interests of shareholders, provided zero vesting credit for both 2016 and 2018. This resulted in a total three-year cumulative payout for the 2016-2018 ROTC PSUs at 58% of target shares, just above threshold.2018-2020 rTSR-PSUs was 0%.

 

 ·  

In 2018,2020, named executive officers were granted annual long-term incentive plan (“LTI”LTIP”) awards which were allocated 50% to PSUsAdj. OI-PSUs that may be earned based on achievement of return on tangible capitalAdjusted Operating Income (“ROTC”Adj. OI”) growth goals over three years (2020-2022), 20% to PSUsrTSR-PSUs that may be earned based on our relative rTSRtotal shareholder return (“rTSR”) performance versus peersthe relevant peer group over three years, and 30% to stock optionsRSUs vesting over three years.

·

Executive officers received aone-time special retention LTI awardyears—meaning 70% of our Executives’ Target Long-Term Incentive compensation is subject to performance hurdles in 2018 upon the transition of Murray S. Kessler as CEO.order to vest.

Questions and Answers, Voting and VotingVirtual Meeting Access Information

Please see the Questions and Answers and Voting Information section beginning on page 7168 for important information about voting, the proxy materials, and deadlines for submitting shareholder proposals and director nominees for the 20202022 Annual General Meeting of Shareholders. Additional questions may be directed to Perrigo Company plc, Attn: General Counsel, Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland or GeneralMeeting@perrigo.com.

 

ivv  2021 Proxy Statement


    Corporate Governance

Corporate Governance

General

We manage our business under the direction of our Board of Directors. The Chief Executive Officer (“CEO”) is a member of, and reports directly to, our Board, and members of our executive management team regularly advise our Board on those business segments for which each executive has management responsibility. Our Board is kept informed through discussions with our CEO and other officers, by reviewing materials provided to them, by visiting our offices and by participating in Board and committee meetings.

Corporate Governance Guidelines

The Board of Directors has adopted Corporate Governance Guidelines that are available on our website (http://www.perrigo.com) under the heading Investors – Corporate Governance – Governance Guidelines. The Board may amend these guidelines from time to time. We will mail a copy of these guidelines to any shareholder upon written request to our Company Secretary, Todd W. Kingma, at Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland or by email at GeneralMeeting@perrigo.com. As part of our ongoing commitment to corporate governance, we periodically review our corporate governance policies and practices for compliance with the provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations of both the U.S. Securities and Exchange Commission (“SEC”) and the NYSE.New York Stock Exchange (“NYSE”).

Code of Conduct

Our Code of Conduct acknowledges that a reputation for ethical, moral and legal business conduct is one of Perrigo’s most valuable assets. In addition to acknowledging special ethical and legal obligations for financial reporting, the Code requires that our employees, officers and directors comply with laws and other legal requirements, adhere to our policies and procedures, avoid conflicts of interest, protect corporate opportunities and confidential information, conduct business in an honest and ethical manner and otherwise act with integrity and in Perrigo’s best interest. Our Code of Conduct is available on our website (http://www.perrigo.com) under the heading Investors – Corporate Governance – Code of Conduct, and we will promptly post any amendments to or waivers of the Code on our website. We will mail a copy of our Code of Conduct to any shareholder upon request to our Company Secretary, Todd W. Kingma, at Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland, or at GeneralMeeting@perrigo.com.

Director Independence

Our Corporate Governance Guidelines provide that a substantial majority of our directors should meet NYSE independence requirements. A director will not be considered independent unless the Board of Directors determines that the director meets the NYSE independence requirements and has no relationship that, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Based on its most recent annual review of director independence, the Board of Directors has determined that ten of our current elevendirectorselevendirectors are independent, including Bradley A. Alford, Laurie Brlas,Orlando D. Ashford, Rolf A. Classon, Gary M. Cohen,Katherine C. Doyle, Adriana Karaboutis, Jeffrey B. Kindler, Erica L. Mann, Donal O’Connor, Geoffrey M. Parker, and Theodore R. Samuels and Jeffrey C. Smith. The Board has also determined that director nominee Erica L. Mann is independent.Samuels. Murray S. Kessler is not independent under these standards because he is currently serving as an officer of Perrigo.

1  2021 Proxy Statement


Corporate Governance

In making its independence determination, the Board of Directors has broadly considered all relevant facts and circumstances and concluded that there are no material relationships that would impair these directors’ independence.

Board Oversight of Risk

While management is responsible forday-to-day risk management, the Board of Directors is responsible for the overall risk oversight, and the Audit Committee is responsible for the overall framework for the risk assessment and enterprise risk management (“ERM”) process for the Company. The Board’s committees take the lead in discrete areas of risk oversight when appropriate. For example, the Audit Committee is primarily responsible for risk oversight relating to financial statements,statements; the Remuneration Committee is primarily responsible for risk oversight relating to executive compensation and the Company’s compensation policies and practices, along with corporate culture and diversity,diversity; and the Nominating & Governance Committee is primarily responsible for risk oversight relating to corporate governance and cybersecurity, along with sustainability and environmental matters. These committees report to the Board of Directors on risk management matters.

Management periodically presents to the Board of Directors its view of the major risks facing the Company, which may include a dedicated “enterprise risk management” presentation. Matters such as risk appetite and management of risk are also discussed at this meeting. In addition, risk is regularly addressed in a wide range of Board discussions, including those related to segment or business unit activities, specific corporate functions (such as treasury, intellectual property, capital allocation and taxation matters), acquisitions, divestitures and consideration of other extraordinary transactions. As part of these discussions, our directors ask questions, offer insights and challenge management to continually improve its risk assessment and management. The Board has full access to management as well as the ability to engage advisors to assist the Board in its risk oversight role.

The following chart provides a summary overview of key areas of risk oversight for the Board and management.

 

Board of Directors

Oversees Major Risks

 

 

Strategic and Competitive – Financial – Brand and Reputational – Legal and Regulatory

Operational – Cybersecurity – CEOOrganizational Succession Planning

 

LOGOLOGO

 

LOGO2


Corporate Governance

 

Management

 

Key Risk Responsibilities

 

·   Business units identify and manage business risks

 

·   Central functions design risk framework, including setting boundaries and monitoring risk appetite

 

·   Internal audit provides independent assurance on design and effectiveness of internal controls and governance practices

 

 

Board Leadership

Our governance documents provide the Board with flexibility to select the appropriate leadership structure for the Company. In making leadership structure determinations, the Board considers many factors, including the specific needs of the business and what is in the best interests of the Company’s shareholders.

Our current leadership structure consists of a separate Chairman of the Board and Chief Executive Officer, and strong, active independent directors. The Board believes that the Company and its shareholders are well-served by this leadership structure at this time. In addition, having three independent Board Committees chaired by independent directors provides a formal structure for strong, independent oversight of the President and Chief Executive Officer and the rest of the Company’s management team.

Chairman of the Board

In May 2018,We have had a separate, independent Chairman of the Board since 2016. The Board has appointed Rolf A. Classon as Chairman of the Board. Previously, between August 2003 and April 2016, the Board of Directors appointed an independent director to serve as lead independent director. In April 2016, the Board decided to separate the roles of the Chairman of the Board and Chief Executive Officer and appointed Laurie Brlas as Chairman of the Board, which eliminated the need for a lead independent director. Ms. Brlas served as Chairman of the Board until Maysince 2018.

The role of the Chairman includes:

 

 ·  

presiding at all Board meetings, including executive sessions of the independent directors;

 ·  

serving as a liaison between the CEO and the independent directors, including being responsible for communicating with the CEO regarding CEO performance evaluations and providing feedback from the independent director sessions;

 ·  

having the authority to call meetings of the independent directors; and

 ·  

approving Board meeting agendas and schedules to assure there is sufficient time for discussion of all agenda items.

The Chairman is selected from those Perrigo directors who are independent and who have not been a former executive officer of Perrigo. The Chairman position is for an initial term of three years,subject to annual reviews by our Nominating & Governance Committee, annualre-election of that director at the intervening AGMs, and an annual appointment by the independent directors.

Shareholder Engagement

We believe that ongoing, transparent communication with our shareholders is critical to our long-term success. We have a robust shareholder engagement program, and we regularly communicate with our shareholders through a number of forums, including quarterly earnings presentations, investor conferences, securities filings, phone calls, correspondence, plant tours and individual meetings. During 2018, we engaged in2020, most of our

3  2021 Proxy Statement


Corporate Governance

shareholder communications were done virtually due to COVID-19 travel restrictions. We were able to conduct meaningful dialogue with many of our top shareholders, as well as numerous other current and prospective shareholders, on topics such as our business performance and overall corporate strategy, capital allocation, industry and market trends, corporate governance, M&A strategy and executive compensation. Our shareholders have provided us with valuable feedback and external viewpoints that inform the way we think about our business and strategy, and we are committed to a continuing dialogue.

Anti-Hedging and Anti-Pledging Policies

Our insider trading policy prohibits executive officers and directors of the Company from trading in options, warrants, puts and calls or similar instruments on Company securities and holding Company securities in margin accounts, as well as from pledging Company securities as collateral for a loan. In addition, the policy prohibits Company directors and all employees, including executive officers, from selling Company securities “short”, engaging in “short sales against the box”, and entering into hedging or monetization transactions or similar arrangements with respect to Company securities.

Corporate Social ResponsibilityPolitical and Lobbying Activities and Expenditures

WeGiven the nature and extent of political and lobbying activities by many companies, shareholders are committedoften concerned about how boards oversee these types of activities and expenditures and desire disclosure of related policies and procedures to doing business inthe extent the disclosure does not place the company at a responsible and ethical manner. We have a long history of environmentally sound and efficient operations, safe and healthy working conditions, active

engagement in the communities wherecompetitive disadvantage. In this regard, we are located and strong corporate governance. As reflected in our Corporate Social Responsibility (CSR) Commitment Statement, we remain committed to:note that:

 

 ·  

Making lives better by bringing quality, affordable self-care products that consumers trust everywhere they are sold;Perrigo does not regularly engage in political or lobbying activity and, historically, it has had limited, if any, expenditures associated with such activities.

 ·  

Strong corporate governance;As an Irish domiciled company, we are required to report any lobbying activity in Ireland, and we have not had to report any such activity in the last several years.

 ·  

Complying with regulatory and legal requirements;Our Code of Conduct, which is available on our website, states that Perrigo does not make political contributions.

However, in February 2020 our Nominating & Governance Committee and Board reviewed our governance policies and disclosures related to political and lobbying activities and adopted a written policy regarding political lobbying activities and expenditures that can be accessed on our website at:

https://investor.perrigo.com/corporate-governance.

LOGO4


Environmental, Social & Governance (ESG)

Environmental, Social & Governance (ESG)

Perrigo is committed to doing business in a socially, environmentally and fiscally responsible manner and being transparent with its reporting. That commitment is reflected in our well-established governance (as described above), corporate responsibility and sustainability programs as well as by our board oversight of governance and sustainability. We have self-reported on our ESG impact, goals, and progress in our Corporate Social Responsibility Report since 2013, which is published annually mid-year and can be found under “Corporate Social Responsibility” (CSR) on perrigo.com. Much of the below information can be found in the most recent report, which will be refreshed upon the next publication later this year.

Our Framework: The United Nations Sustainable Development Goals (SDG)

In 2020, Perrigo proudly adopted the United Nations SDGs as a global framework and committed to several specific targets within this framework for our ESG strategy, which are discussed here. More specifically, we committed to targets within Goals 12 and 13 related to the environment, targets within Goals 3 and 4 for education and wellness social impact, and targets within Goals 5 and 10 for diversity and inclusion initiatives. These initiatives are overseen primarily by the Nominating & Governance Committee, which is responsible for risk oversight relating to corporate governance, cybersecurity, sustainability and environmental matters.

While we adopted the UN SDG, we seek to accommodate aspects of other ESG reporting frameworks, including the Sustainability Accounting Standards Board (SASB), the Task Force on Climate-Related

Disclosures (TFCD), and the Carbon Disclosure Project (CDP) standards. We will continue to enhance our reporting consistent with these frameworks.

SUSTAINABILITY AND CLIMATE CHANGE

SDG targets 12.2, 12.5, 12.6

and

SDG targets 13.2 and 13.3

LOGOLOGO

Perrigo’s commitment to the environment is supported by our global drive to enhance the sustainability of our operations, packaging, and supply chain as highlighted below. We formalized that commitment in 2015 by establishing a corporate sustainability strategy focused on reducing the environmental impact in these areas through 2020. Our performance through 2019 is summarized below. We will provide updated information on 2020 and the next iteration of our sustainable operations strategy and goals later this year in our 2021 CSR report.

5  2021 Proxy Statement


Environmental, Social & Governance (ESG)

OPERATIONS
Focus AreaHighlights
Reduce Greenhouse Gas
Emissions by 15% from 2015
by 2020
· Trending at a 22% reduction against 2015 baseline
· 2019 emissions reduced by 0.5% over 2018, reducing 646
metric tons of CO2-e
· Continued implementing our strategy of increasing energy
efficiency, reducing usage, leveraging cleaner sources

Reduce Water Usage by 15%
from 2015 by 2020

· Trending at an 8% reduction against 2015 baseline

· 2019 usage reduced by 12% over 2018

·Facility Highlight: Our Vermont facility implemented projects to regulate and reduce water flow rates and to replace solenoids for water cooling, resulting in a 12% reduction in usage despite a 3% increase in production volume

· Facility expansions and production increases have challenged our ability to achieve the 15% goal, but we remain committed to reducing overall consumption

PACKAGING
Focus AreaHighlights
Increase Recycle-Ready
Packaging
(CSCA 100%, CSCI 80% by
2025)
· As of 2020, approximately 69% of CSCA primary packaging was
recycle-ready by weight
· As of 2020, approximately 66% of CSCI packaging was recycle-
ready
· Several initiatives are underway to improve recyclability, including
the elimination of PVC plastic, label material changes and
partnership with the How2Recycle initiative

Increase use of Post-
Consumer Recycled content
(PCR) in Packaging
(CSCA 20%, CSCI 30% by
2025)
· As of 2020, corrugated shippers for CSCA contain 50% to 100%
PCR paper
· Regulations relating to drug packaging in the US and Europe
present sizeable challenges for PCR use in primary product
packaging, but we continue to work with industry groups and
regulators to promote use of PCR materials
· Several innovative sustainability projects underway to add PCR
content in packaging
SUPPLY CHAIN
Focus AreaHighlights
Sustainable Palm Oil· Perrigo is a member of the Roundtable for Sustainable Palm Oil
(RSPO) and is committed to sourcing RSPO-certified palm oil
and purchasing RSPO credits
· Three manufacturing sites are physically certified to RSPO
standards, including our only two factories handling palm oil directly
· In 2019 we used over 1,200 metric tons of certified mass
balance palm oil and applied over 650 RSPO credits to offset a
wide range of derivative usage in the US, UK, and the Nordics

Sustainable Sourcing· Nearly 100% of the paper and cartons in our U.S. business are
certified by the Sustainable Forestry Initiative or a similar
organization

LOGO6


Environmental, Social & Governance (ESG)

Perrigo’s vision is to “make lives better, by bringing quality affordable self-care products that consumers trust, everywhere they are sold”. We are proud to save consumers billions of dollars a year on healthcare costs by providing high quality, affordable brands and brand alternatives. But our commitment to making lives better does not end there. We are also dedicated to promoting well-being initiatives for our employees, education and community engagement and giving, diversity and inclusion, and ethical supply chains.

GOOD HEALTH AND WELLBEING

SDG targets 3.2, 3.4, and 3.5

LOGO

Promoting good health and well-being is what we do. Perrigo develops thousands of affordable products that enhance health and well-being, such as nutritional products, diabetes care, and nicotine replacement (supporting SDG goals 3.2, 3.4, and 3.5). However, we go beyond the inherent social benefits of our business model.

The Perrigo Company Charitable Foundation: Established in 2000, the Perrigo Company Charitable Foundation is a private, nonprofit organization wholly funded by Perrigo Company plc. As the philanthropic arm of the company, the Perrigo Foundation supports initiatives that promote investments in healthcare, education, and support services in communities where Perrigo operates. It also makes annual “signature gift” donations, as well as donation matching, scholarship programs, disaster relief, and charitable donations to incent associates to volunteer their own time.

The Perrigo Foundation donated a record $3.25 million in cash across the globe during 2020, with an additional $2.2 million worth of products donated to support COVID relief and other critical needs.

Visit the Corporate Responsibility page on www.perrigo.com to learn more.

Employee Wellness: Launched in 2016, Perrigo’s HEALTHYyou well-being program supports team members and their families in their holistic wellbeing. In addition to offering online tools, healthcare discounts, and a number of other benefits, Perrigo maintains both an onsite fitness and medical center at our largest campus in Allegan, Michigan, while offering fitness center reimbursements for employees not in Allegan.

COVID Response: At the onset of the pandemic, Perrigo shifted the manufacturing priority away from higher profit products to focus on those items that society needed. At the news of a mass shortage of hand sanitizer, we quickly developed and produced a formula in our New York facility, donating hundreds of thousands of units of hand sanitizer, together with nutritional drinks, toothbrushes, thermometers, medical kits, in multiple countries around the world. In addition to the more than $1 million in product donated in April 2020, the Perrigo Foundation donated over $600,000 in cash to support blood drives and local food charities.

QUALITY EDUCATION

SDG targets 4.1 – 4.7

LOGO

7  2021 Proxy Statement


Environmental, Social & Governance (ESG)

Due to the heavy reliance on Science, Technology, Engineering, and Math within our industry

and company, SDG Goal 4 is a passion for our employees and the other key focus for giving by the Perrigo Foundation. Last year, we donated over $765,000 in support of promoting quality education, supporting targets 4.1- 4.7.

Perrigo maintains programs such as Caring 4 Communities, which donated more than $16,000 in 2019 to nonprofits based on time volunteered at that nonprofit by our associates. Perrigo partners with a number of local schools and nonprofits to support other unique and impactful programs, such as the “Bigs in Business” mentor program, Society of Women’s Engineers, and MiCareerQuest.

LOGO

Goal 5: Gender Equality

Goal 10: Reduced Inequalities

Diversity and Inclusion (D&I): Perrigo’s inclusive culture values the unique diversity of our workforce, the consumers we serve, and our surrounding communities. We are committed to helping end inequity and promote acceptance and belonging across the globe. Our commitment to self-care, relentless obsession with our people and consumers, strong moral compass, and evolving social issues serve as our D&I guide.

Our three-year strategy focuses on driving maturity in three key areas:

 ·  

Demonstrating environmental stewardship;Educating our workforce on our D&I strategy and initiatives

 ·  

Continuously improving packaging sustainability;Strengthening our talent management practices through a lens of inclusion

 ·  

Protecting human rights ofCreating our global employeesgovernance and challengingkey metrics to establish our partners to do the same;foundation and monitor progress

We have set several D&I goals for 2021, including:

 ·  

Diversity of thought, experienceTaking action to reduce inequalities and perspective;promote inclusivity through Global D&I campaigns

 ·  

Providing a safeEducating our workforce on preventing illegal harassment / discrimination and healthy work environment for our employees; andUnconscious Bias

 ·  

Establishing effective community partnerships.Publishing our first stand-alone Inclusion report

Through these efforts, we strive

·

Increasing our People of Color representation in alignment with U.S. Affirmative Action goals

·

Implementing employee resource groups

·

Continued roundtable discussions on D&I to hear the voice of our associates

LOGO8


Environmental, Social & Governance (ESG)

Global Diversity Statistics

LOGO

Global D&I Campaigns: We highlight key D&I topics throughout the year to minimizeeducate, engage and inspire our impactassociates. Our recent topics include:


Promoting
Racial Equity

Lead by our President and CEO, Perrigo is committed to help end racial inequity. We promote education and recognizing, respecting, and leveraging our differences as a strength.
PridePerrigo hosted our first global Pride campaign updating our corporate logos and engaging the heart and head of our associates through powerful, personal storytelling.
Diverse AbilitiesPerrigo has partnered with the Valuable 500; 500 global organizations committed to disability inclusion. With heightened pandemic stress, Perrigo has prioritized invisible disabilities.

Mental Health
Advocates

Self-care starts with our own team. Perrigo takes a six-pronged approach to promote wellbeing focusing on physical, emotional, financial, work-life, community, and education.
WomenFrom global International Women’s Day events, to extensive on-demand learning, Perrigo is committed to promoting gender equality.
MenWe embrace the unique diversity Perrigo men bring to our workforce. Our Movember campaign raises awareness with respect to men’s health and suicide awareness.

D&I and COVID: Perrigo educated our workforce on avoiding any social stigma associated with COVID-19 and leaders were informed about how COVID-19 is disproportionately impacting people of color. Leaders and Human Resources partnered with each individual essential worker, as needed, to discuss healthcare, childcare, mental well-being and more. All associates that could work at home, were set up with the environment, drive responsible business practices,resources and ensuresupport needed for success. Leaders met regularly to discuss the welfareunique needs of our employeesdiverse workforce, as we navigate a global health pandemic.

Together, we make lives better!

Visit the Diversity and Inclusion page on www.perrigo.com to learn more.

9  2021 Proxy Statement


Environmental, Social & Governance (ESG)

Human Rights and Supply Chain Ethics:

Perrigo’s Human Rights policy and commitments take a zero-tolerance stance on modern slavery, human trafficking, and all other forms of human rights abuse. Our Ethical and Social Compliance Program monitors our suppliers around the communitiesglobe and is designed to ensure they are operating in whichaccordance with our ethical expectations. In 2019, we operate. To viewconducted more than 85 third-party ethical and social compliance audits in our annual progress on these commitments, orsupply chain, an increase from 15 the year before. We also added 18 additional sites and suppliers into the Sedex platform, the world’s largest collaborative platform for companies to share responsible sourcing data and progress.

For more information regardingon our CSR program please visitapproach to Human Rights, see our website and/or download our annual CSR reportmodern slavery statement at https://www.perrigo.com/believe/responsibility.aspx.modernslaverystatement.

Human Capital Management

We are passionate about making lives better. At Perrigo, we believe that the continuous personal and professional development of our people is an important component of our ability to attract, retain, and motivate top talent, which are all important aspects of our self-care strategy. Our global workforce consists of more than 11,500 full time and part time employees spread across 34 countries, of which approximately 17% were covered by collective bargaining agreements as of December 31, 2020. We continuously endeavor to provide a diverse, inclusive, and safe work environment so our colleagues can bring their best to work, every day. We are all responsible for upholding Perrigo’s Core Values – Integrity, Respect, and Responsibility – in addition to the Perrigo Code of Conduct which, together, form the foundation of all our policies, procedures, and practices. Together, we drive Perrigo forward to deliver on our vision to make lives better by bringing Quality, Affordable Self-Care Products that consumers trust everywhere they are sold.

Compensation, Benefits, Health, Safety, and Well-being

Perrigo’s commitment to self-care starts with our own team. Our top priority during the global COVID-19 pandemic has been, and continues to be, the safety of our colleagues. When faced with the challenges of this pandemic, we focused on understanding and supporting each diverse individual and the unique circumstances impacting their ability to serve as an essential worker. We have implemented safety measures to protect our on-site essential colleagues, while asking those who can safely work from home to do so. On-site, we’ve implemented a multi-step pre-screening process before entry into any facility, deep-cleaning protocols, and other safety precautions, all consistent with the rules and guidelines in each jurisdiction. As a thank you for their bravery and commitment, management issued a special cash bonus for our colleagues who worked on-site to keep our products flowing to consumers.

We strive to provide pay, benefits and services that support the total well-being of our people, which is an exceptionally important topic within Perrigo. Our total rewards package delivers competitive pay, broad-based stock grants, cash-based annual incentives, healthcare, retirement benefits, paid time off, and on-site services, amongst other benefits.    

Perrigo’s total rewards complement a strong health and safety culture that continues with our global well-being program designed to inspire colleagues to maintain and improve their health. Launched in 2016, Perrigo’s “HEALTHYyou” well-being program continues to support colleagues and their families as they

LOGO10


Environmental, Social & Governance (ESG)

navigate their own self-care and well-being journeys. Our colleagues highly value this program and it continues to be recognized externally by receiving the Best and Brightest in Wellness Award since 2017.

Growth, Development, and Engagement

We are committed to engaging our colleagues and to fostering a belonging culture, where our people feel enabled to contribute their best to Perrigo’s self-care transformation. This includes initiatives supporting overall job satisfaction, diversity and inclusion, personal and professional skill development, work/life balance, and an environment that encourages good health and safety, while upholding our core values of Integrity, Respect, and Responsibility.

Perrigo regularly conducts global engagement surveys to gather feedback from colleagues to identify strengths and opportunities within our culture. Additionally, we use a variety of channels to facilitate open and direct communication, including regular open forums and town hall meetings with our executive leadership team.    

Our development philosophy focuses on a 70-20-10 approach, which provides a practical, blended framework for learning to support individual long-term success (where individuals obtain 70% of their knowledge from job-related experiences, 20% from interactions with others, and 10% from formal educational events). We believe this model enables our people to deliver on our self-care vision by empowering them to be their best and make a difference to Perrigo Colleagues, Customers, Consumers, Communities, and Shareholders.

11  2021 Proxy Statement


Board of Directors and Committees

Board of Directors and Committees

Perrigo’s Board of Directors met 159 times during 2018.The2020. The Board of Directors has standing Audit, Remuneration and Nominating & Governance Committees, and there were a total of 3022 committee meetings during 2018.2020. Each director attended at least 75% of the regularly scheduled and special meetings of the Board and Board committees on which he or she served during 2018.2020.

We encourage all of our directors to attend our annual general meetings, and all directors then serving participated in the AGM in 2018.2020.

The Board has adopted a charter for each of the Audit, Remuneration and Nominating & Governance Committees that specifies the composition and responsibilities of each committee. Copies of the charters are available on our website (http://www.perrigo.com) under Investors – Corporate Governance – Committees and are available in print to shareholders upon request to our Company Secretary, Todd W. Kingma, Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland, or GeneralMeeting@perrigo.com.

Audit Committee

During 2018,2020, the Audit Committee met17met 6 times. TheUntil July 29, 2020, the Audit Committee currently consistsconsisted of the following independent directors: Donal O’Connor (Chair), Laurie Brlas and Geoffrey M. Parker.Parker and Theodore R. Samuels. Since that time the Audit Committee has consisted of the following independent directors: Donal O’Connor (Chair), Katherine C. Doyle, Geoffrey M. Parker and Theodore R. Samuels.

The Audit Committee monitors our accounting and financial reporting principles and policies and our internal controls and procedures. It is directly responsible for the compensation and oversight of the work of the independent registered public accounting firm in the preparation and issuance of audit reports and related work, including the resolution of any disagreements between management and the independent registered public accounting firm regarding financial reporting. It is also responsible for overseeing the work of our internal audit function. Additional information on the committee and its activities is set forth in the Audit Committee Report on page 45.

As noted above, one of the Audit Committee’s responsibilities is to oversee the Company’s internal control over financial reporting. During 2016, management identified several material weaknesses in our internal controls over financial reporting and, as discussed in our Annual Report on Form10-K for fiscal 2017, determined the weaknesses related to our income tax accounting processes continued to exist as of December 31, 2017. Since identifying these control deficiencies in 2016, with oversight from the Audit Committee, we took significant steps to remediate our internal control deficiencies in income taxes by redesigning our controls, many of which operated for the first time at December 31, 2017. Our efforts consisted primarily of strengthening our tax organization and designing a suite of controls related to the components of our income tax process, including valuation allowances, uncertain tax positions and non-routine events and transactions, to enhance our management review controls over income taxes. The key remediation actions taken included:

·

Reviewing our income tax processes and controls and enhanced the overall design and procedures performed in calculating our income tax provision on an interim and annual basis;

·

Significantly strengthening our tax capabilities through a combination of key new hires and providing additional resources;

·

Re-designing our management review controls and enhanced the precision of review around the key income tax areas; and

·

Demonstrating consistent operating effectiveness of our management review controls over income taxes over a number of quarterly periods.

We believe our remediation efforts have strengthened our internal control over financial reporting. As described in our Annual Report on Form10-K for fiscal 2018, the weaknesses have been remediated and our internal controls over financial reporting are effective as of December 31, 2018.52.

The Board of Directors has determined that each member of the Audit Committee (1) meets the audit committee independence requirements of the NYSE listing standards and the rules and regulations of the SEC and (2) is able to read and understand fundamental financial statements, as required by the NYSE listing standards. The Board has also determined that Donal O’Connor, Laurie Brlas andKatherine C. Doyle, Geoffrey M. Parker and Theodore R. Samuels have the requisite attributes of an “audit committee financial expert” under the SEC’s rules and that such attributes were acquired through relevant education and work experience.

Remuneration Committee

During 2018,2020, the Remuneration Committee (the “Committee”) met 78 times. TheUntil December 15, 2020, the Remuneration Committee currently consistsconsisted of the following independent directors: Jeffrey B. Kindler (Chair), Bradley A. Alford and Theodore R. Samuels.Erica L. Mann. Since that time the Remuneration Committee has consisted of the following independent directors: Jeffrey B. Kindler (Chair), Bradley A. Alford, Orlando D. Ashford and Erica L. Mann.

LOGO12


Board of Directors and Committees

The Remuneration Committee reviews and recommends to the Board compensation arrangements for the CEO andnon-employee directors. It also reviews and approves the annual compensation for executive officers, including salaries, bonusesannual incentives, and long-term incentive compensation. The Remuneration Committee administers Perrigo’s annual incentive and equity compensation, and administers Perrigo’slong-term incentive and other long-term employee compensation plans. The Remuneration Committee also reviews and makes recommendations to the Board regarding corporate culture, diversity and diversity initiatives and issues.inclusion initiatives.

The Remuneration Committee engaged FWFrederic W. Cook & Company, Inc. (“FW Cook”) as its independent consultant to provide independent, outside perspective and consulting services on Perrigo’s executive compensation program.and non-employee director programs. Additionally, FW Cook assists the Committee in considering and analyzing market practices, and trends, as well asand management’s compensation recommendations. Perrigo did not

retain FW Cook to perform any other compensation-related or consulting services for the Company. Interactions between FW Cook and management were generally limited to discussions on behalf of the Committee or as required to compile information at the Committee’s direction. Based on these factors, its own evaluation of FW Cook’s independence pursuant to the requirements approved and adopted by the SEC and the NYSE, and information provided by FW Cook, the Committee has determined that the work performed by FW Cook did not raise any conflicts of interest.

Additional information regarding the processes and procedures of the Remuneration Committee is presented in the Compensation Discussion and Analysis, beginning on page 14.22.

Nominating & Governance Committee

During 2018,2020, the Nominating & Governance Committee met 68 times. The Nominating & Governance Committee currently consists of the following independent directors: Jeffrey C. SmithAdriana Karaboutis (Chair), Gary M. CohenRolf A. Classon, and Adriana Karaboutis.Theodore R. Samuels.

The Nominating & Governance Committee identifies and recommends to the Board qualified director nominees. This committee also develops and recommends to the Board the Corporate Governance Guidelines applicable to Perrigo, leads the Board in its annual review of Board performance and makes recommendations to the Board with respect to the assignment of individual directors to various committees as well as succession planning. The Nominating & Governance Committee also oversees and makes recommendations to the Board regarding Perrigo’s cybersecurity policies and practices as well as sustainability and environmental efforts.

Executive Sessions of Independent Directors

The independent members of the Board of Directors hold regularly scheduled meetings in executive session without management, and they also meet in executive session with the CEO on a regular basis.

Board and Committee Self-Assessments

The Board and the Audit, Remuneration and Nominating & Governance Committees have historically conducted annual self-assessments. In recent years,self-assessments, either through the Board has relied onuse of extensive internal questionnaires or third parties to conduct the annual self-assessments.parties. Through this process, directors evaluate the composition, effectiveness, processes and skills of the Board and

13  2021 Proxy Statement


Board of Directors and Committees

individual Committees and identify areas that may merit further focus or consideration. The results of the assessments are reviewed and discussed by members of the Nominating & Governance Committee, which then reports to and leads a discussion with the full Board.

Shareholder Communications with Directors

Shareholders and other interested parties may communicate with any of our directors or with the

independent directors as a group by writing to them in care of our Company Secretary, Todd W. Kingma, at Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland. Relevant communications will be distributed to the appropriate directors depending on the facts and circumstances outlined in the communication. In accordance with the policy adopted by our independent directors, any communications that allege or report significant or material fiscal improprieties or complaints about internal accounting controls or other accounting or auditing matters will be immediately sent to the Chair of the Audit Committee and, after consultation with the Chair, may be sent to the other members of the Audit Committee. In addition, the Chairman of the Board will be advised promptly of any

communications that allege misconduct on the part of Perrigo management or that raise legal or ethical concerns about Perrigo’s practices or compliance concerns about Perrigo’s policies. The General Counsel maintains a log of all such communications, which is available for review by any Board member upon his or her request.

Director Nominations

The Nominating & Governance Committee is responsible for screening and recommending candidates for service as a director and considering recommendations offered by shareholders in accordance with our Articles of Association. The Board as a whole is responsible for approving nominees. The Nominating & Governance Committee recommends individuals as director nominees based on various criteria, including their business and professional background, integrity, diversity, understanding of our business, demonstrated ability to make independent analytical inquiries and the willingness and ability to devote the necessary time to Board and committee duties. A director’s qualifications in meeting these criteria are considered at least each time the director is recommended for Board membership. Should a new director be needed to satisfy specific criteria or to fill a vacancy, the Nominating & Governance Committee will initiate a search for potential director nominees, and it will seek input from other Board members, including the CEO and Chairman of the Board, senior management and any outside advisers retained to assist in identifying and evaluating candidates.

Shareholders may nominate candidates for consideration at an annual general meeting by following the process described in the Articles of Association and summarized in this proxy statement under “Voting Information – How do I submit a shareholder proposal or director nomination for the next AGM?”

Upon a change in a director’s job responsibility, including retirement, our Corporate Governance Guidelines require the director to tender his or her resignation from the Board. The Nominating & Governance Committee will consider the change in circumstance and make a recommendation to the Board to accept or reject the offer of resignation.

LOGO14


Board of Directors and Committees

Proxy Access

In JulyProxy access has been a part of Perrigo since 2017 upon the recommendation of our Board, our shareholders overwhelmingly approved amending our Articles of Association to implement proxy access. Proxy accessand allows eligible shareholders to include their own director nominees in Perrigo’s proxy materials along with the candidates nominated by the Board. This right is summarized in this proxy statement under “Voting Information – How do I use proxy access to nominate a director candidate for the next AGM?”

Board Refreshment

The Board is committed to thoughtful board refreshment and ongoing board succession planning. During 2016 and 2017, seven new independent directors were added to our Board. Mr. Kessler was appointed as a director upon his appointment as our President and CEO in October 2018, following Uwe Roehrhoff’s resignation from these positions in October 2018.

At this AGM, Erica Mann was appointed to the Board is recommending that our shareholders elect Erica Mann as a new director. Ms. Mann was identified as a nominee by the Nominatingin 2019. Katherine C. Doyle and Governance Committee. In addition, after fifteen years of distinguished service, Laurie Brlas and Gary Cohen are coming off the Board. The Board thanks both Laurie and Gary for their many years of valuable service on the Board andOrlando D. Ashford were appointed to the Companyboard in July 2020 and December 2020, respectively.

As of the date of the AGM, the average tenure of ournon-employee directors will be approximately 1.83.36 years.

Stock Ownership

Under our Corporate Governance Guidelines, each director who is not a Perrigo employee is required to attain stock ownership at a level equal to six times his or hertheir annual cash retainer.retainer, or $450,000. Non-employee directors are subject to the same definition of stock ownership and retention requirements as executive officers, theofficers. The details of whichthe Stock Ownership Guidelines (“SOGs”) are described in the Compensation Discussion and Analysis – Other Policies, Practices and Guidelines – Executive Stock Ownership Guidelines section, on page 26.34. All of ournon-employee directors and named executive officers are in compliance with these guidelines, either by satisfying applicable ownership levels or complying with the retention requirements.

15  2021 Proxy Statement


Certain Relationships and Related-Party Transactions

Certain Relationships and Related-Party Transactions

Our Code of Conduct precludes our directors, officers and employees from engaging in any type of activity, such as related-party transactions, that might create an actual or perceived conflict of interest. In addition, our Board of Directors adopted a Related-Party Transaction Policy that requires that all covered related-party transactions be approved or ratified by the Nominating & Governance Committee. Under that policy, each executive officer, director or director nominee must promptly notify the Chair of the Nominating & Governance Committee and our General Counsel in writing of any actual or prospective related-party transaction covered by the policy. The Nominating & Governance Committee, with input from our Legal Department, reviews the relevant facts and approves or disapproves the transaction. In reaching its decision, the Nominating & Governance Committee considers the factors outlined in the policy, a copy of which is available on our website (http://www.perrigo.com) under the heading Investors – Corporate Governance – Related-Party Transaction Policy.

In addition, on an annual basis, each director and executive officer completes a directors’ and officers’ questionnaire that requires disclosure of any transactions with Perrigo in which he or she, or any member of his or her immediate family, has a direct or indirect material interest in Perrigo. The Nominating & Governance Committee reviews the information provided in response to these questionnaires.

Agreement with Starboard Value LPBased on its review of applicable materials, the Nominating & Governance Committee has determined that there are no transactions that require disclosure in this proxy statement.

On February 6, 2017, we entered into an agreement with Starboard (the “Starboard Agreement”), which was intended to define the ongoing relationship between Perrigo and Starboard in its capacity as a significant shareholder. The Starboard Agreement was reviewed and approved by our Board of Directors in accordance with the terms of our Related-Party Transaction Policy.

As of February 6, 2017, Starboard beneficially owned approximately 6.7% of Perrigo’s outstanding ordinary shares. Pursuant to the Starboard Agreement, we (i) accepted the resignation of Michael J. Jandernoa, Gerald K. Kunkle, Jr., Herman Morris, Jr. and Shlomo Yanai from the Perrigo Board of Directors, and (ii) appointed Jeffrey C. Smith of Starboard and two other independent directors, Bradley A. Alford and Jeffrey B. Kindler, to the Board to fill three of the resultant vacancies. Pursuant to the Starboard Agreement, Starboard had the right to recommend to the Board two additional nominees to serve as independent directors. Upon Starboard’s recommendation, on May 2, 2017, the Board appointed Adriana Karaboutis and Rolf A. Classon as directors and accepted the resignation of Ellen R. Hoffing effective upon Ms. Karaboutis’ and Mr. Classon’s appointments.

LOGO16


Director Compensation

With respect to the 2017 AGM, Starboard agreed to, among other things, vote in favor of Perrigo’s director nominees and, subject to certain conditions, vote in accordance with the Board’s recommendation on all other proposals. Starboard also agreed not to submit director nominations or proposals at the 2017 AGM. In addition, we agreed to nominate Messrs. Alford, Kindler, Smith, and Classon and Ms. Karaboutis forre-election at the AGM.

Under the terms of the Starboard Agreement, until the earlier of (i) 15 business days prior to the deadline for the submission of shareholder nominations for the 2018 AGM and (ii) the date that is 100 days prior to the first anniversary of the AGM, Starboard agreed not to, among other things: (a) solicit proxies; (b) join any “group” or voting arrangement; (c) propose certain extraordinary transactions or encourage third parties to do so; (d) call or seek to call an extraordinary general meeting of Perrigo’s shareholders; (e) seek board representation other than as provided in the Starboard Agreement; or (f) influence third parties with respect to the voting or disposition of Perrigo ordinary shares. Starboard also agreed to customary confidentiality restrictions.

The Starboard Agreement expired in February 2018.

Director Compensation

The Remuneration Committee reviews and makes a recommendation to the Board regardingnon-employee director compensation. In determining the level and mix of compensation fornon-employee directors, the Remuneration Committee considers peer and other market data, practices and trends as well as information and analyses provided by FW Cook, its independent consultant.

In 2018,2020, all of ournon-employee directors were paid an annual cash retainer, and a supplemental annual cash retainer was also paid to committee chairs, the Chairman, andnon-chair committee members all as described below.

 

Chairman Annual Cash Retainer:

$150,000

(in lieu of director retainer)

  
$150,000

Director Annual Cash Retainer

  $75,000

Committee Member Retainer:

  

Audit

  $12,500

Remuneration

  $12,500

Nominating & Governance

  $ 8,000

Committee Chair Retainer:

(in lieu of member retainer)

  

Audit

  $25,000

Remuneration

  $25,000

Nominating & Governance

  $16,000

For 2018,2020, our Chairman of the Board and othernon-employee directors received annual equity awards in the form of restricted stock units having a value of approximately $375,000 and $300,000, respectively. These awards vest on the earlier of one year from the grant date or the date of the next AGM, and are intended to directly link an elementthe majority of director compensation to shareholders’ interests.

Directors who are Perrigo employees receive no compensation for their services as directors.

17  2021 Proxy Statement


Director Compensation

The following table summarizes the 20182020 compensation of ournon-employee directors who served during the year.

Director Compensation

 

Name

  Fees Earned or
Paid in Cash ($)
   Stock
Awards ($) 1
   Total ($) 

Bradley A. Alford

   87,500    300,000    387,500 

Laurie Brlas

   109,452    300,000    409,452 

Rolf A. Classon

   127,988    375,000    502,988 

Gary M. Cohen

   83,000    300,000    383,000 

Adriana Karaboutis

   83,000    300,000    383,000 

Jeffrey B. Kindler

   100,000    300,000    400,000 

Donal O’Connor

   100,000    300,000    400,000 

Geoffrey Parker

   87,500    300,000    387,500 

Theodore R. Samuels

   87,500    300,000    387,500 

Jeffrey C. Smith

   91,000    300,000    391,000 
 NameFees Earned or
Paid in Cash ($)
Stock Awards ($)1Total ($)

 Alford, Bradley A.

87,500300,009387,509

 Ashford, Orlando D. (2)

4,07504,075

 Classon, Rolf A.

158,000375,011533,011

 Doyle, Katherine C. (3)

36,428300,001336,429

 Karaboutis, Adriana

91,000300,009391,009

 Kindler, Jeffrey B.

100,000300,009400,009

 Mann, Erica L.

87,500300,009387,509

 O’Connor, Donal

100,000300,009400,009

 Parker, Geoffrey M.

87,500300,009387,509

 Samuels, Theodore R.

95,500300,009395,509

1) Represents the grant date fair value of 3,9715,804 service-based restricted stock units granted to eachnon-employee director on May 15, 20187, 2020, calculated in accordance with U.S. GAAP. As Chair of the Board, RolfMr. Classon received 4,9647,255 service-based restricted stock units. Ms. Doyle received 5,637 service-based restricted stock units on August 12, 2020. The shares vest on the earlier of one year after the grant date or the date of the next AGM.date. The grant date fair value is based on $75.55 per share, the closing price of Perrigo Company plc ordinary shares on the NYSE on the grant date. During 2018, no stock options were granted tonon-employee directors.date which was $51.69 per share for all directors, except for Ms. Doyle, which was $53.22. No other unvested stock awards were outstanding as of December 31, 2018.2020.

2) Mr. Ashford joined the Board on December 15, 2020.

3) Ms. Doyle joined the Board on July 29, 2020.

LOGO18


Ownership of Perrigo Ordinary Shares

Ownership of Perrigo Ordinary Shares

Directors, Nominees and Executive Officers

The following table shows how many Perrigo ordinary shares the directors, nominees, and named executive officers, individually and collectively, beneficially owned as of February 26, 2019.March 15, 2021. The percent of class owned is based on 135,873,069 Perrigo ordinary shares outstanding as of that date. The named executive officers are the individuals listed in the Summary Compensation table on page 31.38.

Beneficial ownership is a technical term broadly defined by the SEC to mean more than ownership in the usual sense. In general, beneficial ownership includes any shares a shareholder can vote or transfer and stock options and restricted stock units that are vested currently or become vested within 60 days. Except as otherwise noted, the shareholders named in this table have sole voting and investment power for all shares shown as beneficially owned by them.

 

  

    Ordinary Shares    
Beneficially

Owned

  Shares
Acquirable
Within 60 Days of
Record Date (1)
  Total  Percent
    of Class    
 
 

 

 

 

Directors

 

Bradley A. Alford

  2,748   -   2,748   * 

Laurie Brlas

  15,329   7,225   22,554   * 

Rolf A. Classon

  2,217   -   2,217   * 

Gary M. Cohen

  20,317   7,225   27,542   * 

Adriana Karaboutis

  2,217   -   2,217   * 

Jeffrey B. Kindler

  2,745   -   2,745   * 

Donal O’Connor(2)

  6,423   -   6,423   * 

Geoffrey M. Parker(3)

  8,879   -   8,879   * 

Theodore R. Samuels(4)

  11,883   -   11,883   * 

Jeffrey C. Smith(5)

  10,044,170   -   10,044,170   7.4

Murray S. Kessler

  15,683   -   15,683   * 
Named Executive Officers Other Than Directors    

Todd W. Kingma(6)

  25,587   66,858   92,445   * 

Ron Winowiecki

  5,663   14,949   20,612   * 

Jeffrey R. Needham

  11,044   30,376   41,420   * 

Svend Andersen(7)

  7,200   8,251   15,451   * 

Uwe Roehrhoff

  8,679   24,050   32,729   * 

John T. Hendrickson(8)

�� 11,885   150,731   162,616   * 
Directors and Executive Officers as a Group (22 Persons) (9)  10,214,905   242,758   10,457,663   7.7
  Ordinary Shares
Beneficially Owned
 Shares Acquirable
Within 60 Days of
Record Date(1)
 Total  Percent of
Class

 Director

     

 Bradley A. Alford

 7,960 5,804 13,764  *

 Orlando D. Ashford

 0 0 0  *

 Rolf A. Classon

 10,870 7,255 18,125  *

 Katherine C. Doyle

 0 0 0  *

 Adriana Karaboutis

 7,429 5,804 13,233  *

 Murray S. Kessler

 254,712 211,230 43,482  *

 Jeffrey B. Kindler

 7,957 5,804 13,761  *

 Erica L. Mann

 2,905 5,804 8,709  *

 Donal O’Connor (2)

 11,635 5,804 17,439  *

 Geoffrey M. Parker (3)

 14,061 5,804 19,865  *

 Theodore R. Samuels (4)

 32,408 5,804 38,212  *

 Named Executive Officers Other Than Directors

     

 Raymond P. Silcock

 6,232 29,803 36,035  *

 Svend Andersen (5)

 29,244 24,749 53,993  *

 Todd W. Kingma (6)

 50,856 98,333 149,189  *

 Richard Sorota (7)

 11,530 0 11,530  *

 Directors and Executive Officers as a Group (21 Persons) (8)

 333,781 540,353 874,134  0.7%

19  2021 Proxy Statement


Ownership of Perrigo Ordinary Shares

* Less than 1%.

1) Includes stock options that are exercisable within 60 days of the record date as well as restricted stock units that willmay vest within 60 days of the record date.

2) Shares owned include 1,198 shares in a retirement fund.

3) Shares owned include 150 shares in a revocable trust, of which Mr. Parker and his spouse are the trustees, and 5,500 shares in the Geoffrey Parker Roth IRA.

4) Shares owned include 7,61818,118 shares in the Ted and Lori Samuels Family Trust, of which Mr. Samuels and his spouse are the trustees.

5) Includes 10,041,425 shares held by certain funds and managed accounts for which Starboard Value LP serves as manager or investment manager. Mr. Smith serves as a Managing Member, Chief Executive Officer, and Chief Investment Officer of Starboard Value LP. Mr. Smith has shared voting and shared dispositive power over Starboard’s shares.

6) Shares owned include 2,000 shares in Mr. Kingma’s Charitable RemainderUni-Trust.

7) All 7,20010,028 shares are owned indirectly via the Panel ApS, an entity wholly-owned by Mr. Andersen.

8)6) Shares owned include 9,8792,000 shares in Mr. Kingma’s Charitable Remainder Uni-Trust.

7) Shares owned by the John T. Hendrickson Trust, of which Mr. Hendrickson is the trustee.include 369 shares in a retirement fund.

9)8) See footnotes 1 through 7. Includes directors and executive officers as of February 26, 2019. Of these shares, 10,041,425 are beneficially owned indirectly by Mr. Smith.15 March 2021.

Other Principal Shareholders

The following table shows all shareholders other than directors, nominees and named executive officers that we know to be beneficial owners of more than 5% of Perrigo’s ordinary shares. The percent of class owned is based on 135,873,069Perrigo133,567,151 Perrigo ordinary shares outstanding as of February 26, 2019.March 15, 2021.

 

Name and Address
of Beneficial Owner

    

Ordinary Shares

Beneficially Owned

   

Percent
of Class

 

T. Rowe Price Associates, Inc.(1)

100 E. Pratt Street

Baltimore, MD 21202

     16,068,975    11.8

The Vanguard Group(2)

100 Vanguard Blvd.

Malvern, PA 19355

     14,936,268    11.0

Starboard Value LP(3)

777 Third Avenue, 18th Floor

New York, NY 10055

     10,044,170    7.4

BlackRock Inc.(4)

55 East 52nd Street

New York, NY 10055

     8,613,825    6.3

Franklin Resources, Inc.(5)

One Franklin Parkway

San Mateo, CA 94403

     8,491,469    6.2

FMR LLC(6)

245 Summer Street

Boston, MA 02210

     8,091,799    6.0

 Name and Address

 of Beneficial Owner

Ordinary Shares

Beneficially Owned

Percent of Class

 

 T. Rowe Price Associates, Inc. (1)

 100 E. Pratt Street

 Baltimore, MD 21202

 

17,586,621

 

13.2%

 

 The Vanguard Group (2)

 100 Vanguard Blvd.

 Malvern, PA 19355

 

15,289,381

 

11.5%

 

 BlackRock Inc. (3)

 55 East 52nd Street

 New York, NY 10055

 

10,138,572

 

7.6%

1) T. Rowe Price Associates, Inc. has sole voting power with respect to 7,453,321 of the shares and sole dispositive power with respect to 17,586,621 shares. This information is based on a Schedule 13G/A filed with the SEC on February 16, 2021.

2) The Vanguard Group, Inc. has shared voting power with respect to 222,971 of the shares, sole dispositive power with respect to 14,685,593 of the shares and shared dispositive power with respect to 603,788 of the shares. This information is based on a Schedule 13G/A filed with the SEC on February 10, 2021.

3) BlackRock, Inc. has sole voting power with respect to 8,673,806 of the shares and sole dispositive power with respect to 10,138,572 shares. This information is based on a Schedule 13G/A filed with the SEC on January 29, 2021.

 

1)

T. Rowe Price Associates, Inc. has sole voting power with respect to 5,709,852 of the shares and sole dispositive power with respect to all of the shares. This information is based on a Schedule 13G/A filed with the SEC on February 14, 2019.

  2)LOGO

The Vanguard Group, Inc. has sole voting power with respect to 149,266 of the shares, shared voting power with respect to 36,721 of the shares, shared dispositive power with respect to 215,329 of the shares and sole dispositive power with respect to 14,195,308 shares. This information is based on a Schedule 13G filed with the SEC on February 11, 2019.

  3)

Based on information provided by the shareholder as of February 22, 2019, pursuant to which (a) each of Starboard Value LP, Starboard Value GP LLC, Starboard Principal Co LP and Starboard Principal Co GP LLC has sole voting and dispositive power with respect to 10,041,425 shares; (b) Starboard Value and Opportunity Master Fund Ltd has sole voting and dispositive power with respect to 3,123,464 shares; (c) each of Starboard Value A LP and Starboard Value A GP LLC has sole voting and dispositive power with respect 2,386,757 shares; (d) each of Starboard Leaders Kilo LLC and Starboard Leaders Fund LP has sole voting and dispositive power with respect to 2,018,065 shares; (e) Starboard Value and Opportunity S LLC has sole voting and dispositive power with respect to 446,645 shares; (f) each of Starboard Leaders Select III LP and Starboard Leaders Select III GP LLC Value has sole voting and dispositive power with respect 368,692 shares; (g) each of Starboard Value and Opportunity C LP and Starboard Value R LP has sole voting and dispositive power with respect to 257,947 shares; (h) each of Starboard Value and Opportunity Master Fund L LP and Starboard Value L LP has sole voting and dispositive power with respect to 164,392 shares; (i) Starboard Value R GP LLC has sole voting and dispositive power with respect to 422,339 shares; and (j) each of Jeffrey C. Smith and Peter A. Feld has shared voting and dispositive power with respect to 10,041,425 shares. In addition, Jeffrey C. Smith has sole voting and dispositive power with respect to 2,745 shares he owns directly.

20


4)

BlackRock Inc. has sole voting power with respect to 7,409,719 of the shares and sole dispositive power with respect to 8,491,469 shares. This information is based on a Schedule 13G/A filed with the SEC on February 6, 2019.

Delinquent Section 16(a) Reports

 

5)

Based on a Schedule 13G filed with the SEC on January 28, 2019 by Franklin Resources, Inc. (“FRI”), Charles B. Johnson and Rupert H. Johnson, Jr. These securities are beneficially owned by one or more open- orclosed-end investment companies or other managed accounts that are investment management clients of investment managers that are direct and indirect subsidiaries of FRI. Charles B. Johnson and Rupert H. Johnson, Jr. (the “Principal Stockholders”) each own in excess of 10% of the outstanding common stock of FRI and are the Principal Stockholders of FRI. FRI and the Principal Stockholders may be deemed to be, for purposes of Rule13d-3 under the Exchange Act, the beneficial owners of securities held by persons and entities for whom or for which FRI subsidiaries provide investment management services. However, FRI and the Principal Stockholders disclaim any pecuniary interest in and beneficial ownership of any of such securities. Pursuant to the Schedule 13G, (a) Templeton Global Advisors Limited has sole voting power over 4,823,259 shares, shared voting power over 2,059 shares, and sole dispositive power over 4,852,058 shares, (b) Franklin Advisers, Inc. has sole voting and dispositive power over 1,973,052 shares, (c) Franklin Templeton Investments Corp. has sole voting and dispositive power over 384,530 shares, (d) Franklin Templeton Investment Management Limited has sole voting power over 324,105 shares and sole dispositive power over 324,105 shares, (e) Templeton Investment Counsel, LLC has sole voting power over 320,752 shares and sole dispositive power over 434,515 shares, (f) Franklin Templeton Investments Australia Limited has sole voting power over 23,225 shares and sole dispositive power over 77,080 shares, (g) K2/D&S Management Co., L.L.C. has sole voting and dispositive power over 15,509 shares, (h) Templeton Asset Management Ltd has sole voting power over 13,788 shares, shared voting power over 34,310 shares, sole dispositive power over 184,198 shares, and shared dispositive power over 34,310 shares, and (i) Franklin Templeton Investments (Asia) Limited has sole voting and dispositive power over 11,520 shares.

6)

Based on a Schedule 13G filed with the SEC on February 13, 2019 by FMR LLC (“FMR”) and Abigail P. Johnson. FMR LLC has the sole voting power with respect to 306,564 of the shares and sole dispositive power with respect to 8,091,799 of the shares. The filing reports that Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders’ voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders’ voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act (“Fidelity Funds”) advised by Fidelity Management & Research Company (“FMR Co”), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds’ Boards of Trustees. Fidelity Management & Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds’ Board of Trustees.

Delinquent Section 16(a) Beneficial Ownership

Reporting ComplianceReports

Section 16(a) of the Securities Exchange Act of 1934 requires that Perrigo’s executive officers, directors

and 10% shareholders file reports of ownership and changes of ownership of Perrigo ordinary shares with the SEC. Based on a review of copies of these reports provided to usfiled with the SEC and written representations from executive officers and directors, we believe that all filing requirements were met during 2018, with the exception of one transaction for Mr. Needham occurring on April 2, 2018,2020, such that was filed on April 27, 2018, as the result of an administrative error.there were no delinquent reports in 2020.    

21  2021 Proxy Statement


Executive Compensation

Executive Compensation

Compensation Discussion and Analysis

Introduction

 

Fiscal 2018 was aIn fiscal year of transition at Perrigo. We kicked off a number of initiatives to position the business for long-term growth, while maintaining our focus on operational execution.

A key initiative during 2018 was a comprehensive portfolio evaluation led by former CEO Uwe Roehrhoff. That process generated other initiatives to improve the Company’s performance, including

the Board’s decision to separate the Rx business, which will empower the Company to commit its resources to its consumer core2020, management and enable both businesses to flourish.

As that decision pivots Perrigo back to its consumer focus and requires a growth strategy to support it, the Board appointed consumer packaged goods veteran Murray S. Kessler as Presidentof Directors took decisive action and CEO. Mr. Kessler has over 30 years of experiencemade significant progress in growing consumer products companies and managing businesses in regulated environments. Murray has already begun refocusing our strategy and energizing and inspiring our organization and the Company transitions from a healthcare companyits three-year plan to transform Perrigo into a consumer self-care company.

2018 Performance Highlights4Self-Care market leader. Some of our highlights include:

 

 ·  

Delivered consolidated reported net sales of $4.7$5.1 billion, reported operating income of $0.1 billion, and adjusted operating profitincome of $0.9$0.8 billion.

 ·  

Increased investments in R&D to enhance our new product pipeline as well as in advertising and promotion to driveGrew consolidated adjusted net sales which were up nearly 5% year-over-year; additional investments were made to address supply constraints.by 5.0%5, net sales excluding divested businesses and currency by 6.4%6 and organic net sales by 1.9%7, despite a negative 1.4 percentage point impact from the extraordinary weak cough/cold/flu season.

 ·  

Consumer Healthcare International improved itsSelf-Care Americas adjusted operating marginnet sales grew 9.0% to an annuala record $2.7 billion; excluding the impact of 16% through new productscurrency and better SG&A efficiencies.divestitures, net sales grew 10.3%, with organic net sales growing by 3.4%.

 ·  

Consumer Healthcare Americas deliveredSelf-Care International adjusted net sales growth of 1.4% year-over-year5 driven by new productsincreased 0.8% to $1.4 billion; excluding divested businesses and currency, net sales in the analgesics and dermatological categories.grew 3.6%.

 ·  

Prescription Pharmaceuticals reported net sales increased R&D investments by 18%0.8%.

Advanced the consumer self-care growth strategy with the acquisitions of:

·

The assets of Steripod®, a leading toothbrush accessory brand and innovator in the toothbrush protector market;

·

The oral care assets of High Ridge Brands, which strengthens Perrigo’s oral self-care leadership position as the team continued to identify attractive opportunities for new products.#1 fastest growing value brand player in the children’s oral care category; and

·

Three Eastern European OTC skincare and hair loss treatment brands, expanding Consumer Self-Care International’s robust dermatology platform into growing geographies with market-leading, margin accretive brands.

·

Entered the CBD market through a strategic investment in and long-term supply agreement with Kazmira LLC, a leading supplier of hemp-based zero-THC CBD.

5

Adjusted net sales excludes the 2019 net sales from the divested animal health business when the business was classified as held-for-sale and reverses certain product returns relating to the voluntary global market withdrawal of ranitidine in the third quarter of 2019.

6

Net sales growth excluding currency and divested businesses excludes the 2019 net sales from the divested animal health business when the business was classified as held-for-sale, reverses certain product returns relating to the voluntary global market withdrawal of ranitidine in the third quarter of 2019, excludes 2019 net sales from the divested animal health business before the business was classified as held-for-sale, excludes 2019 net sales from the Rosemont Pharmaceuticals business, excludes 2019 net sales from the Canoderm prescription product, and are on a constant currency basis.

7

Organic net sales growth excludes net sales from the 2020 acquisition of the Oral Care Assets purchased from High Ridge Brands from CSCA and CSCI, excludes net sales from the 2020 Eastern European Brands acquisition from CSCI, and Ranir net sales through the second quarter of 2020 from CSCA and CSCI.

LOGO22


Executive Compensation

·

Reconfigured our portfolio by divesting the U.K.-based Rosemont Pharmaceuticals business, a generic prescription pharmaceuticals manufacturer focused on liquid medicines, for approximately $195 million; and completed our portfolio reconfiguration after announcing on March 1, 2021 an agreement to sell the Rx Pharmaceutical business for $1.5 billion in cash and more than $50 million in other considerations, establishing Perrigo as a pure-play global consumer self-care company positioned to significantly enhance shareholder value.

 ·  

Achieved 102% operating cash flow conversion to adjusted net income and cash from operations of $643 million.6more than $300 million in new product sales.

 ·  

Used balance sheet strength to repurchaseGrew our e-commerce sales by more than 100%.

·

Improved customer service levels while successfully managing through the COVID-19 pandemic without missing a single shift at our global facilities.

·

Invested in repeatable growth platforms through a centralized R&D team that added and replenished approximately 5.1 million shares and pay approximately $105$500 million in dividends.future new product pipeline potential.

Above all else, we

·

Increased our dividend for the 18th consecutive year; issued $750 million in new debt at an attractive rate, repurchased $164 million of our stock, committed more than $300 million to capacity improvements and ended the year with $642 million of cash on the balance sheet.

·

ESG – strong progress in support of Perrigo’s commitment to environmental, social and governance matters, as described in detail on pages 5-11, including

·

Adoption of the United Nations Sustainable Development Goals,

·

Quantifiable goals to reduce carbon emissions, reduce water usage, and increase recycle ready packaging

·

Strong focus and support of diversity and inclusion and human capital management.

LOGO

23  2021 Proxy Statement


Executive Compensation

Our Named Executive Officers for 2020

Perrigo’s named executive officers (“NEO”) for 2020 were:

  Named Executive OfficerPosition

Murray S. Kessler

President and Chief Executive Officer

Raymond P. Silcock

Executive Vice President and Chief Financial Officer

Svend Andersen

Executive Vice President and President, Consumer Self-Care International

Todd W. Kingma

Executive Vice President, General Counsel, and Company Secretary

Richard S. Sorota

Executive Vice President and President, Consumer Self-Care Americas

This Compensation Discussion and Analysis provides information about our executive compensation program, factors that were considered in making compensation decisions for our NEOs, and details on our programs designed to drive Perrigo’s performance into the future.

2020 Say-on-Pay Voting Results

At the 2020 AGM, our shareholders strongly supported our executive compensation, with 88% of the votes cast voting in favor of the say-on-pay proposal. The Committee considered our shareholders support of our compensation programs in its evaluation of our compensation policies and program design for fiscal 2020. All changes made to our program design were intended to better support our business strategy. We continue to actively listen to our shareholders and take action to respond toincorporate their valuable input.input to our incentive programs and policies. Further, we continue to engage with shareholders on a regular basis in order to maintain an open line of communication on executive compensation issues.

Our Named Executive Officers for 2018

In January 2018, John T. Hendrickson stepped down as Chief Executive Officer following the Board’s appointment of Uwe F. Roehrhoff as President and Chief Executive Officer. In February 2018, the Board appointed Ronald L. Winowiecki as Chief Financial Officer, formerly the Senior Vice President of Business Finance and Acting CFO. In October 2018, Uwe F. Roehrhoff stepped down as President and Chief Executive Officer upon the Board’s appointment of Murray S. Kessler as President and Chief Executive Officer.

4

See Exhibit A for reconciliation of Adjusted(non-GAAP) to Reported GAAP.

5

On a constant currency basis and excluding animal health.

6

Cash flow conversion to adjusted net income and cash from operations excludes a $50 million payment for Nasonex® OTC.

Perrigo’s named executive officers for 2018 are:

  Named Executive
  Officer
Position

Murray S. Kessler

President and Chief Executive Officer

Ronald L. Winowiecki

Executive Vice President, Chief Financial Officer

Todd W. Kingma

Executive Vice President, General Counsel and Secretary

Jeffrey R. Needham

Executive Vice President and President, Consumer Healthcare Americas

Svend Andersen

Executive Vice President and President, Consumer Healthcare International

Uwe F. Roehrhoff

Former Chief Executive Officer

John T. Hendrickson

Former Chief Executive Officer

This Compensation Discussion and Analysis provides information about our executive compensation program, the factors that were considered in making compensation decisions for our named executive officers and how we have modified our programs to meet Perrigo’s needs for the future.

Executive Summary

2018 Year in Review

2018 was a year in which the Company underwent a number of leadership changes. In January 2018, Uwe Roehrhoff, an experienced pharmaceutical executive, was appointed President and CEO of Perrigo, replacing, John Hendrickson, who stepped down after more than 30 years of service to Perrigo. Mr. Roehrhoff initiated a strategic roadmap process to evaluate the entire Perrigo portfolio and accelerate growth, however, in August 2018, the Board modified the Company’s strategy and approved a plan to separate the Rx Segment to better enable this unique asset to capitalize on its platform of differentiated generic pharmaceutical products and allow Perrigo to focus on expanding its leading consumer businesses. Soon after this decision, on October 8, 2018, Murray S. Kessler, who has a proven track record with over 30 years in leadership positions among multiple consumer products goods companies, joined Perrigo as President and CEO and as a director to drive Perrigo’s new consumer-focused strategy, following the resignation of Mr. Roehrhoff from those positions on the same day.

2018Say-on-Pay Voting Results

At the 2018 AGM, our shareholders strongly approved our executive compensation, with over 92% of the votes cast voting in favor of thesay-on-pay proposal.

Best Compensation Governance and Practices

Our executive compensation program continues to be grounded in the following policies and practices, promoting sound compensation governance, enhancing alignment of ourpay-for-performance philosophy and furthering our named executive officers’NEOs’ interests with those of our shareholders:

 

LOGO

What We Do  What We Do Not Do

LOGO   Place a significant emphasis on variable, performance-based, andat-risk, performance-based pay

 

LOGO   Permit hedging or pledging of
Perrigo stock

LOGO   Provide significant perquisites

LOGO   Reprice options

LOGO   Provide “single trigger” change in control cash severance benefits

LOGO   Directly align totalexecutive reward with shareholder returns through long-term corporate,operational, financial, and share price performance

LOGO   Include clawback provisions in our incentive agreements

LOGO   Have rigorous stock ownership guidelines

 

LOGO   Use an independent compensation consultant

 

LOGO   Conduct independent annual risk assessments

 

2018

LOGO24


Executive Compensation

2020 Compensation Decisions

The Committee’s key compensation decisions, based on the Company’s results in 2018,2020, were aligned with actual performance in the year:

 

Program Element

 Committee Decisions

Annual Base Salary

 Based on the Committee’s review of the compensation market data and assessment of individual performance in the prior year, as well as Perrigo’s business priorities and strategy, all executive officers received an increase in base pay for 20182020 that was in line with all other global employees, except our former CEOs, John Hendrickson and Uwe Roehrhoff, and our current CEO, Murray Kessler, whose base salaries were determined as part of their respective employment contracts.
for Mr. Sorota, who was newly promoted into his role on March 23, 2020.

MIBAnnual Incentive Plan (AIP)

 The then-serving named executive officersNEOs received annual incentive awards based on corporate, segment, and individual performance against strategic objectives aligned with delivery of our self-care transformation and strategy under the MIB Plan,AIP, which ranged from at 64.7%98% to 100%125% of target.

LTILong-Term Incentive Plan (LTIP)

 In 2018,2020, all of the then-serving named executive officers were granted annual LTILTIP awards, which were allocated 50% to PSUsPerformance-Based Restricted Stock Units (“PSUs”) that may be earned based on achievement of ROTCAdjusted Operating Income (“Adj. OI”) growth goals over three years, 20% to PSUs that may be earned based on our rTSRRelative Total Shareholder Return (“rTSR”) performance versus peersthe relevant peer group over three years, and 30% to stock optionsService-Based Restrict Stock Units (“RSUs”) ratably vesting over three years.

  Program ElementCommittee Decisions

Based on 2018 ROTC performance, there was 0% of target vesting credit for the 2018 tranche of the ROTC performance-based equity incentive, which will apply to the full three-year vesting credit for the PSUs granted in the periods ended December 31, 2016, 2017, and 2018. 2018 was the third and final year for the 2016 ROTC PSUs; in combination with ROTC performance in the prior two years, the total payout for 2016 ROTC PSUs was 58% of target.

What Guides Our Executive Compensation Program

 

Our Executive Compensation Principles

Perrigo’s executive compensation program is designed to attract, motivate and retain our entire executive team, including our named executive offers,officers, who are critical to the execution of Perrigo’s Self-Care strategy and the long-term success of the company. Perrigo’s executive compensation program reflects our core principles:

 

 ·  

Pay is linked to performance: A significant portion of total compensation should be variable, performance-based(“at-risk”), and linked to the attainment of specific, measurable objectives.objectives, including the delivery of our strategic and transformation plan.

·

Pay opportunities are market-competitive: Compensation opportunities and program design should attract, motivate, and retain highly-qualified executives who can best deliver our strategies and are focused on the long-term interests of our shareholders.

 ·  

Pay is shareholder-aligned: Compensation should be provided through multiple pay elements (base salaries, annual and long-term incentives) designed to drive sustainable business performance, build a strong internal culture of company ownership, and create long-term value for all our shareholders.

25  2021 Proxy Statement


·
  

Pay opportunities are market-competitive: Provide compensation at levels that will attract, motivate, and retain highly qualified executives who are focused on the long-term best interests of our shareholders.

Executive Compensation

The core elements of our executive compensation program are summarized in the table below.

 

  Element  Form  What It Does

Base Salary

  Cash
(Fixed)
  Provides a competitive rate of fixed compensation relative to similar positions in pharmaceutical industry and consumer-goodsat relevant peer companies that enables us to attract and retain critical executive talent.

MIB PlanAIP

  Cash (Variable)  Focuses executives on achieving measurable, annual financial, operational, and operationalstrategic goals that, drivein the aggregate, create long-term, sustainable shareholder value.

LTI PlanLTIP

  Equity (Variable)  Provides incentives for executives to execute on long-term financial/strategic growth goals that drive shareholder value creation and support our long-range talent development and retention strategy.

The charts below show the target compensation of our current Chief Executive OfficerCEO in 20192020 and our other named executive officersNEOs for fiscal 2018. Mr. Kessler did not receive an annual LTI award in 2018, but received a grant of options when he joined Perrigo in October 2018.2020. These charts illustrate

that a majority of named executive officerNEO compensation is performance-based andand/or variable (89%(88% for our Chief Executive OfficerCEO and an average of 74%77% for our other named executive officers)NEOs). The weighting of these pay elements is consistent with the market and best practices and puts a largesubstantial majority of the named executive officers’NEOs’ total direct compensation at risk if performance goals are not achieved or if Perrigo performance declines.

 

LOGOLOGO

The Decision-Making Process

The Role of the Remuneration Committee. The Committee, which is composed entirely of independent directors, oversees our executive compensation program. The Committee works very closely with FW Cook, its independent executive remuneration consultant, and management to examine the efficacy of Perrigo’s executive compensation program throughout the year.program. Details of the Committee’s authority and responsibilities are specified in the Committee’s charter, which may be accessed at http://perrigo.investorroom.com/corporate-governance.

Each year, the Committee reviews and approves the elements of compensation for all executive officers, including the named executive officers.NEOs. The Committee submits its recommendations regarding the Chief Executive Officer’sCEO’s compensation to the independent directors of the Board for approval.

To assist it in making compensation decisions, the Committee annually reviews compensation tally sheets that contain comprehensive historical, current and projected data on the total compensation and benefits package for each of our named executive officers. These tally sheets also includeNEOs. As needed,

LOGO26


Executive Compensation

additional analyses for various termination events are provided (including terminations with and without cause and for death, disability, retirement or following a change of control) so that the Committee can consider and understand the nature and magnitude of potential payouts and obligations under the various circumstances. These tally sheets, which areThe information is prepared by management and reviewed by FW Cook, generally containcontaining data that are substantially similar to the datathat contained in the tables on presented below.

The Role of Management. The Chief Executive OfficerCEO makes recommendations to the Committee regarding the compensation of all other executive officers for the Committee’s approval. The Chief Executive OfficerCEO does not participate in the deliberations of the Committee regarding his own compensation. Management is responsible for implementing the executive compensation program as approved by the Committee and the Board.

The Role of the Independent Consultant. For 2018,2020, the Committee continued to engage FW Cook as its independent remuneration consultant to provide advice on various aspects of our executive andnon-employee director compensation programs. Other than the support that it provided to the Committee, FW Cook provided no other services to the Company or Perrigo management.

The Role of Market Comparison Data.The Committee uses information provided by FW Cook regarding the compensation practices of select companies (the “Peer Group”), in addition to applicable broader market data, as one of the factorsan element in evaluating both the structure of our executive compensation program and target levels of compensation. Management also periodically reviews survey and industry data periodically from Mercer Human Resource Consulting,Willis Towers Watson, Aon Hewitt, the Korn Ferry Hay Group, and others regarding the market positioning for base salary, annual, and long-term incentive target levels for all employees, including executives. The Committee considers this information, together with the factors described above under “Our Executive Compensation Principles”, on page 25, in determining executive compensation.

For fiscal 2018,After our Boardapproved our consumer Self-Care strategy as outlined by our CEO in May 2019, the Committee undertook a reviewreviewed the 2019 Peer Group with the goal of the existing Peer Group.ensuring that it aligned with our stated transformational strategy. The Committee continued to focusfocused on comparably sized pharmaceutical and consumer goods companies, taking into account continued consolidation in the pharmaceutical industry, as well as Perrigo’s changingevolved Self-Care consumer strategy and core business focus. WithAs a result, the assistance of its independent consultant and management, the Committee considered additions and deletions to the existing Peer Group, and approved the below Peer Group for fiscal 2018 pay decisions, including their use as therTSR-PSU Peers for the 2018 grants. The Peer Group consists of 16peer group included 14 publicly-traded companies that arewere similarly sized with comparable customer and/or strategic business profiles:

 

Baxter International Inc.

Church & Dwight Co., Inc.

  Conagra Brands,

Clorox

Este Lauder

Nu Skin Enterprises

Reckitt Benckiser Group plc

TreeHouse Foods, Inc.

The Clorox Company

  

Endo International plc

Henry Schein, Inc.

Colgate-Palmolive

Helen of Troy

Post Holdings

Revlon

Edgewell Personal Care
Kimberly-Clark

Jazz Pharmaceuticals plcPrestige Consumer

Mallinckrodt plcMylan N.V.

Healthcare, Inc.

Patterson Companies,Spectrum Brands
Holdings, Inc.

Prestige Brands Holdings, Inc.Reckitt Benckiser Group plc

Shire plc

Spectrum Brands Holdings, Inc.TreeHouse Foods, Inc.

Zoetis Inc.

In establishing compensation levels for the named executive officers, theThe Committee does not focus exclusively on market comparisonbenchmarking data when making compensation decisions for positions with comparable responsibilities.the NEOs. Instead, that market data is one of many contributing factors and reference points that the Committee uses when determining appropriate compensation levels for each element of our program (salary, target annual, cash incentives, and equity-basedlong-term incentives) and for the combined sum of these elements. Although Perrigo does not specifically target a stated pay percentile objective, theThe Committee considers the 50th percentile of market data to be a valuablesalient indication of what is competitive in the market.market, though it does not specifically target a pay percentile.

27  2021 Proxy Statement


Executive Compensation

In addition to market comparison data, the Committee also considers an individual’s competencies, experience, and overall performance against measurable objectives; Company, segment, and divisiondivisional financial and strategic performance; and the aggregate costexpense and benefit of executive rewards to Perrigo. Ultimately, considerationConsideration of market comparison data in setting compensation levels is ultimately intended to ensure that our compensation practices are competitive in terms of attracting, motivating, rewarding and retaining executives.

executive leaders who can, and do, drive Perrigo’s long-term performance.

20182020 Executive Compensation Program in Detail

 

Base Salaries

 

  Name  FY2017 Base Salary     FY2018 Base Salary    

Murray S. Kessler

  N/A $1,200,000

Ronald L. Winowiecki*

  $400,000 $625,000

Todd W. Kingma

  $526,330 $545,000

Jeffrey R. Needham

  $507,500 $600,000

Svend Andersen**

  $500,000 $540,000

Uwe R. Roehrhoff***

  N/A $1,000,000

John T. Hendrickson***

  $900,000 $900,000
*

Appointed to CFO in February 2018, FY2018 value represents promotional base salary.
 NameFY2019 Base SalaryFY2020 Base Salary

 Murray S. Kessler

$1,200,000$1,236,000

 Raymond P. Silcock

$650,000$670,000

 Svend Andersen*

$617,875$656,177

 Todd Kingma

$561,000$578,000

 Rich Sorota

N/A$597,000

* Amounts paid in pounds sterling or euros were converted to U.S. dollars based on foreign exchange rates on the last day of the respective fiscal year.

**

Amounts paid in pounds sterling were converted to U.S. dollars based on foreign exchange rates on the last day of the respective fiscal year.

***

Mr. Roehrhoff left the Company on October 8, 2018, and Mr. Hendrickson left the Company on March 15, 2018.

The Committee approves base salaries for the named executive officersNEOs other than the CEO. For the CEO, the Committee submits its recommendation for the CEO base salary to the independent directors of the Board for approval. In approving a named executive officers’an NEOs’ base salary, the Committee may consider comparisons among positions internally and externally, proxy and survey data, performance against measurable financial and strategic objectives, job experience, and unique role responsibilities.responsibilities (in addition to any other data points determined to be relevant). To assist the Committee in this process, each year the CEO provides the Committee with base salary recommendations for each of the other named executive officers,NEOs, as well as summaries of such named executive officers’NEOs’ individual performance.

The named executive officers are eligible for annual salary increases based on an evaluation of individual performance and the market level of pay for comparable positions at other companies in the Peer Group. Named executive officers are also eligible for salary adjustments in the event of promotions or other changes/increases in role responsibilities.

For 2018, at the recommendation of the CEO,2020 the Committee approved increases in base salaries for the named executive officersNEOs, except Mr. Sorota, that were in line with other employees.the Company’s overall salary increase budget of 3%. Mr. Sorota’s increase was greater, reflecting his promotion to EVP & President, Consumer Self-Care Americas on March 23, 2020.

Annual Incentive Award Opportunities

The ManagementPerrigo Annual Incentive Bonus Plan (“MIB Plan”AIP”) is designed to motivate and reward the named executive officersemployees for achieving and exceeding specific, measurable, strategic and financial goals that support our objective of sustainably creating and increasing long-term shareholder value. Participants in the MIB PlanAIP include our named executive officers, otherexecutives, broader management-level personnel, and other eligible employees. Substantially all other employees participate in other annual incentive plans. MIB PlanAIP awards are paid in cash.cash following completion of the performance year.

Near the beginning of each annual performance period, theThe Board approves the financial plan for that year from whichnear the beginning of each annual performance period. The Committee determines and approves the performance target goals and payout schedules for the MIB Plan.AIP. These goals and individual bonusannual incentive targets, which are stated as a percentage of salary, are then communicated to the participants. The payout schedules reflect a range of potential award opportunities that are set around the targets. 

Individual performance goalsstrategic objectives were not a formulaic input for determining the bonus opportunity in 2018.2020. These individual strategic objectives of executive officers were focused on the execution of our consumer-focused Self-Care transformation strategy. However, to ensure that awards reflect a named executive officer’s contribution to

LOGO28


Executive Compensation

our results, the Committee has, or, in the case of the CEO, the independent directors have, the discretion to adjust any executive officer’s actual award down to as low as 0% payout based on overall individual performance. The maximum incentive award payout for any individual executive is capped at 200% of the target award opportunity.

Target Award Opportunity and Actual Payouts. The 2020 target AIP award opportunities (as a percentage of base salary) and actual payouts (as a percentage of target) for the NEOs are shown in the table below. The range of award opportunities is listed in the Grants of Plan-Based Awards for 2020 table on page 40.

Named Executive Officer2020 Target AIP
(as % of Salary)

2020 Actual AIP Payout

(as % of Target)

Mr. Kessler

125%124.83%

Mr. Silcock

80%118.83%

Mr. Andersen

65%98.49%

Mr. Kingma

65%122.83%

Mr. Sorota

65%122.95%

Earned awards can range from 0 to 200% of target based on actual performance against the pre-established goals. In addition, to ensure that awards reflect an executive officer’s contribution to our results, the Committee has, or in the case of the CEO, the independent directors have, the discretion to adjustreduce any named executive officer’s actual award up by as much as 50%, or down to as low as 0% payout0 based on individual performance, provided that, inperformance.

AIP Design. The Board approved the case of any upward adjustment, the maximum incentive award payout for any individual executive is capped at 200% of the target award opportunity.

Target Award Opportunity. The 2018 target MIB Plan award opportunities for the named executive officers are shown in the table below. The range of award opportunities is listed in the Grants of Plan-Based Awards for 2018 table on page 33.

  Named Executive Officer2018 Target Bonus
(as % of Salary)

Mr. Kessler

125%

Mr. Winowiecki

80%

Mr. Kingma

65%

Mr. Needham

65%

Mr. Andersen

65%

Mr. Roehrhoff*

125%

Mr. Hendrickson*

120%
*

Mr. Roehrhoff left the Company on October 8, 2018, and Mr. Hendrickson left the Company on March 15, 2018.

MIB Plan Design.Near2020 financial plan near the beginning of 2018, the Board approved the 2018 financial plan, from which the2020. The Committee determined and approved the performance target goals and payout schedules for the 20182020 Corporate and Segment MIB Plans. All Named Executive Officers participateLeader AIPs, which corresponded to the 2020 financial plan. Messrs. Kessler, Silcock, and Kingma participated in the Corporate MIB Plan, except for Business Segment Leaders who participateAIP, and Messrs. Andersen and Sorota participated in their respective Segment plans.

Eighty percent of each NEO’s AIP is tied to financial measures: Adjusted Operating Income (“Adj. OI”) at the corporate level (and for segment leaders, the segment level) and Days Working Capital (“DWC”) performance are weighted, for Corporate MIB, 80%corporate or segment revenue. “Corporate” OI and 20% DWC,revenue are based on the aggregate financial performance of our consumer businesses and for Segment MIB, 40%exclude the pharmaceutical segment, which we intend to divest. Twenty percent of each NEO’s AIP is tied to individual strategic objectives focused on the execution of our Self Care transformation strategy.

LOGO

29  2021 Proxy Statement


Executive Compensation

For purposes of the AIP, Corporate Revenue and Corporate Adj. OI 40% Segment OI,represented net sales and 20% DWC.adjusted operating income of our consumer businesses, excluding our pharmaceutical segment, which we are intending to divest.

Perrigo Company plc

CY 2018 MIB Plan2020 AIP Targets and Actual Results

 

       Threshold*  Target  Maximum  Actual
     (50% Payout)  (100% Payout)  (200% Payout)   
Corporate OI ($mil.)  $863.1  $1,078.9  $1,294.7  $900.8
  DWC  131.9 days  109.9 days  87.9 days  114.9
CHC Americas OI ($mil.)  $432.6  $540.8  $648.9  $475.4
  DWC  136.7 days  113.9 days  91.1 days  114.1
CHC Intl. OI ($mil.)  $197.7  $247.1  $296.5  $242.1
  DWC  126.7 days  105.6 days  84.5 days  105.6
   Consumer Adj. OI  Segment / Business Unit Adj. OI  Corp / Segment / BU Net Sales
Plan  Target  Actual  Metric Payout  Target  Actual  Metric Payout  Target  Actual  Metric Payout
Perrigo Corporate  $519  $546  125%  N/A  N/A  N/A  $4,024  $4,052  107%
CSC Americas  $519  $546  125%  $503  $519  116%  $2,635  $2,637  100%
CSC International  $519  $546  125%  $221  $212  90%  $1,458  $1,415  85%

Revenue Threshold/Max is 90%/110% performance for 50%/200% payout; OI Threshold/Max is 80%/120% performance for 50%/200% payout

* PerformancePayout for performance between levels is interpolated; payout for performance below the threshold level on each metric would result in no payout for that metric.

Under the MIB Plan,AIP, the Committee may adjust performance measures to prevent dilution or enlargement of awards by excluding the effects of, among other things, extraordinary, unusual or non-recurring items, asset impairments, and non-cash items. Perrigo’s adjusted MIB OIAIP Adjusted Operating Income performance for 20182020 was $900.8$546 million, which consisted of a $236.5millionprofit$293 million profit from operations as reported in our financial statements, plus $664.3million$253 million of net, non-operational adjustments reviewed and approved

by the Committee. These adjustments included $224.4million of asset impairments and $338.6million$210 million of amortization expense, as well as adjustments related primarily to unusual litigation charges, acquisition and integration related tocharges, restructuring charges, separation and reorganization expenses, acquisitions and divestitures not included in Perrigo’s original plan for 2018, restructuring charges, separation2020 and reorganization expense, and unusual litigation charges.currency.

Twenty percent (20%) of each NEO’s AIP payout is based on performance against pre-established, measurable individual strategic objectives. The independent directors in the case of the CEO, and the Committee in the case of the other named executive officers, haveNEOs, assessed each NEO against his individual goals and determined the ability to adjust individual MIBpayouts as a percentage of target, as laid out in the table below:

NEOPayout on Individual Strategic
Objectives Component
(% of Target)
Performance Summary

 Murray S. Kessler

150Successfully led the efforts to effectuate Perrigo’s Self-Care transformation, substantially strengthened organizational effectiveness and capabilities, and enhanced credibility with stakeholders.

 Raymond P. Silcock

120Simplified and transformed the global finance organization, continued to develop his team’s talent pipeline, and made progress in the transition of Perrigo from Healthcare to Consumer Self-Care.

 Svend Andersen

95Effectively allocated resources to accomplish CSCI sales growth, continued to implement strategies to enhance margins, and eliminated organizational complexity.

LOGO30


Executive Compensation

NEOPayout on Individual Strategic
Objectives Component
(% of Target)
Performance Summary

 Todd W. Kingma

140Effectively and efficiently managed critical risks, successfully supported self-care business transformation initiatives, and continued to drive a compliance-driven corporate culture.

 Richard S. Sorota

163Drove a cultural transformation within CSCA, successfully launched CPG2.0 transformation, drove long-term growth through strategic acquisitions and bolt-ons.

Messrs. Kessler, Silcock, and Kingma received payouts based on personal performance. Individual adjustments may be based on the assessmentoverall corporate financial results and attainment of personaltheir individual strategic objectives. Payouts for Messrs. Andersen and Sorota reflected corporate performance, segment performance contributionsand attainment of their individual strategic objectives. All payouts reflected the strong financial performance of Perrigo in 2020 in addition to business success and, in some cases, overall Company performance.

Messrs. Roehrhoff, Hendrickson, Winowiecki, and Kingma received the full payouts for which they were eligible based solely on overall corporate results, which were 64.7% of target, with Messrs. Roehrhoff and Hendrickson’s payouts prorated for the time they worked during the year. Payouts for Messrs. Needham and Andersen were 85% and 88% of target, respectively, reflecting the personal and business unit performance versus each of the goals. Payout for Mr. Kessler was 100% of target, prorated for the time worked during the year, reflecting the RemCo’s evaluation of his performance since being hired.

On February 13, 2019, the Company amended and restated the MIB Plan to (i) provide for increased flexibility in plan administration due to the elimination of the performance-based compensation exception under Section 162(m) of the Internal Revenue Code, (ii) provide the CEO the authority to grant incentive bonuses to non-executive employees, and (iii) authorize the Remuneration Committee and Board’s evaluation of performance relative to approve amendments to the plan.each individuals’ strategic objectives.

Long-Term Incentive Award Opportunities

Long-term stock-based compensation, awarded under our shareholder-approved LTI plan,Long-Term Incentive Plan (LTIP), is intended to motivate and reward executivesPerrigo employees, including the NEOs, for creating sustainable, shareholderlong-term value, as reflected in the total shareholder return of Perrigo’s ordinary shares.Perrigo stock. Awards under the LTI PlanLTIP may be in the form of incentive stock options,non-statutory stock options, stock appreciation rights or stock awards, including restricted shares or restricted sharestock units, or performance sharesstock or performance stock units. We provide long-term incentive opportunities to all eligible employees solely through stock-based awards.

As a variable component of compensation, the amount realized from stock-based compensation will vary based on the market pricelong-term performance of Perrigo’s ordinary shares. In addition performance-based restricted stock unitsto share price performance, PSUs are only earned if specific, measurable financial and/or market-based performanceperformance-conditioned goals are achieved.achieved over the applicable performance periods.

The Committee sets stock-based grantaward levels based onafter consideration of a named executive officers’an NEO’s position, review of market competitive reward and grant practices, and the aggregate expense impact to Perrigo. Grants to named executive officers are subject to the approval of the Committee and, in the case of the CEO, the independent directors.

During our regularly scheduled meetings in the first quarter of the calendar year, the independent directors approve all regular annual stock-based awards for the CEO, and the Committee approves all stock-based awards for the other named executive officers,NEOs, as well as the maximum potential total grants for other employee levels. All regular annual stock-based awards are granted on, and priced at,upon, the closing price of Perrigo’sPerrigo stock on the fifth trading day after Perrigo publicly releases itsyear-end earnings for the previous fiscal year.earnings.

Off-cycle stock-based awards may be granted at various times during the year to new hires or to existingnon-executive employees under special circumstances (e.g. promotions, retention, performance, etc.) through the shareholder-approved LTI Plan.LTIP. Though they rarely occur, Off-cycleoff-cycle stock-based awards may also be granted during the year to the executive officers other than the CEO with the approval of the Committee and to the

31  2021 Proxy Statement


Executive Compensation

CEO with the approval of the independent directors as permitted under the LTI Plan.LTIP. Such awards are priced at the closing price of Perrigo’s shares on the day the awards are granted. No such awards were granted to the NEOs in 2020.

2018-2020 LTI Grant Performance – Summary

The LTIP is designed to align executive rewards with Perrigo performance and investor expectations, and we believe it is working. When Perrigo’s performance did not meet our targets, LTIP awards paid below target. This means, ultimately, only 22% of the initial 2018-2020 LTIP award was realized at the time of vesting (see chart below)

2018 LTI Grant  % Vesting  % Realized

Total

  76%  22%

Options

  100%  0%

rTSR-PSUs

  0%  0%

ROTC-PSUs

  92%  44%

PSU Performance Cycles Ending in 2020

2018-2020 ROTC PSUs. 2020 was the last year of the three-year performance period for the 2018-2020 ROTC PSUs. Vesting credit for each of the three respective years was 0%, 124%, and 151%. The final vesting was 92% and was determined by averaging the vesting credit for each of the 3 years in the 3-year performance period.

2018-2020 rTSR PSUs. 2020 was the last year of the three-year performance period for the 2018-2020 rTSR PSUs. The Company’s relative TSR was below the 30th percentile versus the applicable peer group, and therefore no shares were earned under this award.

2018 LTI Plan Grants.2020 Regular Annual LTIP Awards. All of the named executive officers, with the exception of Messrs. Kessler and Hendrickson,NEOs received their target annual LTI PlanLTIP award grant for 2018,2020, which consisted of 50% ROTC-PSUsAdj. OI-PSUs that may be earned based on achievement of ROTCAdjusted Operating Income growth goals over three years,(from fiscal 2020 through fiscal 2022), 20% rTSR-PSUs that may be earned based on our rTSRRelative Total Shareholder Return (“rTSR”) performance versus peers over three years,the other companies in the S&P 500 from 2020 through 2022, and 30% stock optionsRSUs vesting over three years. In addition to the annual LTI plan awards provided in 2018, named executive officers received a retention award upon the hire of Murray Kessler as CEO. Mr. Kessler was given asign-on grant of stock options upon becoming CEO in October 2018, in order to align his compensation with the achievement of Perrigo’s strategic transformation. The table and chart below showsshow the LTI PlanLTIP award values granted in fiscal 20182020 for each of the named executive officers.NEOs.

 

Named Executive
Officer
 ROTC PSUs
At Target*
 rTSR PSUs
At Target*
 Stock
Options**
 RSUs*** Target Total Grant
Value

Mr. Kessler

 - - 110,074 - 2,500,000

Mr. Winowiecki

 8,817 3,527 17,084 8,585 2,125,000

Mr. Kingma

 8,229 3,292 15,945 7,486 1,945,000

Mr. Needham

 7,054 2,822 13,667 14,411 2,300,000

Mr. Andersen

 6,025 2,410 11,674 7,527 1,572,952

Mr. Roehrhoff

 37,237 14,895 72,149 5,721 6,854,485

Mr. Hendrickson

 - - - - 

LOGO

*
LOGO32


Award amounts for PSUs were determined based on the closing price of Perrigo ordinary shares on the date of grant.

Executive Compensation

 

**

Award amounts were calculated based on Black-Scholes values.

Named Executive Officer  

Adj. OI-PSUs

(50%)

  rTSR-PSUs
(20%)
  RSUs
(30%)
  Target Total Grant
Value (100%)

Mr. Kessler

  $3,875,000  $1,550,000  $2,325,000  $7,750,000

Mr. Silcock

  $1,000,000  $400,000  $600,000  $2,000,000

Mr. Andersen

  $700,000  $280,000  $420,000  $1,400,000

Mr. Kingma

  $700,000  $280,000  $420,000  $1,400,000

Mr. Sorota

  $700,000  $280,000  $420,000  $1,400,000

*Award amounts were determined based on the closing price of Perrigo ordinary shares on the date of grant.

***

RSU retention grant awarded on October 8, 2018; for Mr. Roehrhoff the value represents his award granted to him upon joining Perrigo in January 2018.

ROTCAdjusted Operating Income PSUs (Adj. OI-PSUs)

Fifty percent of each executive’s target annual grant value is in the form of ROTC-PSUs.Adj. OI-PSUs. The number of ROTC-PSUsAdj. OI-PSUs to be earned for the 20182020 grant is dependent on Perrigo’s average performance vest credit during three distinctthe three-year performance periods (for which a separate ROTC goal is established) as follows:period of January 1, 2020 through December 31, 2022.

·

January 1, 2018 through December 31, 2018;

·

January 1, 2019 through December 31, 2019; and

·

January 1, 2020 through December 31, 2020.

The Board sets challenging target ROTC goals based on each year’sthe annual financial plan. Earned awards, if any, can range from 0% to 200% of the target number of shares granted and will become 100% vested on March 8, 2021 (threevest and pay out approximately three years from the grant date).date, following certification of performance by the Committee.

The Committee selected ROTCAdj. OI as the applicable long-term performance measure for these PSUs because it measuresdirectly aligns with our ability to generate profits fromstated strategic long-term growth “3/5/7” objectives. For past Adj. OI-PSUs, the effective usegoals were set at the beginning of all tangible capital invested ineach year of the business. Tangible capitalthree-year performance period. Beginning with the 2020 Adj. OI-PSUs, goals for the three-year period are set up front as follows: the target goal for the first year of the three-year performance period is defined as Perrigo’s operating assets and liabilities excluding all acquisition-related

intangible assets and goodwill. ROTC is calculated by dividing Perrigo’s net operating profit after tax (“NOPAT”) by its tangible capital. Both managementbased on the Board-approved annual financial plan, and the Boardtarget goals for the second and third years of Directors regularly review both ROTCthe three-year performance period are determined by applying a pre-determined, and returnfixed, growth rate (+5%) over the prior year’s actual Adj. OI. This change was intended to increase the long-term performance focus of the program and align with our stated strategy.

The 2018 award, vesting based on invested capital (“ROIC”) to measure Perrigo’s ability to provide a return on all assets greater than its cost of capital. The ROIC calculation includes goodwill as well as intangible assets from acquisitions.

CY2018 Budget ROTC1

 

     

CY2018 Actual ROTC1

 

 

NOPAT

 

  

 

852.0

 

 

 

   

NOPAT

 

  

 

711.6

 

 

 

Tangible Capital

 

  

 

2,206.9

 

 

 

   

Tangible Capital

 

  

 

2,112.5

 

 

 

ROTC

 

  

 

38.6%

 

 

 

   

ROTC

 

  

 

33.7%

 

 

 

    
   

CY2016

 

  

CY2017

 

  

CY2018

 

 
  

Maximum (200% Vesting)

 

  

 

81.3

 

 

  

 

40.1

 

 

  

 

42.5

 

 

   
    

 

39.2

 

 

  
  

Target (Plan—100% Vesting)

 

  

 

73.9

 

 

  

 

36.5

 

 

  

 

38.6

 

 

  

Minimum (50% Vesting)

 

  

 

66.5

 

 

  

 

32.8

 

 

  

 

34.7

 

 

   
   

 

62.3

 

 

      

 

33.7

 

 

  

Performance Period Vesting Credit

 

  

 

0

 

 

  

 

173

 

 

  

 

0

 

 

  

 

a

 

 

 

  

 

b

 

 

 

  

 

c

 

 

 

   

Performance Vesting Credit for CY16 Grant2 (a+b+c)/3 =

 

      

 

58

 

 

 

1. Return on Tangible Capital = ROIC, excluding impact of goodwill, intangiblesfinal fiscal 2018, 2019, and related amortization and non-operating results, consistent with prior year's metric.

20182020 ROTC performance, of 33.7% resulted inhad an actual vesting credit of 0%92% of target for 2018, which will be relevant for any performance period that includes 2018.

With respect totarget. This was the ROTC-PSUs that vested following fiscal 2018, the vesting credits for fiscal 2018, fiscal 2017, and fiscal 2016 were 0%, 173%, and 0%, respectively,final outstanding award based on Perrigo’s financialannual ROTC performance. Given these percentages, the full three-year vesting credit for the PSUs granted in fiscal 2016 was 58% of target.

Information regarding fiscal 20162018 grant is included in footnote 4 to the Outstanding Equity Awards at 20182020 Year End table on page 34.The41. The actual number of restricted stock units that vested in 20182020 for each of our named executive officersNEOs is listed under Number of Shares Acquired on Vesting in the Option Exercises and Stock Vested in 20182020 table on page 35.42.

Theper-share accounting cost of the ROTC PSUs is based on the stock price on the grant date. The ultimate expense for the ROTC-PSUsPSUs is based on the number of shares actually earned and is accrued over the three-year performance period.

The grant date fair value, as calculated under the applicable accounting standard (FASB ASC Topic 718), for 2018 stock-based2020 share-based grants is presented in the Grants of Plan-Based Awards for 20182020 table on page 33.40.

Relative Total Shareholder Return (“rTSR”) PSUs

Twenty percent of each executive’s target annual grant value is in the form of rTSR PSUs. The number of rTSR PSUs to be earned for the 2020 grant is dependent on Perrigo’s rTSR performance versus the other companies in the S&P 500 over the three-year performance period of January 1, 2020 through December 31, 2022.

33  2021 Proxy Statement


Executive Compensation

The Committee approved the continued use of rTSR as thea performance metric with a three-year measurement period in the performance-based equity mix as a way of directly aligning the interests of the executive team with the long-term market performance of Perrigo’s shares. The 2018 award, vesting based on the 2018 to continue alignment2020 performance period, had an actual vesting credit of executive

compensation with long-term Company performance. The rTSR-PSUs account for 20%0% of each executive’s target and grant value.target. The Committee believes the rTSR PSUsuse of rTSR-PSUs in the LTILTIP mix further aligns executive interests with that of shareholders. The inclusion of rTSRrTSR-PSUs in the overall LTIP mix elevates the percentage of each executive’s annual LTI grantaward that is subject to measurable performance achievement, and also provides for a relative external performance metric to balance the internal performance metric of ROTC.Adj. OI growth.

TheFor the 2020 grant, the number of rTSR PSUsrTSR-PSUs that may be earned is based on our relative total shareholder return versus peer companies,the constituents of the S&P 500, measured cumulatively over the three-year performance period. Total shareholder return for Perrigo and the peer companies is calculated using an average of adjusted closing prices for the30-trading20-trading day periods starting on the first and ending on the last day of the performance period (January 1, 20182020 and December 31, 2020,2022, respectively, for the 2018-20202020 rTSR-PSUs). The Committee determined that the S&P 500 was an appropriate, less volatile, and more consistent rTSR PSUs).peer group to use for comparison purposes rather than the custom peer group. Earned shares can range from 0 to 200% of the target number of rTSR PSUs,rTSR-PSUs, as outlined in the following table.

 

2018-20202020-2022 Relative TSR Percentile Rank

  

Payout (% of Target Shares)

>= 80th Percentile

  

200%

55th Percentile

  

100%

30th Percentile

  

50%

<30th Percentile

  

0%

Payout for performance between levels is linearly interpolated. If our absolute TSR is negative, the maximum number of shares that may be earned is 100% of target, regardless of our relative performance. In addition, the overall earned value is capped at 500% of the target value. Total shareholder return for Perrigo and the peer companies is calculated using an average of adjusted closing prices for the 20-trading day periods starting on the first and ending on the last day of the performance period (January 1, 2020 and December 31, 2022, respectively, for the 2020 rTSR-PSUs).

Other Policies, Practices and Guidelines

Executive Stock Ownership Guidelines

Consistent with our compensation philosophy of tying a significant portion of the total compensation to performance, our executive compensation program facilitates and encourages long-term ownership of Perrigo stock. Our stock ownership guidelines reinforce that philosophy by requiring executive officers to maintain specific levels of stock ownership.

Each executive officer is required to attain certain target levels of stock ownership. These ownership guidelines are expressed in terms of a multiple of base salary. The current ownership guidelines are as follows:

 

Chief Executive Officer: 6 times base salary

Executive Vice President: 3 times base salary

Senior Vice President: 2 times base salary

·
  

Chief Executive Officer: 6 times base salary

LOGO
�� 34


·

Executive Compensation

 

Executive Vice President: 3 times base salary

·

Senior Vice President: 2 times base salary

For purposes of determining an executive officer’s stock ownership, at least fifty percent (50%) must consist of (i) shares purchased on the open market, (ii) shares owned jointly with a spouse and/or children, (iii) shares acquired through the exercise of stock options or vesting of restricted shares or restricted stock units,RSUs, or (iv) shares held through the Perrigo Company Profit-Sharing and Investment Plan. The balance of an executive officer’s stock ownership may be satisfied through (a) unvested butearned performance-based restricted stock sharesPSUs or restricted share unitsRSUs that have not been forfeited, and (b) unvested service-based restricted shares or restricted share unitsRSUs that have not been forfeited.

Until each executive officer attains the applicable target stock ownership level, he or she is required to retain a stated percentage of shares received through our incentive plans, including shares obtained through the exercise of stock options, vesting of restricted shares or RSUs, payout of performance sharesPSUs and any other vehicle through which the individual acquires shares. At any time that an executive’s direct stock ownership is below the required levels set forth above, (i) with respect to restricted shares and units, he or she is restricted from selling more than 50% of the net shares received following the vesting of any service-based or performance-based restricted sharesPSUs or restricted share unitsRSUs under any of the Company’s compensation plans, and (ii) with respect to stock options, he or she is restricted from selling more than 50% of the net value received upon the exercise of any stock option (i.e. after the cost of the option and taxes are remitted), such that at least 50% of the net value received upon the exercise of any stock option must be converted to directly owned shares. In these cases, however, the participants must still adhere to the retention requirements with respect to the remaining shares.

As of the end of 2018,2020, all of our executive officers, including our named executive officers,NEOs, were in compliance with these guidelines, either by satisfying applicable ownership levels or complying with the retention requirements.

Clawback Policy

Our MIB PlanAIP and 2019 LTIP (including in the LTIP grant documents for the LTI Plandocuments) include claw-back provisions that allow Perrigo to recover incentive compensation paid to an executive if Perrigo’s financial results are later restated due to the individual’s misconduct, including, without limitation, fraud or knowing illegal conduct.

Anti-Hedging and Anti-Pledging Policy

Our insider trading policy prohibits executive officers and directors from trading in options, warrants, puts and calls or similar instruments on Perrigo securities and holding Perrigo securities in margin accounts, as well as from pledging Perrigo securities as collateral for a loan. In addition, the policy prohibits our directors and all employees, including executive officers, from selling Perrigo securities “short,” engaging in “short sales against the box,” and entering into hedging or monetization transactions or similar arrangements with respect to Perrigo securities.

Compensation Risk Assessment

At the Committee’s request, FW Cook, the Committee’s independent consultant, conducted an assessment of Perrigo’s compensation policies and practices for 20182020 to determine whether any practices might encourage excessive risk taking on the part of executives. This assessment included a review of Perrigo’s pay philosophy, competitive position, annual incentive arrangements (including broad-based incentive plans, based on an inventory of such plans that management provided to FW Cook) and long-term incentive arrangements (including stock option, restricted stock unit and performance share unitPSU design, as well as potential mitigating factors such as stock ownership requirements, caps on incentive plan payouts, and recoupment policies).

35  2021 Proxy Statement


Executive Compensation

After considering FW Cook’s assessment, the Committee concluded that our compensation programs are designed and administered with the appropriate balance of risk and reward in relation to our overall business strategy and are not designed in such a way to encourage executives and employees to take unnecessary risks that would be reasonably likely to have a material adverse effect on Perrigo.

Benefits and Perquisites

Retirement Benefits.We offer retirement benefit plans to provide financial security and to facilitate employees’ saving for their retirement. We make annual contributions under our Profit Sharing Plan for employees, including the executive officers. We also make matching contributions up to the limits as defined in the applicable regulations under our 401(k) Plan to certain of our employees, including the named executive officers.NEOs.

Executive Perquisites.Benefits. We provide a limited number of perquisites to our named executive officers.NEOs. Benefits and perquisites may include supplemental long-term disability insurance premiums, executive physical exams, relocation benefits, pension emolument benefits and financial counseling/tax advice.

Non-Qualified Deferred Compensation Plan.We maintain aNon-Qualified Deferred Compensation Plan (the “Deferred Compensation Plan”) that allows certain executives, including the named executive officers,NEOs, and other management level personnel to voluntarily elect to defer base salary and earned annual incentive awards. Under that plan, we provide annual profit-sharing contributions and matching contributions that cannot be provided under Perrigo’s Profit-Sharing and Investment Plan (the“Tax-Qualified Plan”) because of the limitations of Sections 415 and 401(a)(17) of the Code. Code Section 415 limits the total annual additions to a participant’s account under theTax-Qualified Plan to a specified dollar amount, which was $55,000$57,000 for 2018.2020. Code Section 401(a)(17) limits total compensation that can be considered under theTax-Qualified Plan. This limit is currently $275,000.$285,000. Due to these limits, certain Perrigo employees would not receive profit-sharing contributions and matching contributions under theTax-Qualified Plan on their full compensation. Therefore, we provide affected employees who contribute to the Deferred Compensation Plan, including the named executive officers,NEOs, a company match and a profit sharingprofit-sharing contribution under the Deferred Compensation Plan that they would have been eligible for under theTax-Qualified Plan but for the limitations under the Code.

Employment Agreements (Severance Benefits)

We typically do not enter into employment agreements with our executives other than our CEO.CEO and non-U.S. executives, such as Mr. Andersen, where local laws require it. We entered into an employment agreement with Mr. Kessler when he was appointed as President and CEO in October 2018. The key compensation terms of this agreement are summarized below. In December 2019, based on Svend Andersen’s move to Belgium and based on Belgian law, we terminated Mr. Andersen’s U.K. agreement and replaced it with a Belgian agreement. The key compensation terms of Mr. Andersen’s agreement are also summarized below.

Post-employment payments under employment agreements, as applicable, and the CEO’s employment agreementExecutive Committee Severance Policy, are presented in the section entitled “Potential Payments Upon Termination or Change in Control” beginning on page 36.

In January 2018, we entered into an employment agreement with Uwe Roehrhoff in connection with his appointment as President and CEO.

Additionally, in January 2018, based on Svend Andersen’s move to the United Kingdom during 2018, and based on U.K. law, we entered into an employment contract with him. The key compensation terms of Mr. Andersen’s agreement are summarized below.43.

All other named executive officersNEOs, except Mr. Andersen, are subject to our Executive Committee Severance Policy in the event of termination other than for cause and not in connection with a change in control. Under this policy, executives terminated without cause or who resign for good reason would receive severance pay over 18 months in an amount equal to the one and a half times the sum of the eligible executive’s base salary and target bonus. This policy also provides for career transition assistance (capped at $25,000), an18-month waiver of COBRA premiums, and a pro rata bonus payment for the year in

which the termination occurs. The Executive Committee Severance Policy will terminate on January 15, 2020, after which time executive officers will be subject to our general severance policy.

Mr. Kessler

Mr. Kessler’s employment agreement became effective on October 8, 2018. Consistent with our emphasis on performance-based pay, the majority of Mr. Kessler’s annual compensation is stock-based with the ultimate

LOGO36


Executive Compensation

value realized based on Perrigo’s stock price performance. In accordance with his employment agreement, Mr. Kessler’s compensation includes: a base salary; participation in the MIB Plan;AIP; annual grants of equity under the LTI Plan;LTIP; and participation in Perrigo’s other employee benefit plans.

The employment agreement provides for an initial term of three years, subject to automatic renewal thereafter forone-year periods unless either party provides 180 days’ prior notice ofnon-renewal. The agreement contains customary confidentiality obligations,non-competition restrictions for two years from the date of termination of employment andnon-solicitation restrictions for two years from the date of termination of employment.

If Mr. Kessler were involuntarily terminated by us without cause or voluntarily terminated for good reason (as defined in the agreement), he would receive cash severance benefits and continued vesting of certain stock-based awards. The circumstances under which severance benefits are triggered and the resulting payouts are generally consistent with market practices.

On February 13, 2019, Mr. Kessler’s employment agreement was amended to avoid the unintended forfeiture of equity compensation if he were to retire after the initial three-year term of his contract. It now provides for accelerated vesting of awards granted under the LTIP (other than PSUs, which will vest or be forfeited based on the attainment of performance goals) so long as Mr. Kessler attains age 62 prior to his termination from employment.

On March 1, 2021, Perrigo Management Company (a subsidiary of the Company) signed an Amended and Restated Employment Agreement (the “Amended Agreement”) with Mr. Roehrhoff

Mr. Roehrhoff’s employment agreement became effective on January 15, 2018. Consistent with our emphasis on performance-based pay,Kessler to extend his term as CEO, President and member of the majorityBoard of Mr. Roehrhoff’s annual compensation was stock-based with the ultimate value realized based on Perrigo’s stock price performance. In accordance with his employment agreement, Mr. Roehrhoff’s compensation included: a base salary; participation in the MIB Plan; annual grants of equity under the LTI Plan; and participation in Perrigo’s other employee benefit plans.

The employment agreement providedDirectors for an initialadditional three-year period through October 8, 2024. The term of three years,remains subject to automatic renewal thereafter forone-year periods unless either party provided 180 days’ prior notice ofnon-renewal. The agreement contained customary confidentiality obligations,non-competition restrictions for two years from the date of termination of employment andnon-solicitation restrictions for two years from the date of termination of employment.

If Mr. Roehrhoff were involuntarily terminated by us without cause or voluntarily terminated for good reason (as defined in the agreement), he would have received cash severance benefits and continued vesting of certain stock-based awards. The circumstances under which severance benefits would have been triggered and the resulting payouts were generally consistent with market practices.

Mr. Hendrickson

Mr. Hendrickson’s employment agreement became effective on August 3, 2016. Consistent with our emphasis on performance-based pay, the majority of Mr. Hendrickson’s annual compensation is stock-based with the ultimate value realized based on Perrigo’s stock price performance. In accordance with his employment agreement, Mr. Hendrickson’s compensation included: a base salary; participation in the MIB Plan; annual grants of equity under the LTI Plan; and participation in Perrigo’s other employee benefit plans.

The employment agreement provided for an initial term of three years, subject to automatic renewal thereafter forone-year periods unless either party provides 180 days’ prior notice ofnon-renewal. The agreement contained customary confidentiality obligations,Amended Agreement maintains Mr. Kessler’s current salary and provides a target annual bonus opportunity of $1,545,000 in 2021 and not less than $1,745,000 in 2022 and future years. Beginning in 2022, the fair value of Mr. Kessler’s annual grant under the Long-Term Incentive Plan will be no less than $9,750,000. Under the Amended Agreement, a notice of non-competitionnon-renewal restrictionstimely sent by Perrigo Management Company will not be considered a Termination for two years fromseverance purposes.

Except as described above, the dateterms of termination of hisMr. Kessler’s ongoing employment andnon-solicitation restrictions for two years from the date of termination of his employment.

If Mr. Hendrickson were involuntarily terminated by us without cause or voluntarily terminated for good reason (as defined in the agreement), he would have received cash severance benefits and continued vesting of certain stock-based awards. The circumstances under which severance benefits would have been triggered and the resulting payouts are generally consistent with market practices.

In connection with the announcement that Mr. Hendrickson would be stepping down as CEO, we entered into an amendment to Mr. Hendrickson’s employment agreement on June 5, 2017 to ensure management continuity in a critical turnaround year. Mr. Hendrickson agreed to remain with the Company until his successor commenced employment, and for up to 60 days thereafter to assist in the transition (the “Transition Date”). The amendment provided that if Mr. Hendrickson remained employed through the Transition Date, he would be deemed to have been terminated without cause and would receive the separation payments and benefits to which he was otherwise entitled, which remainedmaterially unchanged from his prior agreement.Employment Agreement, dated October 8, 2018, as amended on February 13, 2019.

Mr. Andersen

Mr. Andersen’s employmentcurrent Belgian management agreement became effective on January 17, 2018.in December 2019. In accordance with his employmentmanagement agreement, Mr. Andersen’s compensation includes a base salary; participation in the MIB Plan;AIP; annual grants of equity under the LTI Plan;LTIP; and certain travel and relocation benefits.an additional fee to use for travel.

The employmentmanagement agreement has an indefinite term and will continue unless either partyMr. Andersen provides six months’ prior notice of termination or the Company provides three months’ prior notice of termination. The agreement contains confidentiality provisions as well asnon-competition andnon-solicitation provisions, for ranging from six monthsone year to one yeartwo years from the date of termination of his employment.agreement.

37  2021 Proxy Statement


Executive Compensation

Summary Compensation Table

The following table summarizes the compensation of our named executive officers for 2018, 2017,2020, 2019, and 2016.2018.

Summary Compensation Table

 

Name and Principal

Position

 Fiscal
Year
 Salary($) Bonus($)(1) Stock Awards($)(2) Option
Awards($)(3)
 Non-Equity
Incentive Plan
Compensation($)(4)
 All Other
Compensation($)(5)
 Total($)

Murray Kessler

 2018 277,692 950,000 - 2,500,001 349,315 25,822 4,102,830

Chief Executive Officer,

        

President(6)

        

Uwe Roehrhoff

 2018 425,000 527,383 4,954,158 1,900,405 619,122 3,504,268 11,930,336

Chief Executive Officer,

        

President(7)

        

John T. Hendrickson Chief

 2018 211,731 - - - 143,630 4,014,196 4,369,557

Executive Officer(8)

 2017 900,000 - 4,200,001 1,799,990 1,322,676 99,561 8,322,229
 2016 810,521 - 3,437,040 1,473,024 - 79,312 5,799,896

Ronald L. Winowiecki

 2018 621,875 250,000 1,674,969 449,993 323,500 39,520 3,359,857

Executive Vice President, Chief

 2017 479,137 116,698 735,074 164,995 509,444 27,699 2,033,047

Financial Officer

        

Todd W. Kingma

 2018 540,333 - 1,524,957 419,991 229,038 53,535 2,767,854

Executive Vice President, General

 2017 526,330 - 918,781 393,746 418,988 67,458 2,325,303

Counsel and Secretary

 2016 522,498 - 875,016 374,989 - 92,434 1,864,937

Jeffrey R. Needham

 2018 576,875 - 1,940,068 359,989 331,500 47,794 3,256,225

Executive Vice President,

 2017 507,500 - 639,391 274,056 403,998 45,324 1,870,269

Consumer Healthcare

 2016 505,625 - 608,932 260,998 170,000 52,869 1,598,424

Svend Andersen

 2018 534,124 - 1,265,447 307,493 308,880 30,622 2,446,566
Executive Vice President,
President Consumer Healthcare International(9)
        
Name and Principal Position 

Fiscal

Year

 Salary($) Bonus($)(1) 

Stock

Awards($)(2)

 

Option

Awards($)(3)

 

Non-Equity

Incentive Plan

Compensation($)(4)

 

All Other

Compensation($)(5)

 Total($)

Murray S. Kessler

Chief Executive Officer,

President

 2020 1,219,500  7,749,982  1,928,593 69,155 10,967,230
 2019 1,200,000  7,750,010  1,791,436 66,326 10,807,772
 2018 277,692 950,000  2,500,001 349,315 25,822 4,102,830

Raymond P. Silcock

Executive Vice

 2020 664,625  1,999,974  636,443 58,378 3,359,420
 2019 500,000 500,000 2,000,033  471,775 8,400 3,480,208

Svend Andersen(6)

Executive Vice President,

President Consumer

Healthcare

 2020 651,400  1,400,048  366,614 103,849 2,521,911
 2019 646,704  1,399,985  398,390 32,394 2,477,473
 2018 534,124  1,265,447 307,493 308,880 30,622 2,446,566

Todd W. Kingma

Executive Vice

President, General

 2020 573,981  1,400,048  461,617 62,566 2,498,212
 2019 557,263  1,399,985  435,498 82,647 2,475,393
 2018 540,333  1,524,957 419,991 229,038 53,535 2,767,854

Richard S. Sorota

Executive Vice President,

President Consumer

Healthcare America

 2020 599,823  1,400,048  477,096 23,415 2,500,382

1) Represents any cash bonus with the exception of the Annual Bonus (captured in the column“Non-Equity Incentive Plan Compensation”): for Mr. Kessler, asign-on bonus of $950,000 in 2018; and for Mr. Roehrhoff,Silcock, asign-on sign on bonus of €425,000$500,000 in 2018 (converted using a foreign currency exchange rate on February 19, 2018); for Mr. Winowiecki, a retention award of $66,968 and a promotion award of $50,000 in 2017 and a bonus of $250,000 in 2018, six months after he was appointed Chief Financial Officer.2019.

2) Represents the full grant date fair value of stock awards granted in the years shown, calculated in accordance with U.S. GAAP. Stock awards include service-based restricted stock units and performance-based restricted stock units. For the performance-based stock awards, the amounts reported were valued using the closing market price of our ordinary shares on the date of grant assuming payout at target performance of 100% (the probable outcome of the relevant performance conditions as of the grant date). See the Grants of Plan-Based Awards for 20182020 table for additional information regarding the full grant date fair value for all stock awards. Additional weighted average valuation assumptions related to stock awards are included in the stockholders’ equity note of the audited financial statements included in our Annual Report on Form10-K for the fiscal years ended December 31, 2018,2020, December 31, 20172019 and December 31, 2016.2018.

3) Represents the full grant date fair value of stock options granted in the fiscal years shown, calculated in accordance with U.S. GAAP.

Stock options were valued using the Black-Scholes model. Additional weighted average valuation assumptions related to option awards are included in the stockholders’ equity note of the audited financial statements included in our Annual Reports on Form10-K for the fiscal yearsyear ended December 31, 2018, December 31, 2017 and December 31, 2016.2020.

4) The compensation amounts set forth in the“Non-Equity Incentive Plan Compensation” column represent the ManagementAnnual Incentive BonusPlan bonus earned for the relevant fiscal year period as described in the Compensation Discussion and Analysis section entitled 20182020 Executive Compensation Program in Detail – Annual Incentive Award Opportunities.

5) The following table discloses the compensation amounts set forth in the “All Other Compensation” column of the Summary Compensation Table:Summary:

 

Name 

Perquisites and

Other Personal
Benefits ($)(1)

  

Registrant

Contributions
to Defined

Contribution
Plans ($ )(2)

  

Registrant

Contributions
to Non-Qualified
Plans

  

Executive

Long-Term
Disability ($)(3)

  

Payments in

Regard to
Termination of
Employment ($)(4)

  Total ($) 

Murray Kessler

  19,822   6,000   -   -    25,822 

Uwe Roehrhoff

  118,232   8,250   -   2,786   3,375,000   3,504,268 

John T. Hendrickson

  -   14,730   38,158   1,307   3,960,000   4,014,196 

Ronald Winowiecki

  -   16,503   18,784   4,233    39,520 

Todd W. Kingma

  15,772   16,503   15,526   5,734    53,535 

Jeffrey R. Needham

  -   16,503   24,682   6,609    47,794 

Svend Andersen(5)

  12,762   17,860   -   -    30,622 
LOGO38


Executive Compensation

All Other Compensation Detail

Name  

Perquisites

and Other

Personal

Benefits ($)(1)

  

Registrant

Contributions

to Defined

Contribution

Plans ($)(2)

  

Registrant

Contributions to

Non-Qualified

Plans

  

Executive

Long-Term

Disability ($)(3)

  Total ($)

Murray S. Kessler

  $14,126  $16,950  $38,079  $—  $69,155

Raymond P. Silcock

  $19,828  $16,950  $21,600  $—  $58,378

Svend Andersen(4)

  $103,849  $—  $—  $—  $103,849

Todd W. Kingma

  $15,238  $16,950  $30,378  $—  $62,566

Richard S. Sorota

  $5,343  $16,710  $—  $1,362  $23,415

1) For Mr. Kingma,Kessler, represents an allowance for tax/executive physical reimbursement and a financial planning services.advice benefit. For Mr. KesslerSilcock, Mr. Kingma and Mr. Roehrhoff,Sorota, represents a relocation reimbursement.financial advice benefit. For Mr. Andersen, represents a car allowance.contractual management fee.

2) Represents the Company’s contributions to 401(k) and Profit-Sharing Plans. For Mr. Andersen represents a monthly tapered pension emolument of £1,166.25.

3) Represents executive long-term disability plan premiums paid by the Company.

4) Represents executive severance payment.

5) Amounts paid to Mr. Andersen were converted from pounds sterling to U.S. dollars based on foreign currency exchange rates on December 31, 2018.2020.

6) Mr. Kessler was appointed on October 8, 2018.

7) Mr. Roehrhoff served as Chief Executive Officer from January 15, 2018 through October 18, 2018.

8) Mr. Hendrickson ceased to be the Chief Executive Officer on January 15, 2018 and left the Company on March 15, 2018.

9) Amounts paid to Mr. Andersen were converted from pounds sterling to U.S. dollars based on the foreign currency exchange raterates on December 31, 2018.2020.

39  2021 Proxy Statement


Executive Compensation

Grants of Plan-Based Awards for 20182020

The following table provides information regarding equity andnon-equity awards granted to the named executive officers during 2018.2020.

 

           Estimated Possible Payouts Under Non-
Equity Incentive Plan Awards(3)
  Estimated Possible Payouts Under
Equity Incentive Plans 
(4)
  All Other Stock
Awards (#) (5)
  All Other Option
Awards: Number of
Securities
Underlying

Options(#) (6)
  Exercise or Base
Price of Option

Awards ($/Sh)
  Grant Date Fair
Value of Stock
and Option

Awards($) (7)
 

Name

 Grant Date (1)  Award Date (2)  Threshold ($)  Target ($)  Maximum ($)  Threshold (#)  Target (#)  Maximum (#) 

Murray Kessler

  10/8/2018    -   750,000   1,500,000   3,000,000   -   -   -   -   -   -   - 
  10/8/2018    10/4/2018   -   -   -   -   -   -   -   110,074   72.80   2,500,001 

Uwe Roehrhoff

  3/8/2018    -   625,000   1,250,000   2,500,000   -   -   -   -   -   -   - 
  1/16/2018    1/15/2018   -   -   -   -   -   -   5,721   -   -   519,810 
  3/8/2018   (8 )    2/14/2018   -   -   -   7,448   14,895   29,790   -   -   -   1,266,969 
  3/8/2018   (9 )    2/14/2018   -   -   -   18,619   37,237   74,474   -   -   -   3,167,379 
  3/8/2018    2/14/2018   -   -   -   -   -   -   -   72,149   85.06   1,900,621 

John T. Hendrickson

  3/8/2018    -   540,000   1,080,000   2,160,000   -   -   -   -   -   -   - 

Ronald L. Winowiecki

  3/8/2018    -   250,000   500,000   1,000,000   -   -   -   -   -   -   - 
  3/8/2018   (8 )    2/14/2018   -   -   -   1,764   3,527   7,054   -   -   -   300,007 
  3/8/2018   (9 )    2/14/2018   -   -   -   4,409   8,817   17,634   -   -   -   749,974 
  3/8/2018    2/14/2018   -   -   -   -   -   -    17,084   85.06   450,044 
  10/8/2018    10/4/2018   -   -   -   -   -   -   8,585   -   -   624,988 

Todd W. Kingma

  3/8/2018    -   177,125   354,250   708,500   -   -   -   -   -   -   - 
  3/8/2018   (8 )    2/14/2018   -   -   -   1,317   3,292   6,584   -   -   -   280,018 
  3/8/2018   (9 )    2/14/2018   -   -   -   3,292   8,229   16,458   -   -   -   699,959 
  3/8/2018    2/14/2018   -   -   -   -   -   -    15,945   85.06   420,039 
  10/8/2018    10/4/2018   -   -   -   -   -   -   7,486   -   -   544,981 

Jeffrey R. Needham

  3/8/2018    -   195,000   390,000   780,000   -   -   -   -   -   -   - 
  3/8/2018   (8 )    2/14/2018   -   -   -   1,411   2,822   5,644   -   -   -   240,039 
  3/8/2018   (9 )    2/14/2018   -   -   -   3,527   7,054   14,108   -   -   -   600,013 
  3/8/2018    2/14/2018   -   -   -   -   -   -   -   13,667   85.06   360,030 
  4/2/2018    2/14/2018   -   -   -   -   -   -   6,169   -   -   499,997 
  10/8/2018    10/4/2018   -   -   -   -   -   -   8,242   -   -   600,018 

Svend Andersen

  3/8/2018    -   173,590   347,181   694,361   -   -   -   -   -   -   - 
  3/8/2018   (8 )    2/14/2018   -   -   -   1,205   2,410   4,820   -   -   -   204,995 
  3/8/2018   (9 )    2/14/2018   -   -   -   3,013   6,025   12,050   -   -   -   512,487 
  3/8/2018    2/14/2018   -   -   -   -   -   -    11,674   85.06   307,528 
  10/8/2018    10/4/2018   -   -   -   -   -   -   7,527   -   -   547,966 
      Estimated Future Payouts Under
Non-Equity Incentive Plan
Awards(3)
 Estimated Future Payouts
Under Equity Incentive
Plans(4)
 

All
Other
Stock
Awards

# of
units(5)

 

 

All Other
Option
Awards:
Number of
Securities
Underlying

Options(#)(6)

 

 

Exercise
or Base
Price of
Option

Awards
($/Sh)

 

 

Grant Date
Fair Value
of Stock
and Option

Awards($)(7)

 

 Name Grant
Date(1)
 Award
Date(2)
 Threshold
($)
 Target
($)
 Maximum
($)
 Threshold
(#)
 Target
(#)
 Maximum
(#)
 Murray S. Kessler   772,500 1,545,000 3,090,000       
  3/5/2020(8) 2/19/2020    14,060 28,120 56,240    1,549,974
  3/5/2020(9) 2/19/2020    35,151 70,301 140,602    3,874,991
  3/5/2020 2/19/2020       42,181   2,325,017
 Raymond P. Silcock   267,800 535,600 1,071,200       
  3/5/2020(8) 2/19/2020    3,629 7,257 14,514    399,996
  3/5/2020(9) 2/19/2020    9,071 18,142 36,284    1,000,016
  3/5/2020 2/19/2020       10,885   600,020
 Svend Andersen   186,121 372,242 744,484       
  3/5/2020(8) 2/19/2020    2,540 5,080 10,160    280,010
  3/5/2020(9) 2/19/2020    6,350 12,700 25,400    700,024
  3/5/2020 2/19/2020       7,620   420,014
 Todd W. Kingma   187,795 375,590 751,179       
  3/5/2020(8) 2/19/2020    2,540 5,080 10,160    280,010
  3/5/2020(9) 2/19/2020    6,350 12,700 25,400    700,024
  3/5/2020 2/19/2020       7,620   420,014
 Richard S. Sorota   194,025 388,050 776,100       
  3/5/2020(8) 2/19/2020    2,540 5,080 10,160    280,010
  3/5/2020(9) 2/19/2020    6,350 12,700 25,400    700,024
  3/5/2020 2/19/2020       7,620   420,014

1) Actual date of grant.

2) Date on which the Remuneration Committee approved the award.

3) These columns show the dollar range of potential payout for fiscal 20182020 performance under the ManagementAnnual Incentive Bonus Plan as described in the section titled 20182020 Executive Compensation Program in Detail in the Compensation Discussion and Analysis. The target values are based on a percentage of each executive’s salary. The maximum incentive award opportunity for any individual participant was 200% of the target award. In addition, the Remuneration Committee, or the Board in the case of the CEO, had the discretion to adjust any named executive officer’s award up by as much as 50% or down by as much as 100% based on individual performance. The actual payments for fiscal 20182020 non-equity incentive awards are shown in the Summary Compensation Table in the column titled“Non-Equity Incentive Plan Compensation.”

4) These columns show the range of performance-based restricted stock units that were granted in fiscal 20182020 and that could be earned in fiscal 20212023 under the LTIP, depending on whether specific performance goals are achieved in each of the three applicable performance periods, as described in the section titled 20182020 Executive Compensation Program in Detail-Long-termDetail — Long-term Incentive Award Opportunities in the Compensation Discussion and Analysis. Earned awards, if any, can range from 0% to 200% of the target grant. The U.S. GAAP value of the 20182020 fiscal performance-based restricted stock units granted on March 8, 20185, 2020 was $85.06$55.12 per share. These awards, to the extent earned, vest three years from the grant date.

5) This column shows the service-based restricted stock units granted during 2018. Mr. Winowiecki, Mr. Kingma, Mr. Needham and Mr. Andersen2020. These award vest in three equal installments on each received a retention equity award on October 8, 2018. Each of these awards vest fully one year from the grant date. Mr. Needham received an additional award on April 2, 2018, which vests on December 31, 2019. Also, Mr. Roherhoff received asign-on award on January 16, 2018 that vested, prorated, upon his departure.anniversary.

6) This column shows thenon-qualifiedNo stock options were granted during 2018 under the LTIP as described in the section titled 2018 Executive Compensation Program in Detail-Long-term Incentive Award Opportunities in the Compensation Discussion and Analysis. The Black- Scholes value of the 2018 fiscal yearnon-qualified stock options granted on March 8, 2018 was $26.343 per option. Annual awards vest ratably over three years beginning on the first anniversary of the grant date. On October 8, 2018, Mr. Kessler received asign-on bonus of stock options that becomes fully vested and exercisable on the third anniversary of the grant date. The Black-Scholes value of this award was $22.712 per option.2020.

7) Amounts are computed in accordance with U.S. GAAP and are included in the Summary Compensation Table in the applicable columns titled “Stock Awards” and “Option Awards.” For performance-based restricted stock units, the amounts disclosed are computed based on a target performance of 100%, which is the probable outcome of the relevant performance conditions as of the grant date.

8) Grant of rTSR performance-based restricted stock units.

9) Grant of ROTCOI performance-based restricted stock units.

LOGO40


Executive Compensation

Outstanding Equity Awards at 20182020 Year End

The following table sets forth information detailing the outstanding equity awards held at December 31, 20182020 by each of our named executive officers.NEOs.

 

     Option Awards  Stock Awards

        Name         

 Option /
Stock Award
Grant Date (1)
  Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable (2)
 Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable (2)
 Option
Exercise
Price ($)
  Option
Expiration
Date
  Number of
Units of Stock
That Have Not
Vested (#)
 Market
Value of
Units of
Stock That
Have Not
Vested ($) (3)
 Equity Incentive
Plan Awards:
Number of
Unearned Units
That Have Not
Vested (#)(4)
 Equity Incentive Plan
Awards: Market or
Payout Value of
Unearned Units
That Have

Not Vested ($) (3)

Murray Kessler

  10/8/2018  - 110,074  72.80   10/8/2028  - - - -

Uwe Roehrhoff

  3/8/2018  - 72,149  85.06   3/8/2028  - - - -

John T. Hendrickson

  8/22/2013  2,394 -  119.78   8/22/2023  - - - -
  8/21/2014  7,133 -  147.75   8/21/2024  - - - -
  2/26/2016  21,943 -  129.23   2/26/2026  - - 5,610 217,401
  6/21/2016  26,968 -  96.45   6/21/2026  - - 7,247 280,803
  6/6/2017  92,293 -  70.34   06/06/2027  - - 55,872 2,165,021

Ronald L. Winowiecki

  8/23/2012  902 -  108.62   8/23/2022  - - - -
  8/22/2013  1,066 -  119.78   8/22/2023  - - - -
  8/21/2014  1,230 -  147.75   8/21/2024  - - - -
  6/29/2015  - -  -   -  818 (7) 31,698 - -
  2/26/2016  1,834 917  129.23   2/26/2026  485 (6) 18,794 704 27,262
  6/6/2017  2,820 5,640  70.34   06/06/2027  - - 5,122 198,481
  7/21/2017  - -  -   -  2,296 (8) 88,970 - -
  3/8/2018  - 17,084  85.06   3/8/2028  - - 9,434 365,583
  10/8/2018  - -  -   -  8,585 (9) 332,669  

Todd W. Kingma

  8/19/2010  8,952 -  58.82   8/18/2020  - - - -
  8/23/2011  10,064 -  90.65   8/23/2021  - - - -
  8/23/2012  8,576 -  108.62   8/23/2022  - - - -
  8/22/2013  7,182 -  119.78   8/22/2023  - - - -
  8/21/2014  7,133 -  147.75   8/21/2024  - - - -
  6/29/2015  - -  -   -  2,987 (5) 115,746 - -
  2/26/2016  7,314 3,657  129.23   2/26/2026  1,935 (6) 74,981 2,805 108,689
  6/6/2017  6,730 13,459  70.34   06/06/2027  - - 12,222 473,614
  3/8/2018  - 5,315  85.06   3/8/2028  - - 8,805 341,210
  10/8/2018  - -  -   -  7,486 (9) 290,083 - -

Jeffrey R. Needham

  8/23/2012  1,962 -  108.62   8/23/2022  - - - -
  8/22/2013  4,163 -  119.78   8/22/2023  - - - -
  8/21/2014  6,029 -  147.75   8/21/2024  - - - -
  6/29/2015  - -  -   -  2,322 (5) 89,978 - -
  2/26/2016  5,091 2,545  129.23   2/26/2026  1,346 (6) 52,158 1,952 75,651
  6/6/2017  4,684 9,368  70.34   06/06/2027  - - 8,506 329,593
  3/8/2018  - 13,667  85.06   3/8/2028  - - 7,548 292,492
  4/2/2018  - -  -   -  6,169(10) 239,049 - -
  10/8/2018  - -  -   -  8,242 (9) 319,378 - -

Svend Andersen

  6/6/2017  4,359 8,716  70.34   06/06/2027  - - 7,915 306,715
  3/8/2018  - 11,674  85.06   3/8/2028  - - 6,447 249,812
  10/8/2018  - -  -   -  7,527 (9) 291,671 - -
    Option Awards Stock Awards
 Name Option /
Stock
Award Grant
Date(1)
 Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable(2)
 Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable(2)
 Option
Exercise
Price ($)
 Option
Expiration
Date
 Number of
Units of
Stock That
Have Not
Vested (#)
 Market
Value of
Units of
Stock That
Have Not
Vested ($)(3)
 Equity
Incentive Plan
Awards:
Number of
Unearned
Units That
Have Not
Vested (#)(4)
 Equity
Incentive Plan
Awards:
Market or
Payout Value
of Unearned
Units That
Have Not
Vested ($)(3)

 Murray S. Kessler

 10/8/2018 0 110,074 72.80 10/8/2028 0 0 0 0
 3/6/2019 0 0   32,769 1,465,430 152,106 6,802,180
 3/5/2020 0 0   42,181 1,886,334 151,147 6,759,294

 Raymond P. Silcock

 4/5/2019 0 0   7,927 354,495 36,795 1,645,472
 3/5/2020 0 0   10,885 486,777 39,006 1,744,348

 Svend Andersen

 6/6/2017 13,075 0 70.34 6/6/2027 0 0 0 0
 3/8/2018 7,783 3,891 85.06 3/8/2028 0 0 7,933 354,764
 3/6/2019 0 0   5,919 264,698 27,477 1,228,771
 3/5/2020 0 0   7,620 340,766 27,305 1,221,080

 Todd W . Kingma

 8/23/2011 10,064 0 90.65 8/23/2021 0 0 0 0
 8/23/2012 8,576 0 108.62 8/23/2022 0 0 0 0
 8/22/2013 7,182 0 119.78 8/22/2023 0 0 0 0
 8/21/2014 7,133 0 147.75 8/21/2024 0 0 0 0
 2/26/2016 10,971 0 129.23 2/26/2026 0 0 0 0
 6/6/2017 20,189 0 70.34 6/6/2027 0 0 0 0
 3/8/2018 10,630 5,315 85.06 3/8/2028 0 0 10,835 484,541
 3/6/2019 0 0   5,919 264,698 27,477 1,228,771
 3/5/2020 0 0   7,620 340,766 27,305 1,221,080

 Richard S. Sorota

 3/5/2020 0 0   7,620 340,766 27,305 1,221,080

1) For better understanding of this table, this column has been added to show the grant date of all stock options and equity awards outstanding at fiscal year end.year-end.

2) All stock option awards vestone-third per year over three years beginning on the anniversary of the grant date, except the option award granted to Mr. Kessler, which vests 100% on the third anniversary of the date of grant.

3) The market value of these unvested awards was calculated using the closing price of our ordinary shares as of December 31, 2018,2020, which was $38.75.$44.72.

4) Performance-based restricted stock units are earned and vest, if at all, three years from the grant date, depending on our performance over three full years for the fiscal 2018, 2019 and 2020 grants, as more fully described in the section entitled 20182020 Executive Compensation Program in Detail-Long-TermDetail — Long-Term Incentive Award Opportunities in the Compensation

Discussion and Analysis. As of December 31, 2018, the number of unearned units for the 2016 award was calculated using vesting credits of    0%, 173% and 0% for 2016, 2017 and 2018, respectively; the number of unearned units for the 2017 award was calculated using vesting credits 173% and 0% for 2017 and 2018, respectively, and assuming 100% for 2019;2020, the number of unearned units for the 2018 award was calculated using a vesting creditcredits of 0%, 124% and 151% for 2018, 2019 and assuming 100%2020, respectively, the number of unearned units for the 2019 award was calculated using vesting credits of 112% and 125% for 2019 and 2020.2020, respectively, and assuming 200% for 2021: the number of unearned units for the 2020 award was calculated using vesting credits of 125% for 2020, and assuming 200% for 2021 and 2022.

5) Service-based restricted stock units cliff vest on the fifth anniversary of the grant date.

6) Service-based restricted stock units cliff vest on the third anniversary of the grant date.41  2021 Proxy Statement

7) Service-based restricted stock units vest 50% on each of the third and fifth anniversaries of the grant date.


Executive Compensation

8) Service-based restricted stock units vest 50% on each of the first and second anniversaries of the grant date.

9) Service-based restricted stock units vest on the first anniversay of the grant date.

10) Service-based restricted stock units vest on December 31, 2019.

Option Exercises and Stock Vested in 20182020

The following table provides information for each named executive officerNEO concerning the vesting of restricted stock during 2018.2020. No named executive officerNEO exercised options in 2018.2020.

 

   Stock Awards

Name

  Number of Shares
Acquired on
Vesting (#)(1)
  Value Realized on
Vesting ($)(2)

Murray Kessler

  -  -

Uwe Roehrhoff

  2,092  152,298

John Hendrickson

  14,243  1,175,241

Ronald Winowiecki

  4,891  375,460

Todd W. Kingma

  4,961  398,626

Jeffrey R. Needham

  1,858  135,467

Svend Andersen

  -  -
   Stock Awards
 Name  Number of Shares Acquired
on Vesting (#)(1)
  Value Realized 
on Vesting ($)(2) 
 Murray S. Kessler  16,385  871,190
 Raymond P. Silcock  3,964  175,843
 Svend Andersen  10,427  554,404
 Todd W. Kingma  17,477  933,404
 Richard S. Sorota  0  0

1) Represents service-based restricted stock and units and performance-based restricted stock units issued under the LTIP.

2) The value realized on vesting was calculated using the closing price of Perrigo shares on the day the awards vested.

Non-Qualified Deferred Compensation in 20182020

The Deferred Compensation Plan allows participants to defer as much as 80% of base salary and 100% of incentive compensation. Participation in the plan is limited to the executive officers (including the named executive officers)NEOs) and other management level personnel. Amounts deferred under the Deferred Compensation Plan earn a return based on measurement funds made available to participants, which are determined by the Retirement Plan Committee. These measurement funds mirror the investment choices available in our 401(k) Plan, with the exception of Company stock, which is not an investment option in the Deferred Compensation Plan. Participants elect the form and timing of distributions of their Deferred Compensation Plan deferrals prior to the year in which it is deferred. Participants may change their distribution elections, however, changes must be made 12 months in advance and are subject to a five yearfive-year delay. Participants may electin-service distributions to be paid in a lump sum up to five annual installments;in-service deferrals must remain in the Deferred Compensation Plan for at least three years prior to distribution. Participants may elect to receive their retirement/termination distributions in a lump sum or annual installments (up to 15 years) upon separation from service. If a participant’sin-service distribution was not paid prior to a separation from service, thein-service distribution will be paid according to their retirement/termination distribution election. All participants with an account balance subject to Section 409A of the Internal Revenue

Code may not begin receiving retirement/termination distributions earlier than the first day of the seventh month following a separation from service.

The following table sets forth information relating to the Deferred Compensation Plan.

 

Name Executive Contributions
in Last FY ($) (1)
  Perrigo Contributions
in Last FY ($) (2)
  Aggregate Earnings
(Losses) in Last FY ($)
  Aggregate
Withdrawals/
Distributions ($)
  Aggregate Balance
at Last FYE ($) (3)

Murray Kessler

  -   -   -   -  -

Uwe Roehrhoff

  12,590   -   (1,185  -  11,405

John T. Hendrickson

  396,803   38,158   76,201   2,154,230  -

Ronald L. Winowiecki

  220,642   18,784   (7,237  -  448,437

Todd W. Kingma

  94,604   15,526   (46,566  -  1,838,833

Jeffrey R. Needham

  49,044   24,682   (83,655  -  1,409,931

Svend Andersen

  -   -   -   -  -
 Name  Executive
Contributions
in Last FY ($)(1)
  Perrigo
Contributions
in Last FY ($)(2)
  Aggregate
Earnings
(Losses) in Last
FY ($)*
  Aggregate
Withdrawals/
Distributions ($)
  Aggregate  
Balance at  
Last FYE ($)(3)  
 Murray S. Kessler    38,079.45  20,489.71    90,816.05
 Raymond P. Silcock    21,600.00  8,826.33    30,426.33
 Svend Andersen          
 Todd W. Kingma  55,029.48  30,378.04  50,368.03    2,278,227.93
 Richard S. Sorota          

1) Of the total amounts shown in this column, the following amounts are included in the Summary Compensation Table as 20182020 salary: Mr. Roehrhoff, $12,590; Mr. Winowiecki, $93,281; Mr. Kingma, $10,807; and Mr. Needham, $28,844;$11,479.68; and the following additional amounts are included for 20182020 in the Summary Compensation Table in the column entitledNon-Equity Incentive Plan Compensation: Mr. Hendrickson, $396,803; Mr. Winowiecki, $127,361; Mr. Kingma, $83,797; and Mr. Needham $20,200.$43,549.80.

2) These amounts are included in the Summary Compensation Table as All Other Compensation.Compensation in the column “Registrant Contributions to Non-Qualified Plans”.

3) In addition to the amounts in footnote 1, this column includes the following amounts included in the Summary Compensation Table in the columns entitled (i) Salary (for fiscal year 2017)2019): Mr. Hendrickson, $90,000; Mr. Kingma, $10,527; Mr. Needham, $25,374;$11,145.24; (ii)Non-Equity Incentive Plan Compensation (for fiscal year 2017)2019): Mr. Winowiecki, $8,635; Mr. Needham, $8,500; (iii)Kingma, $22,903.80; (i) Salary (for fiscal year 2016)2018): Mr. Hendrickson, $243,156; Mr. Kingma, $10,450; Mr. Needham, $25,281; (iv)$10,807; (ii) Non-Equity Incentive Plan Compensation (for fiscal year 2016)2018): Mr. Hendrickson, $52,746; Mr. Winowiecki, $5,963; Mr. Kingma, $23,920; Mr. Needham, $6,014; (v) Salary (for$83,797.

*We do not pay above-market or preferential interest or earnings on amounts deferred under the 2015 stub period): Mr. Hendrickson, $55,075; Mr. Kingma, $5,035; Mr. Needham, $12,400; (vi)Non-Equity Incentive PlanDeferred Compensation (for the 2015 stub period): Mr. Hendrickson, $88,774; Mr. Winowiecki, $15,391; Mr. Kingma, $58,962; Mr. Needham, $14,056.Plan.

LOGO42


 Potential Payments Upon Termination or Change in Control

Potential Payments Upon Termination or Change in Control

All of our current named executive officersNEOs participate in our MIB PlanAIP and LTI PlanLTIP and have the ability to participate in our Deferred Compensation Plan. In addition, all of our current named executive officers,NEOs, other than Mr. Kessler and Mr. Andersen, are covered by our U.S. Severance Policy, our Change in Control Severance Policy for U.S. Employees, and our Executive Committee Severance Policy. Mr. Andersen is covered onlythrough January 15, 2020, by our Executive Committee Severance Policy. These plans and policies may require us to provide compensation to these officers in the event of a termination of employment or achange-in-control of Perrigo. Mr. Kessler’s agreement provides that he would receive compensation under his employment agreement in the event of a termination of employment or achange-in-control of Perrigo; however, any severance benefits payable under that agreement will only occur in the event of a termination of employment that, when following achange-in-control of Perrigo, results in a “double trigger” for severance benefits. The Remuneration Committee retains discretion to provide additional benefits to executive officers upon termination or resignation if it determines the circumstances so warrant.

The following table sets forth the expected benefits to be received by each current named executive officer,NEO, in addition to the amounts shown in theNon-Qualified Deferred Compensation in 20182020 table on page 35in42 in the event of his termination resulting from various scenarios and assuming a termination date of December 31, 2018,2020, the last business day of 2018,2020, and a stock price of $87.16our$44.72our closing stock

price on that date. Assumptions and explanations of the numbers included in the table below are set forth in the footnotes to, and in additional text following, the table.

 

Name and Benefits Change in Control ($) Death, Disability,
Retirement ($)
 Termination for
Cause or Without
Good Reason ($)
 Termination
Without Cause or
for Good Reason ($)
 Involuntary
Termination for
Economic Reasons ($)
   Change in
Control(1) ($)
  Death,
Disability,
Retirement(2) ($)
  Termination for
Cause or Without
Good Reason ($)
  Termination
Without
Cause or for Good
Reason(3) ($)
  Involuntary 
Termination 
for Economic 
Reasons(3) ($) 

Murray Kessler

     

Murray S. Kessler

          

Cash Severance(1)

 5,400,000   -   -  4,050,000  4,050,000   5,562,000      4,171,500  4,171,500

Equity Awards(2)

               

Service-Based Restricted Stock

  -   -   -   -   -   3,351,764  3,351,764    2,723,001  2,723,001

Performance-Based Restricted Stock

  -   -   -   -   -   9,530,503  2,833,236    2,833,236  2,833,236

Stock Options

  -   -   -   -   -           

Other Benefits

  -   -   -   -   -   0      0  0
 

 

 

   

 

Total Estimated Incremental Value

 5,400,000   -   -  4,050,000  4,050,000   18,444,267      9,727,736  9,727,736
 

 

 

   

 

Ronald L. Winowiecki

     

Cash Severance(3)

 2,250,000   -   -  1,687,500  1,687,500 

Raymond P. Silcock

          

Cash Severance

  1,339,000      669,500  669,500

Equity Awards

               

Service-Based Restricted Stock

 472,130  472,130   -  472,130  472,130   841,273  841,273    679,028  679,028

Performance-Based Restricted Stock(4)

 737,451  591,326   -  591,326  591,326 

Performance-Based Restricted Stock

  2,376,600  685,379    685,379  685,379

Stock Options

  -   -   -   -   -           

Other Benefits(5)

 25,000   -   -  25,000  25,000 

Other Benefits(4)

  25,000      25,000  25,000
 

 

 

   

 

Total Estimated Incremental Value

 3,484,581  1,063,456   -  2,775,956  2,775,956   4,581,872  1,526,651    2,058,907  2,058,907
 

 

 

   

 

Todd W. Kingma

     

Cash Severance(3)

 1,798,500   -   -  1,348,875  1,348,875 

Equity Awards

    -   

Service-Based Restricted Stock

 480,810  480,810   -  480,810  480,810 

Performance-Based Restricted Stock(4)

 1,139,986  923,514   -  923,514  923,514 

Stock Options

  -   -   -   -   - 

Other Benefits(5)

 25,000   -   -  25,000  25,000 
 

 

 

 

Total Estimated Incremental Value

 3,444,296  1,404,324   -  2,778,199  2,778,199 
 

 

 

 

Jeffrey R. Needham

     

Cash Severance(3)

 1,980,000   -   -  1,485,000  1,485,000 

Equity Awards

     

Service-Based Restricted Stock

 700,561  700,561   -  700,561  700,561 

Performance-Based Restricted Stock(4)

 865,365  697,736   -  697,736  697,736 

Stock Options

  -   -   -   -   - 

Other Benefits(5)

 25,000   -   -  25,000  25,000 
 

 

 

 

Total Estimated Incremental Value

 3,570,926  1,398,297   -  2,908,297  2,908,297 
 

 

 

 

Svend Andersen

     

Cash Severance(3)

 1,762,610   -   -  1,321,957  1,321,957 

Equity Awards

     

Service-Based Restricted Stock

 291,671  291,671   -  291,671  291,671 

Performance-Based Restricted Stock(4)

 654,643  556,526   -  556,526  556,526 

Stock Options

  -   -   -   -   - 

Other Benefits(5)

 25,000   -   -  25,000  25,000 
 

 

 

 

Total Estimated Incremental Value

 2,733,923  848,198   -  2,195,155  2,195,155 
 

 

 

 

43  2021 Proxy Statement


Potential Payments Upon Termination or Change in Control

 Name and Benefits  Change in
Control(1) ($)
  Death,
Disability,
Retirement(2) ($)
  Termination for
Cause or Without
Good Reason ($)
  Termination
Without
Cause or for Good
Reason(3) ($)
  Involuntary 
Termination 
for Economic 
Reasons(3) ($) 

 Svend Andersen

          

Cash Severance

  1,145,360      572,680  572,680

Equity Awards

          

Service-Based Restricted Stock

  605,464  605,464    491,875  491,875

Performance-Based Restricted Stock

  2,098,888  730,948    730,948  730,948

Stock Options

          

Other Benefits

  0      0  0
  

 

Total Estimated Incremental Value

  3,849,713  1,336,412    1,795,504  1,795,504
  

 

 Todd W. Kingma

          

Cash Severance

  1,155,660      577,830  577,830

Equity Awards

          

Service-Based Restricted Stock

  605,464  605,464    491,875  491,875

Performance-Based Restricted Stock

  2,236,894  811,131    811,131  811,131

Stock Options

          

Other Benefits(4)

  25,000      25,000  25,000
  

 

Total Estimated Incremental Value

  4,023,018  1,416,595    1,905,837  1,905,837
  

 

 Richard S. Sorota

          

Cash Severance

  1,194,000      597,000  597,000

Equity Awards

          

Service-Based Restricted Stock

  340,766  340,766    227,178  227,178

Performance-Based Restricted Stock

  795,122  0    0  0

Stock Options

          

Other Benefits(4)

  25,000      25,000  25,000
  

 

Total Estimated Incremental Value

  2,354,888  340,766    849,178  849,178
  

 

1) Mr. Kessler will receive cash severance representing two timesIn the sumevent of (a) salary and (b) target bonus, and a pro rata bonus payment he would have received for the fiscal year if he experiences a qualifying termination in connection with a change in control. If termination is without cause or for good reason, or involuntary termination for economic reasons, Mr Kesslercontrol, all NEOs will receive the double of the standard cash severance representing onetreatment and half times the sum of (a) salary and (b)immediate vesting on all equity vehicles (value at target bonus, and a pro rata bonus payment he would have received for the fiscal year in which his termination occurs.PSUs).

2) Since being appointed, Mr. Kessler has only received asign-on option award. UnderIn the event of death, disability or retirement, all termination scenarios, basedNEOs will receive immediate vesting on the share price on December 31, 2018, all the options would be underwater and have nopay-out value.equity vehicles (actual performance for PSUs).

3) Mr. Winowiecki, Mr. Kingma, Mr. Needham and Mr. Andersen will receive cash severance representing the sum of (a) two times the salary they would have received for the fiscal year if they had received the standard severance policy treatment (currently one times salary) and (b) two times the target bonus, and a prorated bonus payment for the actual payout they would have received if they experience a qualifying termination in connection with a change in control. Mr. Winowiecki, Mr. Kingma, Mr. Needham and Mr Andersen will receive cash severance representing one and a half times the sum of (a) annual salary and (b) target bonus, and a prorated bonus for the actual payout they would have received if employment inIn the event of termination without cause or involuntary termination for economic reasons.

4) Performance-based restricted stock units were valuedreasons, Mr. Kessler’s and Mr. Andersen’s severance treatment is determined by their respective agreements; Mr. Silcock’s, Mr. Kingma’s and Mr. Sorota’s by the Perrigo Company plc U.S. Severance Policy Amended and Restated Effective February 13, 2019. RSUs, PSUs and NQSOs will continue to vest for 24 months under their original vesting schedule. PSUs will vest based on vesting creditsactual performance at the end of 0%, 173% and 0% for 2016, 2017 and 2018, respectively. The 2017 and 2018 full three-year vesting credit used a targetthe original performance of 100% for performance in any future fiscal year.periods.

5)4) Other benefits include outplacement/career transition services up to $25,000 for Messrs. Winowiecki,Mr. Silcock, Mr. Kingma Needham and Andersen.Mr. Sorota.

Employment Agreement with Chief Executive Officer

Mr. Kessler’s employment agreement provided that his employment may be terminated during the term of the agreement under the following circumstances:

 

 ·  

upon Mr. Kessler’s death or disability;

 ·  

by Perrigo with or without cause (as defined in the agreement);

LOGO44


Potential Payments Upon Termination or Change in Control

 ·  

by mutual agreement; or

 ·  

by Mr. Kessler with good reason (as defined in the agreement).

If during the term of this agreement Mr. Kessler’s employment were terminated by us without cause or by him for good reason and he agrees to a release of claims against Perrigo, he would also be entitled to compensation and benefits earned to that date, as well as:

 

 ·  

a prorated annual bonus for the year of termination (determined based on actual performance);

 ·  

payment of an amount equal to 18 months of his then-current salary and target bonus, payable in a lump sum;

 ·  

a payment of health insurance premiums for 18 months, but only if Mr. Kessler is not entitled to health insurance coverage from another employer-provided plan; and

 ·  

continued vesting for a period of 24 months of all equity incentive awards granted to him, and in the case of performance-based restricted stock,PSUs, based on actual Company performance, provided that any portion of such awards that does not vest pursuant to the above is forfeited and no option may be exercised later than the expiration of the option term as specified in the award agreement.

If any such termination without cause or for good reason were to occur within 24 months following a change of control, Mr. Kessler would be entitled to the same benefits as listed above, except he would be entitled to:

 

 ·  

a cash payment of an amount equal to 24 months of his then-current salary and target bonus rather than 18 months;

 ·  

a cash payment equal to the cost of health insurance premiums for six months; and

 ·  

immediate vesting of all equity incentive awards granted to him, and in the case of performance-based restricted stock,PSUs, based on “target” levels of achievement.

If Mr. Kessler were terminated for cause, he would receive compensation and benefits earned to date, including payment for unused vacation days. If Mr. Kessler’s employment were terminated for death or disability, he would receive compensation and benefits earned to date, including payment for unused vacation days, as well as a prorated annual bonus for the year of termination (determined based on actual performance).

Payments Under the ManagementAnnual Incentive Bonus Plan

Generally, no portion of the payments under the MIB PlanAIP is considered earned or payable for a particular year unless the named executive officerNEO is employed by us and in good standing on the last day of the fiscal year. The MIB Plan,AIP, however, may require us to make payments to named executive

officersNEOs who are no longer employed by us on the last day of the fiscal year under the following circumstances:

 

 ·  

retirement at age 65 or older;

 ·  

retirement at age 60 or older with at least 10 years of service;

 ·  

early retirement of a named executive officer under an early retirement plan;

 ·  

permanent disability as determined by the Remuneration Committee; or

 ·  

death.

45  2021 Proxy Statement


Potential Payments Upon Termination or Change in Control

Under all circumstances listed above, the namedNEO, or the executive officer, or hisofficer’s estate in the case of death, will be entitled to a pro rata portion of any payment under the MIB PlanAIP for that fiscal year, computed to the date of the termination.

A named executive officerAn NEO eligible to receive a post-termination payment under the MIB PlanAIP will be paid in a lump sum within a reasonable time after the close of the fiscal year in which termination occurred.

Payments Under the Long-Term Incentive Plan

If a named executive officeran NEO terminates employment with us due to death, disability or retirement, histhe executive officer’s (i) outstanding options will immediately vest in full, (ii) service-vesting restricted stock units (RSUs) will be free of any restriction period; and (iii) performance-vesting restricted stock units (PSUs)PSUs will vest or be forfeited based on the attainment of performance goals. The outstanding options may be exercised in whole or in part by the participant or hishis/her fiduciary, beneficiary or conservator, as applicable, at any time prior to their respective expiration dates.

If a named executive officeran NEO is involuntarily terminated for economic reasons, hethe executive officer may exercise histhe executive officer’s options, to the extent vested, at any time prior to the earlier of (i) the date that is 30 days after the date that is 24 months after the termination date, or (ii) their respective expiration dates. Any options, RSUs and PSUs that are not vested on the termination date, but are scheduled to vest during the24-month period following the termination date, according to the vesting schedule in effect before termination, will vest as if the participant had continued to provide services to us during the24-month period. Any unvested options, RSUs and PSUs that are not scheduled to vest during that24-month period will be forfeited on the termination date. If a named executive officeran NEO who is involuntarily terminated for economic reasons should die while histhe executive officer’s options remain exercisable, the fiduciary of the namedNEO’s estate or the executive officer’s estate or his beneficiary may exercise the options (to the extent that those options were vested and exercisable prior to the named executive officer’s death) at any time prior to the later of the date that is (i) 30 days after the date that is 24 months after the named executive officer’sNEO’s termination date, or (ii) 12 months after the date of death, but in no event later than the respective expiration dates of the options.

Upon an event of termination for any reason during the restriction period, restricted shares and restricted stock units still subject to restriction generally will be forfeited by the named executive officerNEO and reacquired by Perrigo. Subject to theone-year minimum vesting requirements of the LTI Plan,LTIP, we may in our sole discretion waive in whole or in part any or all remaining restrictions with regard to a named executive officer’san NEO’s shares.

If a named executive officeran NEO is terminated for cause, any restricted shares or restricted stock units subject to a restriction period will be forfeited and histhe executive officer’s right to exercise histhe executive officer’s options will terminate. If

within 60 days after a named executive officeran NEO is terminated for any reason, we discover circumstances that would have permitted us to terminate a named executive officeran NEO for cause, any shares, cash or other property paid or delivered to the named executive officerNEO within 60 days of such termination date will be forfeited and the named executive officerNEO must repay those amounts to Perrigo.

If the named executive officerNEO is terminated for any reason other than those described above, the named executive officerNEO will have the right to exercise histhe executive officer’s options at any time prior to the earlier of (i) the date that is three months after the termination date, or (ii) their respective expiration dates, but only to the extent that those options were vested prior to the termination date. Any options or RSUs and PSUs that are not vested at the termination date will be forfeited on the termination date. If a named executive officeran NEO dies after the termination date while histhe executive

LOGO46


Potential Payments Upon Termination or Change in Control

officer’s options remain exercisable and the termination was not due to death, disability, retirement or an involuntary termination for cause or due to economic reasons, the fiduciary of the namedNEO’s estate or the executive officer’s estate or his beneficiary may exercise the options (to the extent that those options were vested and exercisable prior to the executive officer’s death) at any time prior to the earlier of (i) 12 months after the date of death, or (ii) their respective expiration dates.

Regardless of the vesting requirements that otherwise apply to an award under the LTI PlanLTIP as described above, in the event of a change in control (as defined in the LTI Plan)LTIP), options and RSUs outstanding under the LTI PlanLTIP as of the date of the change in control that have not vested will become vested and the options will become fully exercisable. The restrictions and deferral limitations applicable to any restricted shares and units will lapse and such restricted shares and service-vesting RSUs will become free of all restrictions and limitations and will become fully vested and transferable. In addition, upon a change in control, all performance awards will be considered to be earned and payable in full, and any deferral or other restriction will lapse, and the performance awards will be immediately settled and distributed. The restrictions and deferral limitations and other conditions applicable to any other stock unit awards or any other awards will lapse, and those other stock unit awards and other awards will become free of all restrictions, limitations or conditions and will become fully vested and transferable to the full extent of the original grant.

The above discussion described the default rules applicable to awards. The Remuneration Committee has the discretion to establish different terms and conditions relating to the effect of the named executive officer’sNEO’s termination date on awards under the LTI Plan.LTIP.

Payments Under theNon-Qualified Deferred Compensation Plan

If a named executive officeran NEO is terminated for any reason other than death, he or shethe executive officer will receive a termination benefit under the Deferred Compensation Plan equal to histhe executive officer’s vested account balance. TheNon-Qualified Deferred Compensation in 20182020 table on page 3642 reflects account balances as of the end of 2018.2020.

This termination benefit will be paid to the named executive officerNEO in a lump sum or under an annual installment method of up to 15 years, based on the named executive officer’sNEO’s choice when he or shethe executive officer began participation in the plan or as he or shethe executive officer subsequently changed the election. If the named executive officerNEO did not make an election with respect to method of payment for a termination benefit, he or shethe executive officer will be deemed to have elected to be paid in a lump sum. A lump sum payment of the termination benefit will be made, or annual installments will commence, as of the first day of the seventh month following the date the namedNEO terminates the executive officer terminates hisofficer’s employment with us.

A named executive officer’sAn NEO’s beneficiary will receive a survivor benefit equal to the named executive officer’sNEO’s vested account balance if the namedNEO dies before the executive officer dies before he or she commences payment under the Deferred Compensation Plan. The survivor benefit will be paid to the named executive officer’sNEO’s beneficiary in a lump sum payment as soon as administratively practicable, but in no event later than the last day of the calendar year in which the named executive officer’sNEO’s death occurs or, if later, by the 15th day of the third month following the named executive officer’sNEO’s death.

47  2021 Proxy Statement


Potential Payments Upon Termination or Change in Control

Payments Under the Change in Control Severance Policy for U.S. Employees

On February 13, 2019, we amended and restated our broad-based Change in Control Severance Policy for U.S. Employees to modify the definition of change in control thereunder as it pertains to a change in incumbent directors. As amended, any director whose initial assumption of office was in connection with an actual or threatened proxy solicitation may nonetheless be deemed an incumbent director following such time as such director has been both (i) recommended by our Nominating & Governance Committee for election as a director of the Company and (ii) elected by the Company’s shareholders to serve on the Board of Directors of the Company at three successive annual general meetings.

The change in control policy provides that upon a qualifying termination of employment within two years following a change in control, a named executive officer (other than the CEO)CEO and non-U.S. NEO), would receive a lump sum severance payment equal to two times the sum of histhe executive officer’s base salary and target bonus opportunity, and a prorated annual bonus for the year of termination, based on actual performance.

In addition, the named executive officerNEO would receive payment of health insurance premiums for 18 months, followed by a cash payment equal to the cost of such premiums for another six months, but only if he or shethe executive officer is not otherwise entitled to health insurance coverage under another employer-provided plan.

Payments Under the U.S. Severance Policy

On February 13, 2019, we amended and restated our broad-based severance policy for U.S. employees to modify the definition of change in control thereunder as it pertains to a change in incumbent directors. As amended, any director whose initial assumption of office was in connection with an actual or threatened proxy solicitation may nonetheless be deemed an incumbent director following such time as such director has been both (i) recommended by our Nominating & Governance Committee for election as a director of the Company and (ii) elected by the Company’s shareholders to serve on the Board of Directors of the Company at three successive annual general meetings.

Our broad based severance policy provides that, upon a qualifying termination of employment not within two years following a change in control, an eligible named executive officer, other than the CEO and non-U.S. NEO, would receive a severance payment equal to 52 weeks of histhe executive officer’s base salary, payable in installments, and a pro rata bonus payment for the year in which the termination occurs, based on actual performance.

In addition, the named executive officerNEO would receive payment of health insurance premiums for 12 months, but only if he or shethe executive officer is not entitled to health insurance coverage under another employer-provided plan.

Payments Under the Executive Committee Severance Policy

On October 8, 2018, our Board approved aone-year extension of our Executive Committee Severance Policy, which applies to terminations of employment not in connection with a change in control. On

February 13, 2019, we amended and restated the policy to reflect the extension and to modify the definition of change in control thereunder as it pertains to a change in incumbent directors. As amended, any director whose initial

LOGO48


Potential Payments Upon Termination or Change in Control

assumption of office was in connection with an actual or threatened proxy solicitation may nonetheless be deemed an incumbent director following such time as such director has been both (i) recommended by our Nominating & Governance Committee for election as a director of the Company and (ii) elected by the Company’s shareholders to serve on the Board of Directors of the Company at three successive annual general meetings.

The policy providesprovided that, upon a termination of employment without “cause” or a resignation for “good reason” between June 14, 2017 and January 15, 2020, eligible executive officers (Mr. Kessler is not eligible) would receive severance pay over 18 months in an amount equal to one and a half times the sum of the eligible executive’s base salary and target bonus. The executive officer would also be eligible to receive a pro rata bonus payment for the year in which the termination occurs, based on actual performance, and up to $25,000 of career transition assistance. During the severance period, we will pay the executive officer’s COBRA premiums if the executive officer is based in the U.S. The policy will terminateterminated on January 15, 2020. During the term of the2020 by its terms. While this policy was in effect, to the extent more favorable, executive officers who are U.S. or Belgian employees (other than Mr. Kessler) will receivewould have received payments and benefits under thethis policy instead of the payments and benefits that would have been provided under our other severance arrangements (including the U.S. Severance Policy).

Payments to Former CEOs in Connection with Resignations

In connection with his resignation, Mr. Hendrickson received separation payments and benefits consistent with a termination without cause, as provided under his employment agreement, as amended. This included $3,960,000 in cash related to base salary and target bonus; $24,231 in lieu of accrued vacation; and $2,154,230 in previously earned compensation he had deferred.

In connection with his resignation, Mr. Roehrhoff received separation payments and benefits consistent with a termination without cause, as provided under his employment agreement, including $3,375,000 in cash related to base salary and target bonus.49  2021 Proxy Statement


Remuneration Committee Report

Remuneration Committee Report

The Remuneration Committee of our Board of Directors consists of threefour directors, each of whom is independent, as defined under SEC rules and the NYSE standards.

The Remuneration Committee has reviewed and discussed the “Compensation Discussion and Analysis” with management. Based on the review and discussions, the Remuneration Committee recommended to the Board of Directors that the “Compensation Discussion and Analysis” be included in this proxy statement and incorporated by reference into Perrigo’s Annual Report on Form10-K for the fiscal year ended December 31, 2018.2020.

THE REMUNERATION COMMITTEE

THE REMUNERATION COMMITTEE
Jeffrey B. Kindler, Chair
Bradley A. Alford
Orlando D. Ashford
Erica L. Mann

Jeffrey B. Kindler, Chair

Bradley A. Alford

Theodore R. Samuels

Equity Compensation Plan Information

The table below provides information about Perrigo’s ordinary shares that may be issued upon the exercise of options and rights under all of our equity compensation plans as of December 31, 2018.2020. Shareholder-approved plans include our LTI Plan,LTIP, as well as our Employee Stock Option Plan andNon-Qualified Stock Option Plan for Directors, which were replaced by our LTI Plan.LTIP.

 

  (a)  (b)  (c)

Plan Category

 Number of
securities to be
issued upon
exercise of
outstanding
options, warrants
and rights
 Weighted-average
exercise price of
outstanding options,
warrants and rights
 Number of
securities
remaining available
for future issuance
under equity
compensation
plans (excluding
securities reflected
in column (a))
   Number of securities
to be issued upon
exercise of
outstanding options,
warrants and rights
  Weighted-average
exercise price of
outstanding
options, warrants
and rights
  Number of securities
remaining available
for future issuance
under equity
compensation plans
(excluding securities
reflected in column
(a))

Equity compensation plans approved by shareholders

 2,744,905  (1)   $91.56  2,827,510 (2)    2,744,905(1)  $91.56  4,847,595(2)

Equity compensation plans not approved by shareholders

  -   -   -       
 

 

  

 

  

 

 

Total

 2,744,905    $91.56  2,827,510    2,744,905  $91.56  4,847,595

1) Of these shares, 1,523,957 were subject tonon-qualified stock options, 722,918 were subject to unvested restricted stock units and 498,030 were subject to unvested performance-based stock units at target.

2) All of these shares were available for issuance under our LTI Plan.LTIP.

LOGO50


 CEO Pay Ratio

CEO Pay Ratio

The CEO pay ratio was calculated in accordance with SEC rules and requirements. We identified our median employee in 20172019 using target total cash compensation (base salary plus target bonus) for all individuals, excluding the CEO, who were employed by us on December 31, 2017.2019. We believe target total cash compensation is an appropriate consistently-appliedconsistently applied compensation measure by which to identify our median paid employee. We excluded 512505 individuals in the following jurisdictions because they represent less than 5% of our total employee population: Estonia,India, China, Hungary, Poland, Latvia,Czech Republic, Turkey, Slovenia, Hungary, Czech, Turkey,Ukraine, Slovakia, Serbia, Romania, Serbia, Slovakia, India, KazakhstanBulgaria, Hong Kong, and Ukraine.Latvia. We included all other employees, whether employed on a full- or part-time basis, or seasonally. We did not make any assumptions, and we did not make any adjustments.

Since there were no significant changes in Perrigo’s employee population, we are permitted, and have chosen, to use the same median employee for the 20182020 CEO pay ratio calculation.calculation as 2019. We calculated total compensation for such employee using the same methodology we use for our named executive officers as set forth in the 20182020 Summary Compensation Table in this proxy statement. The total compensation of the median-paid employee, excluding the CEO, was $70,888 $93,355for 2018. During 2018, Perrigo had three CEOs. Perrigo chose to annualize the compensation of Mr. Kessler, who was serving in that role on December 31, 2018, the pay ratio determination date.2020. The annualized Compensation for our CEO for 2018in 2020 was $6,187,041.$10,967,230. Therefore, the ratio of CEO pay to median employee pay was 87:117:1.

This information involves reasonable estimates based on employee payroll records and other relevant company information. In addition, SEC rules for identifying the median employee and determining the CEO pay ratio permit companies to employ a wide range of methodologies, estimates and assumptions. As a result, the CEO pay ratios reported by other companies, which may have employed other permitted methodologies or assumptions, and which may have a significantly different work force structure from ours, are likely not comparable to our CEO pay ratio.

51  2021 Proxy Statement


Audit Committee Report

Audit Committee Report

The Audit Committee of the Board is responsible for monitoring:monitoring the following, including their related risks: (1) Perrigo’s accounting and financial reporting principles and policies; (2) the integrity of Perrigo’s financial statements and the independent audit thereof; (3) Perrigo’s compliance with legal and regulatory requirements; (4) the qualifications, independence and performance of Perrigo’s independent registered public accounting firm; (5) the qualifications and performance of Perrigo’s internal audit function including where the service is outsourced and (6) Perrigo’s internal control over financial reporting. In particular, these responsibilities include, among other things, the appointment and compensation of Perrigo’s independent registered public accounting firm, reviewing with the independent registered public accounting firm the plan and scope of the audit of the financial statements and internal control over financial reporting and audit fees, monitoring the adequacy of reporting and internal controls and meeting periodically with internal auditors and the independent registered public accounting firm. All of the members of the Audit Committee are independent directors, as such term is defined in Section 303A.02of303A.02of the NYSE Listed Company Manual. The Board has adopted an Audit Committee Charter, which it reviews annually based upon input from the Audit Committee.

In connection with the December 31, 20182020 financial statements, the Audit Committee: (1) reviewed and discussed the audited financial statements with management; (2) discussed with the independent registered public accounting firm the matters required to be discussed under current auditing standards, and (3) received and discussed with the independent registered public accounting firm the written disclosures and letter from the independent registered public accounting firm required under PCAOB Ethics and Independence Rule 3526 and has discussed with the independent registered public accounting firm their independence. Based upon these reviews and discussions, the Audit Committee has recommended to the Board of Directors, and the Board of Directors has approved, that Perrigo’s audited financial statements be included in Perrigo’s Annual Report on Form10-K filed with the SEC for the fiscal year ended December 31, 2018.2020.

THE AUDIT COMMITTEE

THE AUDIT COMMITTEE
Donal O’Connor, Chair
Katherine C. Doyle
Geoffrey M. Parker
Theodore R. Samuels

Donal O’Connor, Chair

Laurie Brlas

Geoffrey M. Parker

LOGO52


 Proposals to be Voted on

PROPOSALS TO BE VOTED ON

Proposals to be Voted on

Proposal 1 – Election of Directors

Under the Company’s Articles of Association, the Board of Directors must consist of between two and eleven directors, with the exact number determined by the Board of Directors. Eleven directors currently serve on our Board of Directors.

All directors who are elected will serve until the 20202022 Annual General Meeting.

Based upon the recommendation of the Nominating & Governance Committee, the Board of Directors has nominated Bradley A. Alford, Orlando D. Ashford, Rolf A. Classon, Katherine C. Doyle, Adriana Karaboutis, Murray S. Kessler, Jeffrey B. Kindler, Erica L. Mann, Donal O’Connor, Geoffrey M. Parker, and Theodore R. Samuels and Jeffrey C. Smith for election as directors to serve until the 20202022 Annual General Meeting.

Shareholders are entitled to one vote per share for each of the teneleven nominees. In order to be elected as a director, each nominee must receive the affirmative vote of a majority of the votes cast in person or by proxy. If a director nominee does not receive this majority vote, he or she is not elected.

Information about each nominee is set forth below is based on information provided to us as ofMarch 14, 2018.ofMarch [    ], 2021.

 

All Director nominees exhibit:

· High integrity

  

· An appreciation of multiple cultures

· A proven record of success

  

· Knowledge of corporate governance requirements and practices

 

Our Director nominees bring a balance of relevant skills to our boardroom:

· Global perspective

  

· Regulatory and governmental

· Consumer and pharmaceutical

  

· Financial

· CEO experience

  

· Public company board experience

 

Our Director nominees exhibit an effective mix of diversity, experience and fresh perspectives:

·GenderGender/Racial/Ethnic diversity: 20%40%

· Average age: 60.562 years

· Average tenure: approximately 1.83.36 years

· Ethnic diversity: 20%

· Active versus retired executives: 50/504 of 11

· Countries of origin: Australia, Ireland, Sweden and U.S.A.

53  2021 Proxy Statement


Proposals to be Voted on

Director Skills Matrix

 Area of Expertise / SkillBoard Member
BAOARCKDAKMKJKEMDOGPTS  

 Senior Leadership

 Financial Expertise

 Industry

 OTC/Consumer Commercial

 Manufacturing/Supply Chain

 Global/International

 IT / Cyber Security

 Governance

 Diversity*

*Gender/Ethnic

Election of Directors

The following table provides summary information about our nominees for election to the Board of Directors. Additional information for all of our director nominees may be found on pages48-52. 55-60.

 

Name  Director 
Since
  Primary Occupation  Independent  Number of Other
Public Company
Boards

Bradley A. Alford

  2017  Retired Executive  Yes  One

 Orlando D. Ashford

2020Retired ExecutiveYesTwo

Rolf A. Classon

  2017  Retired Executive  Yes  Two

 Katherine C. Doyle

2020Retired ExecutiveYesOne

Adriana Karaboutis

  2017  Executive  Yes  One

Murray S. Kessler

  2018  Executive  No  None

Jeffrey B. Kindler

  2017  Executive  Yes  ThreeTwo

Erica L. Mann

  -2019  Retired Executive  Yes  Two

Donal O’Connor

  2014  Retired Executive  Yes  One

Geoffrey M. Parker

  2016  Executive  Yes  TwoOne

Theodore R. Samuels

  2017  Retired ExecutiveYesTwo

Jeffrey C. Smith

2017Executive  Yes  Two

Each director will serve for a term expiring at the 20202022 Annual General Meeting, until a qualified successor has been elected, or until his or her death, resignation, retirement or removal by the shareholders for cause.

About the Nominated Directors

Our goal is to assemble a Board that operates cohesively and challenges and questions management in a constructive way. When assessing directors for the Board, we consider:

 

 ·  

the directors’ overall mix of skills and experience;

 ·  

the director’s understanding of our business;

 ·  

how active they are in participating in Board, committee and annual general meetings; and

 ·  

their character, integrity, judgment, record of achievement, diversity and independence.

LOGO54


Proposals to be Voted on

We also look at a director’s ability to contribute to the Board, his or her available time and his or her participation on other boards. We believe these are important factors that impact the quality of the Board’s decision-making and its overall oversight of management and our business. The Nominating & Governance Committee specifically considers diversity in regardsregard to the selection of nominees.

Our Expectations for Directors

We expect each member of our Board of Directors to act honestly and in good faith and to exercise business judgment with a view to the best interests of Perrigo overall. Each director is expected to:

 

 ·  

comply with our Code of Conduct, including conflict of interest disclosure requirements;

 ·  

develop an understanding of our strategy, our business environment and operations, the markets in which we operate and our financial position and performance;

 ·  

diligently prepare for each Board, committee and annual general meeting by reviewing all of the materials he or she receives in advance;

 ·  

actively and constructively participate in each Board meeting and seek clarification from management and outside advisors when necessary to fully understand the issues being considered;

 ·  

participate in continuing education programs, as appropriate; and

 ·  

participate in the Board and committee self-assessment process.

Director Experience

Our Board represents a cross-section of business, industry and financial experience. All of our directors bring to the Board of Directors significant leadership experience derived from their professional experience in either the corporate or academic sectors, as well as their service as executives or board members of other corporations or businesses. The process undertaken by the Nominating & Governance Committee in recommending qualified director candidates is described in “Director Nominations” on page 8.14. Certain individual qualifications and skills of our directors that contribute to the effectiveness of our Board of Directors as a whole are described below.

NineAll of the nominees for this year are current Perrigo directors; Erica L. Mann is not currently a Perrigo director.directors. We will vote your shares as you specify on the enclosed proxy card or through telephone or Internet voting. If you return a proxy card and do not specify how you want your shares voted, we will vote them FOR the election of each of the nominees. If unforeseen circumstances (such as death or disability) make it necessary for the Board of Directors to substitute another person for any of the nominees, we will vote your shares FOR that other person. The Board of Directors does not anticipate that any nominee will be unable to serve.

NOMINEES FOR ELECTION TO THE BOARD OF DIRECTORS AT THE AGM

Bradley A. Alford, 62,64, has been a director of Perrigo since February 2017. Mr. Alford joined Advent International Corporation, a global private equity firm, in 2014 as an Industry Advisor and moved to Operating Partner in March of 2016. From 2006 to 2013, Mr. Alford was Chairman and Chief Executive Officer of Nestlé USA. Mr. Alford also served as CEO and President of Nestlé Brands Company. He currently serves as a director of Avery Dennison Corporation since April 2010 and previously served as a director of Conagra Brands, Inc. from July 2015 to September 2018. Throughout his career, Mr. Alford has been focused on developing brands, initiatives to improve processes and facilitate best practices across an organization.

55  2021 Proxy Statement


Proposals to be Voted on

Director Qualifications:Qualifications:

 ·  

Leadership experience– current and previous executive leadership roles within the private and public sectors.

 ·  

Board and corporate governance experience– board and corporate governance experience from service as a director of public, private andnon-profit companies.

 ·  

Industry knowledge– extensive experience and knowledge in management, operations and supply chain as well as the development and marketing of consumer products.

Orlando D. Ashford, 52, has been a director since December 2020. Mr. Ashford is a strategic advisor with Sycamore Partners in New York, and serves on the board of directors of ITT, Inc., and Array Technologies, Inc., since December 2011 and October 2020, respectively. He most recently served as president of Holland America Line, leading the award-winning cruise line’s brand and business, and was previously president of the Talent Business Segment for Mercer, the global consulting firm. Previous to Mercer he served as senior vice president, chief human resources and communications officer of Mercer’s parent company, Marsh & McLennan Companies and also has held several other leadership roles during the course of his career at Coca-Cola Company and Motorola Inc. Mr. Ashford holds a Bachelor of Science degree and Master of Science degree in Organizational Leadership and Industrial Technology from Purdue University.

Director Qualifications:

·

Leadership experience – current and previous executive leadership roles within the public and private sectors.

·

Board and corporate governance experience – board and corporate governance experience from service as a director of public companies.

Rolf A. Classon, 73,75, has been a director of Perrigo since May 2017. Mr. Classon served as Interim President and Chief Executive Officer of Hillenbrand Industries, a global diversified industrial company, from May 2005 until March 2006. From 2002 until June 2004, Mr. Classon served as

Chairman of the Executive Committee of Bayer Healthcare AG, a subsidiary of Bayer AG. Mr. Classon served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President from 1991 to 1995. Prior to 1991, Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon serves as a director of Fresenius Medical Care AG and Co. since May 2012, and Catalent, Inc. since July 2014. Mr. Classon also served as a director ofHill-Rom Holdings, Inc., from July 2001 to March 2018, Aerocrine AB, Stockholm from May 2013 to July 2015, and Auxilium Pharmaceuticals from July 2005 to January 2015 and served as a director of Tecan Group, Ltd. from 2009 to April 2018.

Director Qualifications:Qualifications:

 ·  

Leadership and operating experience– previous executive leadership roles at Hillenbrand Industries, Bayer Healthcare AG, Bayer Diagnostics and Pharmacia Corporation.

 ·  

Board and corporate governance experience– board and corporate governance experience from current and prior service as a director and committee member on public boards.

 ·  

Industry knowledge– extensive experience in varying roles within the pharmaceutical industry.

LOGO56


Proposals to be Voted on

Katherine C. Doyle, 53, has been a director of Perrigo since July 2020. From 2016 to 2019, Ms. Doyle served as the Chief Executive Officer of Swanson Health Products, Inc, an e-commerce brand. Prior to that, she served as an independent consultant to direct-to-consumer wellness businesses from 2014 to 2016. Ms. Doyle previously worked at Abbott Laboratories in various executive leadership roles from 2011 to 2014, including President of the Abbott Nutrition Product Division and, before that, Vice President and General Manager of Pediatric Nutrition. Prior to 2011, Ms. Doyle gained more than 20 years of experience at McKinsey & Company, Inc., including 10 years as Principal, working in the consumer-packaged goods, consumer healthcare and retail sectors across Europe, Asia, Latin America and Africa. Since April 2019, Ms. Doyle has served as a director of Ahold Delhaize, a global omnichannel grocery retailer, where she is the Chair of the Sustainability and Innovation Committee and serves on the Audit Committee. Previously, she served on the board of Bemis Company, Inc., a former publicly traded global packaging company, from August 2017 to June 2019, where she served on its Audit and Nomination and Governance Committees.

Director Qualifications:

·

Leadership experience – previous Chief Executive Officer and executive leadership roles within the public and private sectors.

·

Board and corporate governance experience – board and corporate governance experience from service as a director of public companies.

·

Industry knowledge – extensive experience and knowledge in management, operations and the development and marketing of healthcare and consumer products and e-commerce.

Adriana Karaboutis, 56,58, has been a director of Perrigo since May 2017. Since August 2017, Ms. Karaboutis has served as Chief Information and Digital Officer of National Grid, a publicly traded utility company. Ms. Karaboutis served as Executive Vice President, Technology, Business Solutions and Corporate Affairs at Biogen Inc., an independent biotechnology company from December 2015 to February 2017, and as Executive Vice President, Technology and Business Solutions from September 2014 to December 2015. Prior to that, Ms. Karaboutis served as Vice President and Global Chief Information Officer of Dell, Inc., a global technology company, from 2011 to September 2014, and as Vice President of IT, Global Operations and Technology from 2010 to 2011. Ms. Karaboutis spent more than 20 years at General Motors Corporation and Ford Motor Company in various leadership positions, including computer-integrated manufacturing, supply chain operations and information technology. In addition,Since July 2019, Ms. Karaboutis has beenserved as a director of Advance Auto Parts,Aspen Technologies, Inc. since 2015., a global leader in optimization software. Ms. Karaboutis served on the board of directors of Advance Auto Parts, Inc. from 2015 to May 2020 as well as Blue Cross Blue Shield of Massachusetts from February 2016 to December 2017.

Director Qualifications:Qualifications:

 ·  

Leadership and operating experience current and previous executive leadership roles including ITin the public and cyber security at Biogen, Inc., and Dell, Inc.non-profit sectors across multiple industries.

 ·  

Board and corporate governance experience board and corporate governance experience from current and prior service as a directorboard and committee member on public boards.experience in the healthcare, retail and cyber security industries.

·

Industry knowledge – extensive experience and knowledge in management, technology, e-commerce and cyber security.

Murray S. Kessler, 59,61, was appointed President, Chief Executive Officer and Board Member of Perrigo Company plc, effective October 8, 2018. Before joining Perrigo, Mr. Kessler served as the Chairman of the

57  2021 Proxy Statement


Proposals to be Voted on

board of directors, President and CEO of Lorillard, Inc. (2010-2015). He served as Vice Chair of Altria, Inc. (2009) and President and CEO of UST, Inc. (2000-2009), a wholly owned subsidiary. Previous to his time at UST, Mr. Kessler had over 18 years of consumer packagedconsumer-packaged goods experience with companies including Vlasic Foods International, Campbell Soup and The Clorox Company. In addition to his board service at Lorillard, Mr. Kessler previously served on the board of directors of Reynolds-American, Inc. from 2015 to 2017. Since 2015, Mr. Kessler has served as voluntary President of the United States Equestrian Federation.Federation from 2015 to January 2020.

Director Qualifications:Qualifications:

 ·  

Leadership experience– current Chief Executive Officer and previous executive leadership roles within the private and public sectors.sector.

 ·  

Board and corporate governance experience– board and corporate governance experience from service as a director and chairman of public private andnon-profit companies.

 ·  

Industry knowledge– extensive experience and knowledge in management, operations and the development and marketing of consumer products.

Jeffrey B. Kindler, 63,65, has been a director of Perrigo since February 2017. Mr. Kindler has been a Venture Partner at Lux Capital, a venture capital firm, since 2012, and has served as CEO of Centrexion Corporation, a privately held bio therapeutics company that develops pain therapies, since 2013. In addition, Mr. Kindler serves as Executive Chairman of vTv, Managing Director at Starboard Capital Partners (unrelated to Starboard Value LP or any of its affiliates), and advisor to a number of healthcare companies. Prior to this, Mr. Kindler was a Venture Partner at Lux Capital from 2012 until January 2020, Executive Chairman of vTv from July 2015 to November 2019, Chairman and CEO of Pfizer, Vice President of Litigation and Legal Policy at General Electric Company, Executive Vice President and General Counsel at McDonald’s, and President at Partner Brands. In addition, Mr. Kindler has served asbeen a director of Terns Pharmaceutical since December 2020, in February 2021 Terns became public company; a director Intrexon, now known as Precigen, since 2011,2011; and PPD since May 2017, in February 2020 PDD became a public company. Mr. Kindler also servingserves as Chairan advisor of the Audit Committee, vTv Therapeutics since 2015, and Siga Technologies since 2013, as well as a number of privately heldhealthcare companies. Mr. Kindler served on the board of Siga Technologies from 2013 until May 2020 and vTv Therapeutics from 2025 until December 2020.

Director Qualifications:Qualifications:

 ·  

Leadership experience– current and previous executive leadership roles within the private and public sectors.

 ·  

Board and corporate governance experience– board and corporate governance experience from service as a director of public, private andnon-profit companies.

 ·  

Legal experience– extensive legal experience in both the public and private sectors.

Erica L. Mann, 60, was nominated by our Board62, has been a director of Directors in February 2019 to stand for election at this AGM.Perrigo since April 2019. Ms. Mann is a seasoned pharmaceutical executive. She served as President of Bayer’s Consumer Health Division from March 2011 until March 2018. Prior to this Ms. Mann was the President of Pfizer’s Global Nutrition Division from 2009 until 2011 and with the Wyeth Group from 1994 until 2009, where she held various senior executive positions. Ms. Mann has served as anon-executive director of the board of SOHO Flordis International, a global natural healthcare company, since August 2018 and as anon-executive director of Kellogg since February 2019, and has served as a non-executive director of DSM, a global Nutrition, Health and Sustainable Living company, since May 2019. She previously served as a non-executive director of SOHO Flordis International from August 2018 until November 2019 and as a director of Bayer AG and Bayer CH from January 2016 until March 2018 and as the chaira director of the World Self Medication Industry Association (Geneva, Switzerland)from 2011 until March 2018.She2018 (chair 2014-2016). She has held executive positions in several industry organizations, including the South African Pharmaceutical Manufacturers’ Association, Medicines Australia, and the International Association of Infant Food Manufacturers.

LOGO58


Proposals to be Voted on

Director Qualifications:Qualifications:

 ·  

Leadership experience– former executive and previous executive leadership roles within the private and public sectors.

 ·  

Board and corporate governance experience– current and prior board and committee experience in the pharmaceutical and other industries.

 ·  

Industry knowledge– extensive experience and knowledge in management, operations and the development and marketing in the pharmaceutical and self-care industries.

Donal O’Connor, 68,70, has been a director of Perrigo since November 2014 and was previously a director of Elan Corporation, plc from May 2008 until Perrigo’s acquisition of Elan in December 2013. He was previously the senior partner of PwC in Ireland from 1995 until 2007. He was also a member

of PwC Global board from 2003 to 2008 and was a former chairman of the PwC Eurofirms board. From December 2008 to May 2012, Mr. O’Connor served as a director for Readymix plc, an Irish concrete manufacturer and supplier. From December 2008 to June 2010, Mr. O’Connor served as the government appointed Chairman of Anglo Irish Bank plc. From July 2017 to July 2018, Mr. O’Connor served as a director of Malin Corporation. Since October 2015, Mr. O’Connor has served as a director of Theravance Biopharma, Inc. Mr. O’Connor also holds directorships on a number of private Irish company boards.

Director Qualifications:Qualifications:

 ·  

Leadership experience –former Senior Partner of Pricewaterhouse Coopers.

 ·  

Board and corporate governance experience– current and prior board and committee experience in the financial, pharmaceutical and other industries.

 ·  

Accounting and financial expertise – qualified chartered accountant currently designated as an “audit committee financial expert” given his skills and attributes acquired through relevant education and work experience.

Geoffrey M. Parker,54,56, has been a director of Perrigo since November 2016. Since April 2017, Mr. Parker has served as Chief Financial Officer of Tricida, Inc., a biopharmaceutical company. Mr. Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals, a biopharmaceutical company, from September 2010 to May 2015. From 1997 to 2009, Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries. Mr. Parker has served as a member of the board of directors of Genomic Health and ChemoCentryx since June 2016, and December 2009, respectively.2009. Mr. Parker previously served on the board of directors of Genomic Health from June 2016 until November 2019 and of Sunesis Pharmaceuticals from March 2016 until December 2017.

Director Qualifications:Qualifications:

 ·  

Leadership experience –current Chief Financial Officer as well as a former investment banking executive.

 ·  

Board and corporate governance experience– current board and committee experience in the health science industry.

 ·  

Accounting and financial expertise – designated as an “audit committee financial expert” given his skills and attributes acquired through relevant education and work experience.

59  2021 Proxy Statement


Proposals to be Voted on

Theodore R. Samuels,64,66, has been a director of Perrigo since January 2017. From 1981 to 2017, Mr. Samuels was an investor at Capital Group, a financial services company, and he served as President of Capital Guardian Trust Company, an affiliated company of Capital Group, from 2010 to 2016. While at Capital Group, he also served on The Capital Group board, audit committee and finance committee, as well as on numerous management and investment committees. Mr. Samuels has been a director for Stamps.com since January 2017 and a director of Bristol-Myers Squibb since February 2017.

Director Qualifications:Qualifications:

 ·  

Leadership experience –former investment management executive and formerco-chair of Children’s Hospital Los Angeles.

 ·  

Board and corporate governance experience– past and current board and committee experience in the financial and health science industries.

 ·  

Accounting and financial expertise – extensive accounting and financial skills and attributes acquired through relevant education and work experience.

Jeffrey C. Smith, 46, has been a director of Perrigo since February 2017. Mr. Smith is a Managing Member, Chief Executive Officer, and Chief Investment Officer of Starboard Value LP. Mr. Smith has extensive experience inbest-in-class corporate governance practices and significantly improving value at underperforming companies. He currently serves as Chairman of the board of Advance Auto Parts, where he has been a director since November 2015 and as a director and Chairman of the board of Papa John’s Pizza since February 2019. Mr. Smith was Chairman of the board of Darden Restaurants from October 2014 to April 2016 and a director of Yahoo! Inc. from April 2016 to June 2017. In addition, during the past five years, Mr. Smith has served on the boards of Quantum Corporation and Office Depot, Inc.

Director Qualifications:

·

Leadership and operating experience– current and previous executive leadership roles within the private and public sectors.

·

Board and corporate governance experience– board and corporate governance experience from service as a director of public and private companies.

·

Accounting and Financial Expertise– extensive accounting and financial skills and attributes acquired through relevant education and work experience, including involvement in capital markets and investment decision making.

Accordingly, we are asking shareholders to approve the following resolutions as Ordinary Resolutions of the Company at the AGM:

RESOLVED that the shareholders elect, by separate resolutions, the following individuals as directors, to serve until the 20202022 Annual General Meeting:

 

 ·  

Bradley A. Alford

·

Orlando D. Ashford

 ·  

Rolf A. Classon

·

Katherine C. Doyle

 ·  

Adriana Karaboutis

 ·  

Murray S. Kessler

 ·  

Jeffrey B. Kindler

 ·  

Erica L. Mann

 ·  

Donal O’Connor

 ·  

Geoffrey M. Parker

 ·  

Theodore R. Samuels

·

Jeffrey C. Smith

 

The Board of Directors unanimously recommends a vote FOR

each of the director nominees

LOGO60


Proposals to be Voted on

Proposal 2 – Ratification, in aNon-Binding Advisory Vote, of the Appointment of Ernst & Young LLP as the Company’s Independent Auditor and Authorization, in a Binding Vote, of the Board of Directors, Acting Through the Audit Committee, to Fix the Remuneration of the Auditor

The firm of Ernst & Young LLP (“EY”) began auditing the consolidated financial statements of Perrigo Company, our predecessor, in fiscal 2009. The Audit Committee has appointed EY to serve as

our independent auditor for fiscal year 2019,2021, and the Board of Directors recommends that the shareholders ratify the appointment of EY to audit our consolidated financial statements for our 20192021 fiscal year. While under Irish law, EY is deemed to be reappointed without the necessity of a shareholder vote, we are submitting the appointment to our shareholders as a matter of good corporate practice to obtain their views. In addition, the shareholders are being asked to authorize the Board of Directors, acting through the Audit Committee, to determine EY’s remuneration. This authorization is required by Irish law. The affirmative vote of a majority of the votes cast at the AGM is required for this proposal.

We expect representatives of EY to be present at the AGM with the opportunity to make a statement if they desire to do so and to respond to appropriate questions.

EY has advised us that neither the firm nor any of its members or associates has any direct financial interest or any material indirect financial interest in Perrigo or any of its affiliates other than as accountants.

During fiscal years 20172019 and 2018,2020, we retained EY to perform auditing and other services for us and paid them the following amounts for these services:

 

Fiscal Year 2017

        

Fiscal Year 2018

    

Audit Fees

  $14,417,000     Audit Fees  $12,278,836 

Audit-Related Fees(1)

  $425,000     Audit-Related Fees(2)  $1,212,369 

Tax Compliance

  $196,000     Tax Compliance  $197,006 

Tax Consulting & Advisory

  $1,823,000     Tax Consulting & Advisory  $1,796,525 
  

 

 

       

 

 

 

Total Tax Fees

  $2,019,000     Total Tax Fees  $1,993,531 

All Other Fees

   -0-     All Other Fees   -0- 
  

 

 

       

 

 

 

Total Fees

  $16,886,000     Total Fees  $15,484,736 
Fiscal Year 2019

Audit Fees

$12,017,011

Audit-Related Fees (1)

$3,610,184

Tax Compliance

$141,000

Tax Consulting & Advisory

$130,000

All Other Fees

-0-

Total Fees

$15,898,195
Fiscal Year 2020

Audit Fees

$11,080,306

Audit-Related Fees (2)

$156,850

Tax Compliance

$204,900

Tax Consulting & Advisory

$579,900

All Other Fees

-0-

Total Fees

$12,021,956

 

(1)

Mainly represents attest services provided to the Company in connection with the requirements of the Irish Takeover Panel.

(1) Relates primarily to services provided in connection with the Company’s strategic portfolio review.

(2) Includes $7,500 for access to an online research tool

(2)

Relates primarily to services provided in connection with the Company’s strategic portfolio review.

The Audit Committee maintains a policy pursuant to which it reviews andpre-approves audit and permittednon-audit services (including the fees and terms thereof) to be provided by our auditor, except for the de minimis exceptions fornon-audit services described in Section 10A(i)(1)(B) of the Securities Exchange Act of 1934 that are approved by the Audit Committee prior to the completion of our audit. The Chair of the Audit Committee, or any other member or members designated by the Audit Committee, is authorized topre-approvenon-auditpre-approve non-audit services, provided that anypre-approval shall be reported to the full Audit Committee at its next scheduled meeting. All audit and other services performed by our auditor in fiscal year 20182020 were approved in accordance with the Audit Committee’s policy.

61  2021 Proxy Statement


Proposals to be Voted on

Accordingly, we are asking shareholders to approve the following resolution as an Ordinary Resolution of the Company at the AGM:

RESOLVED that the shareholders of Perrigo Company plc (the “Company”) ratify, in anon-binding advisory vote, the appointment of Ernst & Young LLP as the Company’s independent auditor for the fiscal year ending December 31, 2019,2021, and authorize, in a

binding vote, the Board of Directors acting through the Audit Committee to fix the remuneration of the auditor.

 

The Board of Directors unanimously recommends that shareholders vote

FOR the ratification, in anon-binding advisory vote, of the appointment of Ernst & Young LLP as our Company’s independent auditor for the fiscal year ending December 31, 20192021 and authorize, in a binding vote, the Board of Directors, acting through the Audit Committee, to fix the remuneration of the auditor

Proposal 3 – Advisory Vote on Executive Compensation

Section 951 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”) requires us to provide our shareholders with an opportunity to cast an advisory vote regarding the compensation of our named executive officers. This is commonly known as a“Say-on-Pay” proposal, as it gives our shareholders the opportunity to communicate to the Remuneration Committee and the Board of Directors their view on our compensation of the named executive officers.

It has been our practice to hold aSay-on-Pay vote annually, and at our 20182020 AGM, our shareholders expressed their preference that we continue to do so. For that reason, we are asking our shareholders to approve, on anon-binding basis, the compensation of the Company’s named executive officers disclosed in this proxy statement. As described in detail in the “Compensation Discussion and Analysis”, beginning on page 16,22, our philosophy in setting executive compensation is to provide a total compensation package that provides the compensation and incentives needed to attract, retain and motivate talented executives who are crucial to our long-term success while aligning our executives’ compensation with our short-term and long-term performance.

Consistent with that philosophy, a significant percentage of the total compensation opportunities for each of our named executive officers is directly related to our stock price performance and to other performance factors that measure progress against operating plans and the creation of shareholder value. Through stock ownership requirements and equity incentives, we also align the interests of our executives with the long-term interests of the Company and our shareholders. For these reasons, we believe that our executive compensation program is reasonable, competitive and strongly focused onpay-for-performance principles.

At the 20182020 AGM, our shareholders strongly approved theSay-on-Pay proposal, with more than 92%88% of the votes cast voting in favor of the proposal.

With respect to executive compensation during 2018, we believe that the Company’s financial performance provides support for the compensation of our named executive officers, including8:

·

Delivered net sales of $4.7 billion and adjusted operating profit of $0.9 billion.

·

Increased investments in R&D to enhance our new product pipeline as well as in advertising and promotion to drive net sales, which were up nearly 5% year-over-year; additional investments were made to address supply constraints.

8

See Exhibit A for reconciliation of Adjusted(non-GAAP) to Reported GAAP.

·

Consumer Healthcare International improved its adjusted operating margin to an annual record of 16% through new products and better SG&A efficiencies.

·

Consumer Healthcare Americas delivered net sales growth of 1.4% year-over-year9 driven by new products and net sales in the analgesics and dermatological categories.

·

Prescription Pharmaceuticals increased R&D investments by 18% as the team continued to identify attractive opportunities for new products.

·

Achieved 102% operating cash flow conversation to adjusted net income and cash from operations of $643 million.10

However, ourOur pay-for-performance compensation program demonstrated once again in 20182020 that it is working as intended:intended.

·

The annual management incentive bonus payed out at 64.7% of target, which is below target and well below historic levels, and

·

The 2018 tranche of our long-term performance-based equity compensation vested at 0% of target.

The Remuneration Committee and Board of Directors believe that the information provided in the

“Compensation Discussion and Analysis” demonstrates that our executive compensation program aligns our

LOGO62


Proposals to be Voted on

executives’ compensation with Perrigo’s short-term and long-term performance and provides compensation and incentives needed to attract, motivate and retain key executives that are crucial to Perrigo’s long-term success.

Although thisSay-on-Pay advisory vote isnon-binding, the Remuneration Committee and the Board will review the results of this vote and take them into account for future determinations concerning our executive compensation program.

Accordingly, we are asking shareholders to approve the following resolution as an Ordinary Resolution of the Company at the AGM:

RESOLVED that the shareholders of Perrigo Company plc (the “Company”) approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement for the 20192021 Annual General Meeting of Shareholders, including the Compensation Discussion and Analysis and the compensation tables and narrative disclosures under the “Executive Compensation” section of this proxy statement.

 

The Board of Directors unanimously recommends that shareholders vote

FOR the approval, on an advisory basis, of the compensation of the

Company’s named executive officers

Proposal 4 – Renew and Restate the Company’s Long-Term Incentive Plan

We are asking our shareholders to approve an amendment and restatement of the Perrigo Company plc 2013 Long-Term Incentive Plan (the “2013 LTIP”), including an increase in the number of shares authorized for issuance under the 2013 LTIP of 3,000,000 shares.

9

On a constant currency basis and excluding animal health.

10

Cash flow conversion to adjusted net income and cash from operations excludes a $50 million payment for Nasonex® OTC.

The board of directors of our subsidiary Perrigo Company originally adopted the Perrigo Company 2003 Long-Term Incentive Plan (the “2003 LTIP”) in August 2003 and the Perrigo Company shareholders approved it on October 28, 2003. Since that time, Perrigo Company shareholders also approved:

·

an amendment to the 2003 LTIP on October 28, 2005, increasing the number of shares issuable under the 2003 LTIP by 4,500,000 shares;

·

an amendment and restatement of the 2003 LTIP on November 4, 2008 that, among other things, renamed the LTIP as the 2008 Long-Term Incentive Plan (the “2008 LTIP”) and increased the number of shares authorized for issuance under the 2008 LTIP by 3,100,000 shares; and

·

an amendment and restatement of the 2008 LTIP on November 18, 2013 that, among other things, renamed the LTIP as the 2013 Long-Term Incentive Plan (the “2013 LTIP”) and increased the number of shares authorized for issuance under the 2013 LTIP by 3,100,000 shares.

On December 18, 2013, Perrigo Company became a wholly-owned subsidiary of the Company and the Company assumed sponsorship of the 2013 LTIP.

On February 13, 2019, our Board of Directors approved an amendment and restatement of the 2013 LTIP based upon the recommendation of the Remuneration Committee, subject to the approval of our shareholders, in order to:

·

rename the LTIP as the 2019 Long-Term Incentive Plan (“2019 LTIP” or the “LTIP”);

·

increase the number of shares authorized for issuance under the LTIP by 3,000,000 shares;

·

extend the period of time that incentive stock options may be granted under the LTIP;

·

establish subplans so that certain awards qualify for preferred tax treatment under applicable foreign laws; and

·

make certain other administrative, clarifying and/ornon-material changes to the LTIP, including, but not limited to, changes to reflect the elimination of the performance-based compensation exception under Section 162(m) of the Code fornon-grandfathered awards.

We believe that equity-based compensation is a critical part of our compensation program. Shareholder approval of the amended and restated LTIP and the associated share increase would enhance our ability to attract and retain talented employees, consultants and directors upon whom, in large measure, Perrigo’s sustained progress, growth and profitability depends. For more information on how the LTIP fits within our existing compensation program and our past and current grant practices, see the “Director Compensation”, “Executive Compensation”, and “Equity Compensation Plan Information” sections of this Proxy Statement. The number of shares requested was determined on the retained advice of our compensation consultants. Using their model, we determined that we could request up to 3.15 million shares with a 5 point margin. However, we did not request the maximum number of shares allowable under their model in an effort to minimize shareholder dilution and maximize shareholder value. Our Average Annual Share Usage (“Run Rate”) was 0.83%, 0.68%, and 0.56% in 2018, 2017, and 2016, respectively. The last time we requested shares was 2013, nearly 6 years ago.

If this proposal is not approved by our shareholders, we will not be able to issue awards under the 2019 LTIP and our ability to continue to issue equity-based incentive compensation to our directors,

employees, and consultants will be limited to the shares available under the 2013 LTIP, which we believe will be insufficient to remain competitive with our peers or to recruit, motivate and retain our employees, directors, and consultants.

Material Terms of the LTIP

The summary of the LTIP provided below describes the material features of the LTIP; however, it is not complete and, therefore, you should not rely solely on it for a detailed description of every aspect of the LTIP. A copy of the entire LTIP has been filed with this proxy statement and is attached for your review as Annex A.

Effective Date and Duration

The effective date of the LTIP will be the date of the AGM if our shareholders approve the amendment and restatement of the LTIP at that meeting. No awards may be granted under the LTIP on a date that is more than ten years after the effective date of the LTIP unless the LTIP is extended by a subsequent vote of our shareholders, but awards theretofore granted may extend beyond that date.

Eligibility

Under the LTIP, the Remuneration Committee may grant share-based incentives to employees, directors and consultants to Perrigo and its affiliates. The LTIP also permits our CEO to grant share-based incentives to employees and consultants to Perrigo and its affiliates; however our CEO may not grant awards to participants who are subject to Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Approximately 2,000 employees, 10non-employee directors, and 5 consultants will be eligible to participate in the LTIP.

Shares Available under the LTIP

As of December 31, 2018, there were 2,827,510 shares available for issuance under the LTIP. As of that date, the number of shares underlying outstanding awards under the LTIP was 2,744,905shares. The number of available shares under the LTIP may change prior to the effective date of the amendment and restatement of the LTIP if additional awards are granted or forfeited under the LTIP between December 31, 2018 and the date of our AGM.

If any award under the LTIP expires, is terminated or forfeited, or is settled in cash or exchanged for other awards, on or after the effective date of the LTIP without the issuance of shares, then the shares subject to the award will be added to the shares available for issuance under the LTIP. In addition, any shares which are used as full or partial payment of the purchase price of shares or the tax withholding requirement with respect to any awards shall again be available for awards under the LTIP. If a stock appreciation right is settled in shares, shares that are in excess of the net shares delivered on exercise of such stock appreciation right shall be added back to the number of shares available for future awards under the LTIP.

The number of shares that may be issued with respect to awards under the LTIP to any one participant in a calendar year may not exceed 400,000 shares. The number of shares that may be issued with respect to awards under the LTIP to any onenon-employee director in a calendar year may not exceed 25,000 shares.

Plan Administration

The Remuneration Committee administers the LTIP. Subject to the terms of the LTIP, the Remuneration Committee determines award eligibility, timing and the type, amount and terms of the awards. The Remuneration Committee also interprets the LTIP, establishes rules and regulations under the LTIP and makes all other determinations necessary or advisable for the LTIP’s administration. With respect to participants who are not subject to Section 16 of the Exchange Act, our CEO has the authority to determine award eligibility and the timing, type, amount and terms of the awards, subject to the terms of the LTIP.

Types of Awards

Awards under the LTIP may be in the form of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted shares, performance shares, performance units and restricted share units. The terms of each award will be set forth in a written agreement.

Stock Options

A stock option provides the option holder with the right to purchase Perrigo ordinary shares at a future date and at a specified price per share called the exercise price. Options under the LTIP may be either “incentive stock options,” as defined under the tax laws, or nonstatutory stock options; however, only employees may be granted incentive stock options. The per share exercise price may not be less than the fair market value of a Perrigo ordinary share on the date the option is granted. The Remuneration Committee (or our CEO, in the case of an option granted to a participant who is not subject to Section 16 of the Exchange Act) may specify any period of time following the date of grant during which options are exercisable, but the period cannot be longer than 10 years. Incentive stock options are subject to additional limitations relating to such things as employment status, minimum exercise price, length of exercise period, maximum value of the share underlying the options and a required holding period for shares received upon exercise of the option.

Upon exercise, the option holder may pay the exercise price in several ways. He or she may pay in cash, in previously acquired shares or, if permitted by terms of his or her award agreement, other consideration having a fair market value equal to the exercise price, or through a combination of the foregoing.

Except for adjustments to effect mergers, reorganizations, consolidations, share splits, share dividends, recapitalizations or similar events, in no event shall the purchase price of an option be decreased after the grant date or surrendered in consideration of a new option grant with a lower exercise price or be cancelled or exchanged for cash without shareholder approval.

Stock Appreciation Rights

A stock appreciation right or “right” allows its holder to receive payment from us equal to the amount by which the fair market value of an ordinary share of Perrigo exceeds the grant price of the right on the exercise date. The grant price may not be less than the fair market value of an ordinary share of Perrigo on the grant date of the right and the term may not be greater than 10 years.

Under the LTIP, the Remuneration Committee may grant rights in conjunction with the grant of stock options or on a stand-alone basis. If the Remuneration Committee grants a right with an option award,

then the holder can exercise the rights at any time during the life of the related option, but the exercise will proportionately reduce the number of his or her related stock options. The holder can exercise stand-alone stock appreciation rights during the period determined by the Remuneration Committee (or the CEO, as applicable). Upon the exercise of a stock appreciation right, the holder receives cash, ordinary shares of Perrigo or other property, or a combination thereof, in the Remuneration Committee’s or the CEO’s discretion, as applicable. Except for adjustments to effect mergers, reorganizations, consolidations, share splits, share dividends, recapitalizations or similar events, in no event shall the grant price of a stock appreciation right be decreased after the grant date or surrendered in consideration of a new stock appreciation right grant with a lower grant price or be cancelled in exchange for cash without shareholder approval.

Restricted Shares and Restricted Share Units

Restricted shares refers to ordinary shares of Perrigo subject to a risk of forfeiture or other restrictions on ownership for a certain period of time. During the restricted period, the holder of restricted shares may not sell or otherwise transfer the shares, but he or she may vote the shares and may be entitled to any dividend or other distributions if determined by the Remuneration Committee or the CEO, as applicable. The restricted shares become freely transferable when the restriction period expires.

A restricted share unit award is an award valued by reference to Perrigo ordinary shares that entitles the holder to receive one ordinary share of Perrigo or cash equal to the value of one ordinary share of Perrigo on the date of vesting of the award. Restricted share units are subject to a risk of forfeiture or other restrictions on ownership for a certain period of time.

The Remuneration Committee (or the CEO, as applicable) sets the terms and conditions of restricted share and restricted share unit awards, including the restrictions applicable to such awards. The Remuneration Committee (or the CEO, as applicable) also determines whether the restrictions have been satisfied and the form of payment of restricted stock units, which may be in cash or Perrigo ordinary shares.

Performance Shares and Performance Units

A performance share is a right to receive ordinary shares of Perrigo or equivalent value in the future, contingent on the achievement of performance goals or other objectives during a specified period. A performance unit represents an award valued by reference to property other than ordinary shares of Perrigo, as designated by the Remuneration Committee (or the CEO, as applicable), contingent on the achievement of performance goals or other objectives during a specified period.

The Remuneration Committee or the CEO, as applicable, sets the terms and conditions of each award, including the performance goals that must be attained and the various percentages of performance unit value to be paid out upon full or partial attainment of those goals. The Remuneration Committee or the CEO, as applicable, also determines whether the goals have been satisfied and the form of payment, which may be in cash, ordinary shares of Perrigo, other property or a combination thereof.

Dividend Equivalents

A dividend equivalent provides a participant with the right to receive an amount equal to the amount of dividends paid on one ordinary share of Perrigo for each share represented by the dividend equivalent award. The Remuneration Committee or the CEO, as applicable, determines whether a participant will

receive dividend equivalents in connection with an award. Such dividend equivalents shall be subject to the same terms and conditions as the award to which the dividend equivalents relate and shall be payable only if and to the extent the underlying awards become vested.

Minimum Vesting Requirements

The LTIP allows for the grant of awards subject to time-based vesting or performance-based vesting or both. Awards have a minimum vesting period ofone-year, except that thisone-year minimum vesting requirement does not apply if the participant’s termination from service occurs due to his or her death, disability, or retirement, upon a change in control, or upon his or her termination without cause or separation for good reason within a specified period following a change in control. Theone-year minimum vesting requirement also does not apply to any award granted in substitution for another award that does not reduce the vesting period of the award being substituted.

Termination of Employment

The LTIP provides that upon a participant’s death, disability or retirement, (i) all outstanding awards (other than performance units) immediately vest, (ii) performance units will vest or be forfeited depending on the attainment of performance goals, and (iii) stock options and stock appreciation rights may be exercised by the participant, or by his or her estate, beneficiary or conservator in the case of death or disability, at any time prior to their stated expiration dates.

If the participant’s employment is terminated involuntarily for economic reasons, for example, restructurings, dispositions or layoffs, as determined in the discretion of the Remuneration Committee (or the CEO, as applicable), the participant may exercise any vested options or stock appreciation rights until the earlier of 30 days following the date that is 24 months after the termination date and the expiration date of the options or stock appreciation rights. Unvested options, stock appreciation rights, restricted shares and service-vesting restricted share units that are scheduled to vest during the24-month period following the termination date will continue to vest as if the participant had continued to perform services during the24-month period. Those not scheduled to vest during the24-month period are forfeited on the termination date. Unvested performance units for which the performance period is scheduled to end during the24-month period following the participant’s termination date will vest or be forfeited depending on the attainment of performance goals. Any shares subject to a performance unit for which the performance period is not scheduled to end during such24-month period shall be forfeited on the participant’s termination date.

If a participant’s termination is for cause, all outstanding awards are forfeited. Except as otherwise provided above, in all other terminations, unvested awards are forfeited on the termination date and the participant may exercise his or her vested options and stock appreciation rights during the three-month period after the termination date, but not later than the expiration date of the option or stock appreciation right. In certain circumstances, the LTIP provides for extended exercisability when a participant dies following termination. The payment of certain awards to officers or other key employees following termination from employment will be delayed by at least six months if earlier payment of the awards would result in the imposition of excise taxes on him or her.

This section describes the default rules applicable to awards. The Remuneration Committee (or the CEO, as applicable) has discretion to establish different terms and conditions relating to the effect of a participant’s termination date on awards under the LTIP.

Change in Control

Regardless of the vesting requirements that otherwise apply to an award under the LTIP, unless the Remuneration Committee (or the CEO, as applicable) determines otherwise in an individual award agreement, if the participant’s termination date occurs by reason of a termination without cause or a separation for good reason on or after a change in control and prior to thetwo-year anniversary of the change in control, all outstanding awards will vest as of such termination date. In the case of performance units, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels.

On a change in control, the Remuneration Committee has the discretion to take any of the following actions with respect to awards granted under the LTIP, without the consent of any participant: (i) require that any outstanding option or stock appreciation right be surrendered for cash or Perrigo shares, (ii) terminate any outstanding option or stock appreciation right after participants have been given an opportunity to exercise such awards, or (iii) convert the award to an award of the surviving corporation.

Generally, a change in control is defined in the LTIP to mean (1) a change in ownership of 50% or more of Perrigo ordinary shares, (2) the consummation of a merger, consolidation or similar transaction following which our shareholders cease to own shares representing more than 50% of the voting power of the surviving entity (or the parent of such entity) or (3) a change in Board composition so that a majority of the Board is comprised of individuals who are neither incumbent members nor their nominees.

Performance-Based Awards Prior to 2018

Prior to January 1, 2018, the Remuneration Committee could designate an award as “performance-based compensation” for purposes of Section 162(m) of the Internal Revenue Code. These awards were conditioned on the achievement of one or more performance measures based on one or any combination of the following, as selected by the Remuneration Committee: cash flow; cash flow from operations; net income; total earnings; earnings per share, diluted or basic; earnings per share from continuing operations, diluted or basic; earnings before interest and taxes; earnings before interest, taxes, depreciation, and amortization; earnings from operations; net asset turnover; inventory turnover; capital expenditures; net earnings; operating earnings; gross or operating margin; debt; working capital; return on equity; return on net assets; return on total assets; return on capital; return on invested capital; return on investment; return on sales; net or gross sales; market share; economic value added; cost of capital; change in assets; expense reduction levels; cost control; debt reduction; productivity; delivery performance; safety record; share price; share price appreciation; and total shareholder return of Perrigo or of a division or affiliate of Perrigo that employs the participant.

The maximum annual cash payment that may be made in settlement of a performance-based compensation award to an executive subject to Section 162(m) of the Code is $6,000,000. No awards granted on or after January 1, 2018 will be considered performance-based compensation for purposes of Section 162(m) of the Code.

Adjustments

The number of shares that may be issued under the LTIP and the number of shares subject to outstanding awards may be adjusted in the event of a merger, reorganization, consolidation, share split,

share dividend, recapitalization or other similar event affecting the number of outstanding ordinary shares of Perrigo. In that event, the Remuneration Committee also may make appropriate adjustments to any options, stock appreciation rights, restricted shares, restricted share units, performance shares, performance units or other awards outstanding under the LTIP.

Transferability

The recipient of an award under the LTIP generally may not pledge, assign, sell or otherwise transfer his or her stock options, stock appreciation rights, restricted shares, restricted share units, performance shares, or performance units other than by will or by the laws of descent and distribution. The Remuneration Committee, however, may establish rules and procedures to allow participants in the LTIP to transfer nonstatutory stock options to immediate family members or to certain trusts or partnerships.

Subplans

The LTIP includes three subplans that reflect the requirements of applicable foreign laws with respect to certain types of awards.

·

The first subplan is for awards granted to participant who are residents of the state of Israel for Israeli income tax purposes. These participants may be granted awards that are intended to meet the requirements of Section 102 or Section 3(i) of the Israeli Income Tax Ordinance [New Version], 1961 (the “Israeli Tax Ordinance”) as amended by Amendment no. 132 to the Israeli Tax Ordinance.

·

The second subplan is for employees and directors who are residents of the Republic of Ireland for tax purposes or who are subject to Irish taxation. These participants may be granted fully vested shares that are subject to restrictions (the shares are “clogged”) that meet the requirements of a clog scheme under Section 128D of the Taxes Consolidation Act 1997 (as amended).

·

The third subplan is for granting awards tonon-employee directors and to consultants, with the intent that the portion of the LTIP covering employees meet the requirements of an “employee share scheme” under Irish company law.

Plan Amendment and Termination

Generally, the Board may amend or terminate the LTIP at any time without shareholder approval. Without shareholder approval, however, the Board may not: (1) increase the number of Perrigo ordinary shares available for issuance under the LTIP (other than as described in “Adjustments” above); (2) change the employees or the class of employees eligible to participate in the LTIP; (3) change the minimum exercise price for any option or stock appreciation right below the grant date fair market value of the award; or (4) materially change the terms of the LTIP. In addition, if any action that the Board proposes to take will have a materially adverse effect on the rights of any participant or beneficiary under an outstanding award, then the affected participant or beneficiary must consent to the action.

Amendment of Awards

The Remuneration Committeeor the CEO may amend the terms of any award previously granted, provided that (i) no such amendment will impair the rights of any participant without his or her

consent, and (ii) the CEO may only amend the terms of awards granted to participants who are not subject to Section 16 of the Exchange Act.

Clawback

The LTIP includes a claw-back provision that allows Perrigo to recover equity-based compensation paid to an executive under the LTIP (and associated gains) if Perrigo’s financial results are later restated due to the individual’s misconduct, including, without limitation, fraud or knowing illegal conduct. In addition, any Perrigo shares acquired under the LTIP (including shares acquired through the exercise of options and/or stock appreciation rights), and any gains or profits on the sale of such shares, will be subject to any clawback or recoupment policy adopted by Perrigo, as in effect from time to time.

Deferral of Awards

At the discretion of the Remuneration Committee (or the CEO, in the case of a participant who is not subject to Section 16 of the Exchange Act), a participant may elect to defer the payment or settlement of awards upon such terms and conditions as the Remuneration Committee (or the CEO) may prescribe.

Tax Consequences

The holder of an award granted under the LTIP may be affected by certain U.S. federal income tax consequences. Special rules may apply to individuals who may be subject to Section 16(b) of the Exchange Act.The following discussion of U.S. federal income tax consequences is based on U.S. federal income tax laws in effect on the date of this Proxy Statement and is not a complete description of the U.S. federal income tax consequences that apply to participants in the LTIP.This summary is not intended to be exhaustive and does not constitute legal or tax advice. This summary does not address municipal, state or foreign income tax consequences of awards, or employment taxes.

Incentive Stock Options.There are no federal income tax consequences associated with the grant or exercise of an incentive stock option, so long as the holder of the option was our employee at all times during the period beginning on the grant date and ending on the date three months before the exercise date. The “spread” between the exercise price and the fair market value of Perrigo ordinary shares on the exercise date, however, is an adjustment for purposes of the alternative minimum tax. A holder of incentive stock options defers income tax on the share’s appreciation until he or she sells the shares.

Upon the sale of the shares, the holder realizes a long-term capital gain (or loss) if he or she sells the shares at least two years after the option grant date and has held the shares for at least one year. The capital gain (or loss) equals the difference between the sales price and the exercise price of the shares. If the holder disposes of the shares before the expiration of these periods, then he or she recognizes ordinary income at the time of sale (or other disqualifying disposition) equal to the lesser of (1) the gain he or she realized on the sale and (2) the difference between the exercise price and the fair market value of the shares on the exercise date. This ordinary income is treated as compensation for tax purposes. The holder will treat any additional gain as short-term or long-term capital gain, depending on whether he or she has held the shares for at least one year from the exercise date. If the holder does not satisfy the employment requirement described above, then he or she recognizes ordinary income (treated as compensation) at the time he or she exercises the option under the tax rules applicable to the

exercise of a nonstatutory stock option. We are entitled to an income tax deduction to the extent that an option holder realizes ordinary income

Nonstatutory Stock Options.There are no federal income tax consequences to us or to the recipient of a nonstatutory stock option upon grant. Upon exercise, the option holder recognizes ordinary income equal to the spread between the exercise price and the fair market value of Perrigo ordinary shares on the exercise date. This ordinary income is treated as compensation for tax purposes. The basis in shares acquired by an option holder on exercise equals the fair market value of the shares at that time. The capital gain holding period begins on the exercise date. Perrigo receives an income tax deduction upon the exercise of a nonstatutory stock option in an amount equal to the spread.

Stock Appreciation Rights. There are no tax consequences associated with the grant of stock appreciation rights. Upon exercise, the holder of stock appreciation rights recognizes ordinary income in the amount of the appreciation paid to him or her. This ordinary income is treated as compensation for tax purposes. Perrigo receives a corresponding deduction in the same amount that the holder recognizes as income.

Restricted Shares. Unless the holder makes an election to accelerate the recognition of income to the grant date (as described below), the holder of restricted shares does not recognize any taxable income on the shares while they are restricted. When the restrictions lapse, the holder’s taxable income (treated as compensation) equals the fair market value of the shares (less the amount paid for the shares, if any). If within 30 days of receiving a restricted share award the holder files with the Internal Revenue Service an election under Section 83(b) of the Code, the holder will recognize ordinary income equal to the fair market value of the shares on the grant date (less the amount paid for the shares, if any) and any future appreciation will be taxed at capital gain rates. Generally, at the time the holder recognizes taxable income with respect to restricted shares, Perrigo will receive a deduction in the same amount.

Performance Shares, Performance Units and Restricted Share Units. There are no tax consequences associated with the grant of performance shares, performance units or restricted share units. The holder recognizes ordinary income (treated as compensation) upon a payment on the performance shares, performance units or restricted share unit awards in amount equal to the payment received, and Perrigo receives a corresponding tax deduction.

Section 280G. Under certain circumstances, the accelerated vesting of an award in connection with a change in control of Perrigo might be deemed an “excess parachute payment” for purposes of the golden parachute tax provisions of Section 280G of the Code. To the extent they are considered excess parachute payments, a participant in the LTIP may be subject to a 20% excise tax and Perrigo may be unable to receive a tax deduction.

Section 409A.Section 409A of the Code imposes complex rules on nonqualified deferred compensation arrangements, including requirements with respect to elections to defer compensation and the timing of payment of deferred amounts. Depending on how they are structured, certain equity-based awards may be subject to Section 409A of the Code, while others are exempt. If an award is subject to Section 409A of the Code and a violation occurs, the affected participant may be subject to a 20% penalty tax and, in some cases, interest penalties. The LTIP and awards granted under the LTIP are intended to be exempt from or conform to the requirements of Section 409A of the Code.

Section 162(m).Generally, whenever an award holder recognizes ordinary income under the LTIP, a corresponding deduction is available to Perrigo. However, Section 162(m) of the Code placed a

$1 million limit on the amount of compensation that Perrigo can deduct in any one taxable year for certain covered employees. Historically, certain performance-based pay has been excluded from this limit. However, the performance-based compensation exception has been repealed, effective for taxable years beginning after December 31, 2017, such that compensation paid to certain covered employees in excess of $1 million per taxable year will not be deductible unless it qualified for the transition relief applicable to certain arrangements in place as of November 2, 2017. Due to uncertainties in the application and the interpretation of the changes to Section 162(m) of the Code and the transition relief for arrangements in place as of November 2, 2017, there is no assurance that compensation intended to be exempt from the $1 million deduction limit will in fact be exempt.

Plan Benefits

The number of ordinary shares that will be awarded under the 2019 LTIP is not currently determinable. As of December 31, 2018, the closing price of a Perrigo ordinary share was $38.75.

The stock options previously granted under the LTIP, on or prior to December 31, 2018, are as follows:

Name/Group

Number of Options

Named Executive Officers:

Murray S. Kessler

110,074

Ronald L. Winowiecki

35,669

Todd W. Kingma

25,595

Jeffrey R. Needham

205,916

Svend Andersen

24,749

John T. Hendrickson

425,313

Uwe F. Roehrhoff

72,149

All current executive officers as a group

1,074,277

All currentnon-executive directors as a group

58,186

All employees (excluding current executive officers)

4,991,426

The Board of Directors unanimously recommends that shareholders vote

FOR the approval of renewing and restating the Company’s Long-Term Incentive Plan

Proposal 5 – Approve the Creation of Distributable Reserves

From time to time, Irish companies seek shareholder approval to create additional “distributable reserves” to give themselves greater flexibility with respect to management of their capital. Under Irish Law, dividends and distributions and, generally, share repurchases or redemptions may only be made from distributable reserves in the Company’s unconsolidated balance sheet prepared in accordance with the Irish Companies Act 2014. Distributable reserves generally means the accumulated realized profits of the Company less accumulated realized losses of the Company and includes reserves created by way of capital reductions. In addition, no distribution or dividend may be made unless the net assets of the Company are equal to, or in excess of, the aggregate of the Company’s called up share capital plus undistributable reserves and the distribution does not reduce the Company’s net assets below such aggregate. Undistributable reserves include the share premium account, the capital redemption reserve fund and the amount by which the Company’s accumulated unrealized profits, so far as not previously utilized by any capitalization, exceed the Company’s accumulated unrealized losses, so far as not previously written off in a reduction or reorganization of capital.

In November 2013, at the Special Meeting of shareholders of Perrigo Company and at the Extraordinary General Meeting of shareholders of Elan Corporation plc, the shareholders of each companypre-approved the creation of distributable reserves in the Company by approving the reduction of some or all of the share premium of the Company resulting from the issuance of shares in the Company in connection with the Elan acquisition.

Following the Elan acquisition, on December 18, 2013, the share premium of the Company was equal to US$19,983,892,898.19. On December 19, 2013, the Company presented a petition to the High Court of Ireland seeking, among other things, the High Court’s confirmation of a reduction in its share premium by US$5,500,000,000. On January 14, 2014, the High Court of Ireland, by way of court order confirmed the requested reduction in share premium of US$5,500,000,000. The High Court order was subsequently filed by the Company with the Registrar of Companies in Ireland, and on January 20, 2014 the Registrar of Companies issued a Certificate of Registration of Order of Court and Minute on Reduction of Share Premium Account, which gave effect to the reduction, resulting in the creation of distributable reserves of US$5,500,000,000 and a balance of share premium of the Company of US$14,483,892,898.19.

In November 2014, at the General Meeting of shareholders of the Company, the shareholders of the Company approved the creation of further distributable reserves in the Company by approving the reduction of some or all of the share premium of the Company of US$14,483,892,898.19.

On December 19, 2014, the Company presented a petition to the High Court seeking, among other things, the High Court’s confirmation of a reduction in its share premium by US$11,000,000,000. On January 30, 2015, the High Court, by way of court order confirmed the requested reduction in share premium of US$11,000,000,000. The High Court order was subsequently filed by the Company with the Registrar of Companies in Ireland, and on February 13, 2015 the Registrar of Companies issued a Certificate of Registration of Order of Court and Minute on Reduction of Share Premium Account, which gave effect to the requested reduction, resulting in the creation of additional distributable reserves of US$11,000,000,000 and a balance of share premium of the Company of US$5,419,400,000.

We are asking the shareholders to approve the creation of further distributable reserves in the Company by approving the reduction of some or all of the balance of share premium of the Company (the final amount to be determined by the directors or the Chief Financial Officer of the Company in their absolute discretion). If the shareholders approve the reduction in share premium, the Company may determine, at its discretion, to seek the confirmation of the Irish High Court for a reduction in share premium. If the Company does decide to seek confirmation from the High Court, whether the High Court determines to issue the required order is a matter for the discretion of the High Court.

The creation of further distributable reserves will give the Company greater flexibility with respect to management of its capital. Accordingly, we are asking shareholders to approve the following resolution as a Special Resolution of the Company at the AGM:

RESOLVED that subject to the confirmation of the High Court of Ireland (the “High Court”) pursuant to sections 84 and 85 of the Companies Act 2014 and the delivery of the relevant order of the High Court and minute approved by the High Court to the registrar of companies and the registration thereof in accordance with section 86 of the Companies Act of 2014, the share premium of the Company be reduced by cancelling all of the balance of the share premium of the Company (the “Authorized Amount”) or such other lesser amount as the directors or the Chief

Financial Officer of the Company or the High Court may determine in their absolute discretion and for the reserve arising as a result of such cancellation to be treated as profits available for distribution as defined by section 117 of the Companies Act of 2014; and that the directors of the Company be and they are authorized to determine, on behalf of the Company, to proceed to seek confirmation of the High Court to a reduction of the share premium account of the Company by the Authorized Amount or such lesser amount as the directors or the Chief Financial Officer of the Company or the High Court may determine in their absolute discretion or to determine not to proceed to seek the approval of the High Court at all pursuant to this resolution.

The Board of Directors unanimously recommends that the shareholders vote FOR the creation of distributable reserves by reducing some or all of the Company’s share premium

Proposal 6 – Renew the Board’s Authority to Issue Shares under Irish Law

Under Irish law, directors of an Irish public limited company must have authority from its shareholders to issue any shares, including shares which are part of the company’s authorized but unissued share capital. On May 4, 2018,6, 2020, shareholders granted the Board authority to issue shares, with such authority to expire on November 5, 2019.6, 2021. The proposed resolution seeks to renew the Board’s authority to issue shares.

It is customary practice in Ireland to seek shareholder authority to issue shares with an aggregate nominal value of up to 33% of the aggregate nominal value of the company’s issued share capital and for such authority to be renewed each year.

Consistent with that practice, we are seeking approval to issue up to a maximum of 33% of our issued ordinaryshare capital for a period expiring 18 months from the passing of this resolution, unless otherwise varied, revoked or renewed. We expect to propose renewal of this authorization on a regular basis at our annual general meetings in subsequent years.

Granting the Board this authority is a routine matter for public companies incorporated in Ireland and is consistent with Irish market practice. This authority is fundamental to our business and enables us to issue shares, including, if applicable, in connection with funding acquisitions and raising capital. We are not asking you to approve an increase in our authorized share capital or to approve a specific issuance of shares. Instead, approval of this proposal will only grant the Board the authority to issue shares that are already authorized under our Articles of Association upon the terms below. In addition, because we are a NYSE-listed company, our shareholders continue to benefit from the protections afforded to them under the rules and regulations of the NYSE and the U.S. Securities and Exchange Commission, including those rules that limit our ability to issue shares in specified circumstances. This authorization is required as a matter of Irish law and is

63  2021 Proxy Statement


Proposals to be Voted on

not otherwise required for other companies listed on the NYSE with whom we compete. Approval of this resolution would merely place us on par with other NYSE-listed companies.

Accordingly, we are asking shareholders to approve the following resolution as an Ordinary Resolution of the Company at the AGM:

RESOLVED that the directors are generally and unconditionally authorized to exercise all powers to allot and issue relevant securities (within the meaning of section 1021 of the Companies Act 2014)

up to an aggregate nominal value of approximately44,838 (44,838,11244,077.16 (44,077,160 shares) (being equivalent to approximately 33% of the aggregate nominal value of the issued share capital of the Company as at the last practicable date prior to the issue of the notice of this meeting) and that the authority conferred by this resolution shall expire 18 months from the passing of this resolution, unless previously renewed, varied or revoked; provided that the Company may make an offer or agreement before the expiry of this authority, which would or might require any such securities to be allotted after this authority has expired, and in that case, the directors may allot relevant securities in pursuance of any such offer or agreement as if the authority conferred had not expired.

 

The Board of Directors unanimously recommends that shareholders vote

FOR the renewal of the Board’s authority to issue shares under Irish law

Proposal 75 – Renew the Board’s Authority toOpt-out of

StatutoryPre-emption Rights under Irish Law

Under Irish law, unless otherwise authorized, when an Irish public limited company issues shares for cash to new shareholders, it is required first to offer those shares on the same or more favorable terms to existing shareholders of the company on apro-rata basis (commonly referred to as thepre-emption right). On May 4, 2018,6, 2020, shareholders granted the Board this authorization, with such authority to expire on November 5, 2019.6, 2021. The proposed resolution seeks to renew the Board’s authority toopt-out of statutorypre-emption rights.

It is customary practice in Ireland to seek shareholder authority toopt-out of thepre-emption rights provision in the event of (1) the issuance of shares in connection with any rights issue and (2) the issuance of shares for cash, if the issuance is limited to up to 5% of a company’s issued ordinary share capital (with the possibility of issuing an additional 5% of the company’s issued ordinary share capital provided the company uses it only in connection with an acquisition or specified capital investment that is announced contemporaneously with the issuance, or which has taken place in the precedingsix-month period and is disclosed in the announcement of the issue), bringing the total acceptable limit to 10% of the company’s issued ordinary share capital.

It is also customary practice for such authority to be limited to a period of up to 18 months. Consistent with these customary practices, we are seeking this authority for a period expiring 18 months from the passing of this resolution, unless otherwise varied, renewed or revoked. We expect to propose renewal of this authorization on a regular basis at our annual general meetings in subsequent years.

Granting the Board this authority is a routine matter for public companies incorporated in Ireland and is consistent with Irish customary practice. Similar to the authorization requested in Proposal 6,4, this authority is fundamental to our business and, if applicable, will facilitate our ability to fund acquisitions and otherwise raise capital. We are not asking you to approve an increase in our authorized share capital. Instead, approval of this

LOGO64


Proposals to be Voted on

proposal will only grant the Board the authority to issue shares in the manner already permitted under our Articles of Association upon the terms below. Without this authorization, in each case where we issue shares for cash, we would first have to offer those shares on the same or more favorable terms to all of our existing shareholders. This requirement could cause delays in the completion of acquisitions and capital raising for our business. This authorization is required as a matter of Irish law and is not otherwise required for other companies listed on the NYSE with whom we compete. Approval of this resolution would merely place us on par with other NYSE-listed companies.

Accordingly, we are asking shareholders to approve the following resolution as a Special Resolution of the Company at the AGM:

RESOLVED that, subject to and conditional on the passing of the resolution in respect of Proposal No. 64 as set out above, the directors are empowered pursuant to section 1023 of the Companies Act 2014 to allot and issue equity securities (within the meaning of section 1023 of the Companies Act 2014) for cash, pursuant to the authority conferred by Proposal No. 64 as if section 1022 of that Act did not apply to any such allotment, provided that this power shall be limited to:

(a) the allotment of equity securities in connection with a rights issue in favor of the holders of ordinary shares (including rights to subscribe for, or convert into, ordinary shares) where the equity securities respectively attributable to the interests of such holders are proportional (as nearly as may be) to the respective numbers of ordinary shares held by them (but subject to such exclusions or other arrangements as the directors may deem necessary or expedient to deal with fractional entitlements that would otherwise arise, or with legal or practical problems under the laws of, or the requirements of any recognized regulatory body or any stock exchange in, any territory, or otherwise); and

(a)

the allotment of equity securities in connection with a rights issue in favor of the holders of ordinary shares (including rights to subscribe for, or convert into, ordinary shares) where the equity securities respectively attributable to the interests of such holders are proportional (as nearly as may be) to the respective numbers of ordinary shares held by them (but subject to such exclusions or other arrangements as the directors may deem necessary or expedient to deal with fractional entitlements that would otherwise arise, or with legal or practical problems under the laws of, or the requirements of any recognized regulatory body or any stock exchange in, any territory, or otherwise); and

(b)

the allotment (otherwise than pursuant tosub-paragraph (a) above) of equity securities up to an aggregate nominal value of approximately13,587 (13,587,306 shares) (being equivalent to approximately 10% of the aggregate nominal value of the issued ordinary share capital of the Company as of February 26, 2019) (the latest practicable date before this Proxy Statement) provided that, with respect to 6,793,653 of such shares, (being equivalent to approximately 5% of the issued ordinary share capital as of February 26, 2019)

(b) the allotment (otherwise than pursuant to sub-paragraph (a) above) of equity securities up to an aggregate nominal value of 13,356.72 (13,356,720 shares) (being equivalent to approximately 10% of the aggregate nominal value of the issued ordinary share capital of the Company as of March15, 2021) (the latest practicable date before this Proxy Statement) provided that, with respect to 6,678,360 of such shares, (being equivalent to approximately 5% of the issued ordinary share capital as of March 15, 2021),such allotment is to be used for the purposes of an acquisition or a specified capital investment;

and, in each case, the authority conferred by this resolution shall expire 18 months from the passing of this resolution, unless previously renewed, varied or revoked; provided that the Company may make an offer or agreement before the expiry of this authority, which would or might require any such securities to be allotted after this authority has expired, and in that case, the directors may allot equity securities in pursuance of any such offer or agreement as if the authority conferred hereby had not expired.

 

The Board of Directors unanimously recommends that shareholders vote FOR the renewal of the Board’s authority toopt-out of statutorypre-emption rights under Irish law

Other Matters

65  2021 Proxy Statement


Other Matters

Presentation of Irish Statutory Financial Statements

The Company’s Irish Statutory Financial Statements for the fiscal year ended December 31, 2018,2020, including the reports of the directors and auditor thereon, will be considered at the AGM. Since we are an Irish company, we are required to prepare Irish statutory financial statements under applicable Irish company law and to deliver those accounts to shareholders of record in connection with our AGM. There is no requirement under Irish law that such statements be approved by shareholders, and no such approval will be sought at the AGM. We will mail without charge, upon written request, a copy of the Irish Statutory Financial Statements to beneficial owners of our shares and shareholders of record. Requests should be sent to: Perrigo Company plc, Attention: Todd W. Kingma, Company Secretary, Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland, or at GeneralMeeting@perrigo.com. The Company’s Irish Statutory Financial Statements are also available on our website at www.perrigo.com.

LOGO66


Annual Report on Form 10-K

Annual Report on Form10-K

A copy of our Annual Report on Form10-K for the fiscal year ended December 31, 2018,2020, including financial statement schedules, is on file with the Securities and Exchange Commission and delivered with this proxy statement. If you would like a copy of the exhibits to the Form10-K, please contact Todd W. Kingma, Company Secretary, Perrigo Company plc, Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland, or at GeneralMeeting@perrigo.com.

67  2021 Proxy Statement


Questions and Answers and Voting Information

Questions and Answers and Voting Information

 

1.

Who may vote and how many votes do I have?

 

    

Shareholders owning Perrigo’s ordinary shares at the close of business on February 26, 2019,March 15, 2021, the record date, or their proxy holders, may vote their shares at the AGM. On that date, there were 135,873,069133,567,151 Perrigo ordinary shares outstanding.

 

    

Each ordinary share held as of the record date is entitled to one vote on each matter properly brought before the AGM.

 

2.

What is the difference between holding shares as a shareholder of record and as a beneficial owner?

 

    

Shareholder of Record:If your ordinary shares are registered directly in your name with Perrigo’s Transfer Agent, Computershare, you are considered, with respect to those shares, the “shareholder of record.”

 

    

Beneficial Owner:If your shares are held in a brokerage account or by another nominee (including through a Tel Aviv Stock Exchange (“TASE”) Clearing House member), you are considered to be the beneficial owner of shares held in “street name,name.andIf you are a beneficial shareholder (other than of shares traded through the TASE), these proxy materials, together with a voting instruction card, are being forwarded to you by your broker, bank or other nominee. As the beneficial owner of the shares, you have the right to direct your broker, bank or other nominee how to vote, and you are also invited to attend, but not vote at, the AGM.vote. If you are a beneficial owner, you may not vote your shares in person at the AGM unless you obtain a legal proxy giving you the right to vote those shares at the AGM from the broker, bank or other nominee holding your shares in street name, or if you are a beneficial owner of shares traded through TASE, the TASE unless you obtain a certificate of ownership from the Tel Aviv Stock Exchange Clearing House Ltd. (the “TASE Clearing House”) member through which you hold your shares are registered.If your shares are held in this way, your broker, bank or other nominee should have enclosed or provided voting instructions for you to use in directing the broker, bank or other nominee how to vote your shares.

 

3.

How do I vote?

 

    

While you should follow the specific voting instructions given by your bank, broker or other nominee; here is a summary of the common voting methods:

 

    

If you own ordinary shares as a shareholder of record, you may vote your shares in any of the following ways:

 

 ·  

mailing your completed and signed proxy card in the enclosed return envelope by following the instructions set forth in the enclosed proxy card;

 ·  

voting by telephone by following the recorded instructions or over the Internet as instructed on the enclosed proxy card;card or by telephone by following the recorded instructions or;

 ·  

attending the virtual AGM and voting in person.electronically.

If you vote by Internet or by telephone, your electronic vote authorizes the named proxies in the same manner as if you signed, dated and returned a proxy card by mail.

If you vote by Internet or by telephone, your electronic vote authorizes the named proxies in the same manner as if you signed, dated and returned a proxy card by mail.

If you hold your shares in street name (other than through a TASE Clearing House member):

 

 ·  

You will needare invited to attend, but not vote at, the AGM unless you obtain a legal proxy from your bank, broker or nominee in order forgiving you the right to vote in personthose shares at the AGM from the broker, bank or other nominee holding your shares in street name and submit thethat legal proxy along with your ballot atto Mediant in advance of the AGM. In addition, you may request paper copies of the Proxy Statement from your broker, bank or nominee by following the instructions on the Internet Notice of Availability provided by your broker, bank or nominee.

LOGO68


Questions and Answers and Voting Information

If you own shares that are traded through the TASE,you may vote your shares in one of the following two ways:

 

 ·  

By mail: complete, sign and date the proxy card (in the form filed by the Company on MAGNA, the distribution site of the Israel Securities Authority, at www.magna.isa.gov.il) and attach to it an ownership certificate from the TASETel Aviv Stock Exchange Clearing House Ltd (the “TASE Clearing House”) member through which your shares are registered (i.e., your broker, bank or other nominee) indicating that you were the beneficial owner of the shares on February 26, 2019,March 15, 2021, the record date for voting, and return the proxy card along with the ownership certificate, to our designated address for that purpose in Israel, P.O. Box 7100, Tel Aviv, 6107002, Israel. The proxy card and ownership certificate must be received no later than April 22, 2019 at 11:49 p.m., to be included in the tally of shares voted at the AGM. If the TASE member holding your shares is not a TASE Clearing House member, please make sure to include an ownership certificate from the TASE Clearing House member in which name your shares are registered. The proxy card and ownership certificate must be received no later than May 9, 2021 at 11:59 p.m. Israel Time to be included in the tally of shares voted at the AGM.

 

 ·  

In person: attendVoting electronically: shareholders who hold shares through members of the AGM, where ballots will be provided.TASE may vote electronically via the electronic voting system of the Israel Securities Authority no later than May 9, 2021 at 11:30 p.m. Israel Time. You should receive instructions about electronic voting from the TASE member through which you hold your shares.

·

Attending and voting at the virtual AGM: If you choosewish to voteparticipate in person at the virtual AGM, you needmust register in advance of the Registration Deadline of May 10, 2021 at 5:00 p.m. (U.S. Eastern Time). To register for the virtual AGM, you must send an email to bringthe Company at GeneralMeeting@perrigo.com, together with an ownership certificate that you may obtain from the TASE Clearing House member through which your shares are registered (i.e., your broker, bank or other nominee) indicating that you were the beneficial owner of the shares on February 26, 2019,March 15, 2021, the record date for voting. If the TASE member holding your shares is not a TASE Clearing House member, please make sure to include an ownership certificate from the TASE Clearing House member in which name your shares are registered. Once ownership is verified, Mediant will send an email to you with registration instructions and a control number in order to register for the virtual AGM which must be completed prior to the foregoing Registration Deadline. After completion of your registration by the foregoing Registration Deadline noted above, further instructions, including a link to access the AGM will be emailed to you to access the virtual AGM.

Other than as set out in this Proxy Statement, the Board knows of no other matter to be presented at the AGM. If any other business properly comes before the AGM, such business will be decided on a poll conducted on www.proxydocs.com/PRGO.

 

4.

If I voted by proxy, can I still attend and vote electronically at the virtual AGM?

Yes. Even if you have voted by proxy, you may still attend and vote electronically at the virtual AGM. Please note, however, that if you are a beneficial owner whose shares are held in street name, you are not the shareholder of record. In that event, if you wish to attend and vote electronically at the virtual AGM, you must obtain a proxy issued in your name from that holder of record giving you the right to vote your shares electronically at the virtual AGM. In either case, you will need to register for the virtual AGM or ifby the foregoing Registration Deadline. Upon completing registration further instructions including a link to access the AGM will be emailed to you.

69  2021 Proxy Statement


Questions and Answers and Voting Information

If you are a beneficial owner of shares traded through the TASE and wish to participate in the virtual AGM, you must obtain a certificate of ownership from the TASE Clearing House member through which your shares are registered.registered and send it to the Company at GeneralMeeting@perrigo.com, following which you will receive an email from Mediant with instructions and a control number to register for the virtual AGM. After completion of your registration for the virtual AGM, prior to the Registration Deadline of May 10, 2021 at 5:00 p.m. (U.S. Eastern Time), further instructions including a link to access the virtual AGM will be emailed to you.

 

5.

May I change my vote after I have mailed my signed proxy card or voted by telephone or over the Internet?

Yes, if you own ordinary shares as a shareholder of record, you may change your vote at any time before your proxy is voted at the AGM in one of four ways:

 

 ·  

timely deliver a valid later-dated proxy by mail by following the instructions set forth in the enclosed proxy card;

 ·  

timely deliver written notice that you have revoked your proxy to the Company Secretary at the following address:

Perrigo Company plc,

Sharp Building,

Hogan Place,

Dublin 2, D02 TY74, Ireland

Attn: Company Secretary;

 

 ·  

timely submit revised voting instructions by telephone or over the Internet by following the instructions set forth on the proxy card; or

 ·  

attend the virtual AGM and vote in person. Simply attending the virtual AGM, however, will not revoke your proxy or change your voting instructions; you must vote by ballotelectronically at the AGM to change your vote. You will need to register for the virtual AGM by the foregoing Registration Deadline. Upon completing registration further instructions including a link to access the virtual AGM will be emailed to you.

If you are a beneficial owner of shares held in street name (including through a TASE Clearing House member) and you have instructed your bank, broker or other nominee to vote your shares, you may revoke your proxy at any time, before it is exercised, by:

 

 ·  

following the requirements of your bank, broker or nominee or, if your shares are traded through the TASE, the TASE Clearing House member through which your shares are registered; or

 ·  

voting in person atattending the virtual AGM, by registering for the AGM prior to the Registration Deadline stated above and voting electronically at it by obtaining a legal proxy from your bank, broker or nominee and submitting the legal proxy with your ballot (ifto Mediant in advance of the AGM(if your shares are traded through the NYSE) or by obtaining a certificate of ownership from the TASE Clearing House member through which your shares are registered and submitting the certificate of ownership alongto the Company at GeneralMeeting@perrigo.com to obtain an email from Mediant with your ballotinstructions and a control number to register for the virtual AGM, which must be completed prior to the Registration Deadline stated above (if your shares are traded through the TASE).

 

LOGO70


Questions and Answers and Voting Information

6.

Participating in the Meeting.

Due to the ongoing public health crisis caused by COVID-19, this year’s AGM will be a virtual only meeting accessible through the internet. If you wish to participate in the AGM, you must be a shareholder on the record date. To be admitted to the virtual AGM, prior registration is required by 5:00 p.m. (U.S. Eastern Time) on May 10, 2021, the Registration Deadline at www.proxydocs.com/PRGO. The Notice, proxy card, or other voting instruction form sent to you with this Proxy Statement contains a control number. If you hold your shares in a broker or bank or other account, and cannot locate your Control Number, you must contact the broker, bank or other institution where you have your account to obtain your Control Number. As part of the registration process, you must enter your Control Number. After completion of your registration by the Registration Deadline, further instructions, including a unique link to access the AGM, will be emailed to you.

If you are a beneficial owner of shares traded through the TASE and wish to participate in the virtual AGM, you must obtain a certificate of ownership from the TASE Clearing House member through which your shares are registered and send it to the Company at GeneralMeeting@perrigo.com, following which you will receive an email from Mediant with instructions and a control number to register for the virtual AGM. After completion of your registration for the virtual AGM, prior to the Registration Deadline of May 10, 2021 at 5:00 p.m. (U.S. Eastern Time), further instructions including a link to access the virtual AGM will be emailed to you.

This year’s shareholder question and answer session will include questions submitted in advance of the virtual AGM. You may submit a question in advance of the meeting at www.proxydocs.com/PRGO after registering for the meeting by logging in with your Control Number.

Shareholders may vote and submit questions while connected to the virtual AGM. Once registered by the Registration Deadline, you must follow the email instructions received from Mediant and click on the unique link to attend the virtual AGM online, to vote or submit comments or questions on proposals, and exercise any other shareholder rights at the virtual AGM. If you have already voted by proxy before the virtual AGM, you are not required to vote again at the virtual meeting unless you want to change your vote after submitting the proxy. Additional information regarding the rules and procedures for participating in the virtual AGM will be set forth in our meeting rules of conduct, which shareholders can view during the meeting at the virtual meeting site.

7.

Technical Support to Participate in Virtual AGM.

Anyone who has technical difficulties accessing or using the virtual meeting site during the AGM should call the technical support number on the virtual meeting site or in the email with instructions. The virtual meeting site is supported on browsers (e.g., Internet Explorer, Firefox, Chrome and Safari) and devices (desktops, laptops, tablets and cell phones) running the most updated version of applicable software and plugins. Each participant should ensure strong Wi-Fi or other internet connection.

8.

How does discretionary voting authority apply?

If you sign, date and return your proxy card or vote by telephone or Internet, your vote will be cast as you direct. If you do not indicate how you want to vote, you give authority to Ron WinowieckiRay Silcock and Todd Kingma to vote on the items discussed in these proxy materials and on any other matter that is properly raised at the AGM. In that event, your proxy will be voted consistent with the Board’s voting recommendations and FOR or AGAINST any other properly raised matters at the discretion of Ron WinowieckiRay Silcock and Todd Kingma.

 

71  2021 Proxy Statement


7.

Questions and Answers and Voting Information

9.

What constitutes a quorum?

According to our Memorandum and Articles of Association and the presence ofIrish Companies Act 2014 (as amended by the Companies (Miscellaneous Provisions)(COVID-19) Act 2020), one or more persons present at the virtual meeting and holding or representing by proxy more than 50% of the total issued shares constitutes a quorum. You will be considered part of the quorum if you return a signed and dated proxy card, vote by telephone or Internet, or attend the AGM in person.virtual AGM. Abstentions and brokernon-votes are counted as “shares present” at the AGM for purposes of determining whether a quorum is present at the meeting.

 

8.10.

What are brokernon-votes?

A brokernon-vote occurs when the broker, bank or other holder of record that holds your shares in street name is not entitled to vote on a matter without instruction from you and you do not give any

instruction. Unless instructed otherwise by you, brokers, banks and other street name holders will not have discretionary authority to vote on any matter at the AGM other than Proposal 2Proposals 2,4 and 5 and will be considered “brokernon-votes” having no effect on the relevant resolution.

 

9.11.

What is the required vote?

To pass an ordinary resolution, a simple majority of the votes cast in person or by proxy must be in favor of the resolution, while 75% of the votes cast is required for a special resolution to pass.

The election of each person nominated to serve as a director in Proposal 1 and Proposals2-41-4 and 6 are ordinary resolutions requiring a simple majority of votes cast. ProposalsProposal 5 and 7 areis a special resolutionsresolution requiring 75% of votes cast to pass. Abstentions and brokernon-votes will have no impact on the outcome of any proposal.

 

10.12.

How do I submit a shareholder proposal or director nomination for the next AGM?

If you want to submit a proposal for inclusion in our proxy statement for the 20202022 AGM or nominate an individual for election as a director at the 20202022 AGM, you should carefully review the relevant provisions of the Company’s Memorandum and Articles of Association. You must submit your proposal no later than November 15, 2019.YourDecember 2, 2021. Your nomination or proposal must be in writing and must comply with the proxy rules of the Securities and Exchange Commission (the “SEC”) and the Memorandum and Articles of Association of the Company. If you want to submit a nomination or proposal to be raised at the 20202022 AGM but not included in the proxy statement, we must receive your written proposal on or after January 27, 2020,February 11, 2022, but on or before February 16, 2020.March 3, 2022. If you submit your proposal after the deadline, then SEC rules permit the individuals named in the proxies solicited by Perrigo’s Board of Directors for that meeting to vote on that proposal at their discretion, but they are not required to do so.

To properly bring a proposal (other than the nomination of a director) before an annual general meeting, the advance notice provisions of our Articles of Association require that your notice of the proposal must include in summary: (1) your name and address and the name and address of the beneficial owner of the shares, if any; (2) the number of Perrigo ordinary shares owned beneficially and of record by you and any beneficial owner as of the date of the notice (which information must be supplemented as of the record date); (3) a description of certain agreements, arrangements or understandings that you or any beneficial owner have entered into with respect to the shares (which information must be supplemented as of the record date) or the business proposed to be brought before the meeting; (4) a representation that you or any beneficial owner are the holder of shares entitled to vote at the meeting and intend to appear at the meeting to propose such business; (5) a representation whether you or any beneficial owner are a part of a

LOGO72


Questions and Answers and Voting Information

group that intends to deliver a proxy statement or otherwise solicit proxies on the proposal; (6) any other information regarding you or any beneficial owner that would be required under the SEC’s proxy rules and regulations; and (7) a brief description of the business you propose to be brought before the meeting, the reasons for conducting that business at the meeting, and any material interest that you or any beneficial owner has in that business. You should send any proposal to our Company Secretary at Perrigo Company plc, Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland.

With respect to director nominations, the advance notice provisions of our Articles of Association require that your notice of nomination must include: (1) your name and address and the name and address of the beneficial owner of the shares, if any; (2) the number of Perrigo ordinary shares

owned beneficially and of record by you and any beneficial owner as of the date of the notice (which information must be supplemented as of the record date); (3) a description of certain agreements, arrangements or understandings that you or any beneficial owner have entered into with respect to the shares (which information must be supplemented as of the record date); (4) a representation that you or any beneficial owner are the holder of shares entitled to vote at the meeting and intend to appear at the meeting to propose such business; (5) a representation whether you or any beneficial owner are a part of a group that intends to deliver a proxy statement or otherwise solicit proxies on the proposal; (6) the name, age and home and business addresses of the nominee; (7) the principal occupation or employment of the nominee; (8) the number of Perrigo ordinary shares that the nominee beneficially owns; (9) a statement that the nominee is willing to be nominated and serve as a director; (10) an undertaking to provide any other information required to determine the eligibility of the nominee to serve as an independent director or that could be material to shareholders’ understanding of his or her independence; and (11) any other information regarding you, any beneficial owner or the nominee that would be required under the SEC’s proxy rules and regulations had our Board of Directors nominated the individual. You should send your proposed nomination to our Company Secretary at Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland.

 

11.13.

How do I use proxy access to nominate a director candidate for the next AGM?

Any stockholder or group of up to 20 stockholders meeting our continuous ownership requirement of 3% or more of our ordinary shares for at least 3 years who wishes to nominate a candidate or candidates for election in connection with our 20202022 AGM and require us to include such nominees in our proxy statement and form of proxy must submit their nomination and request so it is received by us on or after October 16, 2019,November 2, 2021, but on or before November 15, 2019.December 2, 2021. The number of candidates that may be so nominated is limited to the greater of two or the largest whole number that does not exceed 20% of the Board. Loaned shares recallable on five U.S. business days’ notice count as owned for purposes of meeting the continuous ownership requirement, but each stockholder in the requesting group must have full voting and investment rights as well as economic interest in their shares at the time of nomination, record date and meeting date. Two or more investment funds that are under common management and investment control will count as one stockholder for purposes of determining the size of the group. All proxy access nominations must meet the requirements of the Company’s Memorandum and Articles of Association. You should send your nomination and request to our Company Secretary at Perrigo Company plc, Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland.

 

12.14.

What are the Irish Statutory Financial Statements?

The Irish Statutory Financial Statements are the financial statements required to be prepared in accordance with the Irish Companies Act 2014 and cover the results of operations and financial position of the Company for the fiscal year ended December 31, 2018.2020. Our Irish statutory financial statements, including

73  2021 Proxy Statement


Questions and Answers and Voting Information

the reports of the auditor and the directors thereon, will be considered at the AGM and we are mailing those accounts to shareholders of record. Since we are an Irish company, we are required to prepare Irish statutory financial statements under applicable Irish company law and deliver those accounts to shareholders of record in connection with our AGM. However, as shareholder approval of those financial statements is not required, it will not be sought at the AGM. We will mail without charge, upon written request, a copy of the Irish statutory financial statements to beneficial owners and shareholders of record of our shares. Requests should be sent to: Perrigo

Company plc, Attention: Company Secretary, Sharp Building, Hogan Place, Dublin 2, D02 TY74, Ireland or by email at GeneralMeeting@perrigo.com.

 

13.15.

What does it mean if I receive more than one proxy card?

Your shares are likely registered differently or are in more than one account. You should complete and return each proxy card you receive to guarantee that all of your shares are voted.

 

14.16.

Who pays to prepare, mail and solicit the proxies?

Perrigo pays all of the costs of preparing and mailing the proxy statement and soliciting the proxies. We do not compensate our directors, officers and employees for mailing proxy materials or soliciting proxies in person, by telephone or otherwise.

 

15.17.

Can I access these proxy materials on the Internet?

Yes. TheOur Proxy Statement, and our Annual Report on Form10-K, Irish Statutory Financial Statements and a link to the means to vote by Internet are available athttp://www.viewproxy.com/perrigo/2019.at www.proxydocs.com/PRGO.

LOGO74


 Exhibit A

EXHIBIT A

The Company providesnon-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company’s ongoing operating trends, facilitating comparability between periods and companies in similar industries and assessing the Company’s prospects for future performance. Thesenon-GAAP financial measures exclude items, such as impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. Thenon-GAAP measures the Company provides are consistent with how management analyzes and assesses the operating performance of the Company, and disclosing them provides investor insight into management’s view of the business. Management uses these adjusted financial measures for planning and forecasting in future periods, and evaluating segment and overall operating performance. In addition, management uses certain of the profit measures as factors in determining compensation.

PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES

Table I

(in millions)

(unaudited)

 

  Twelve Months Ended 
  December 31, 2018 
  Operating Income   Twelve Months Ended
December 31, 2020

Consolidated

    Net
Sales
  Operating
Income

Reported

  $    236.5   $5,063.3  $115.4

As a % of reported net sales

   5.0

Effective tax rate

  

Adjustments:

  

Pre-tax adjustments:

    

Amortization expense related primarily to acquired intangible assets

  $338.6   $—  $295.0

Acquisition and integration-related charges and contingent consideration adjustments

   56.6     —  13.9

Restructuring charges and other termination benefits

   28.4     —  3.6

Gain/Loss on divestitures

   (5.0

(Gain) loss on divestitures

    —  0.2

Unusual litigation

   3.2     —  19.8

Separation and reorganization expense

   13.9     —  1.1

Impairment charges

   224.4     —  346.8
  

 

   

 

  

 

Adjusted

  $896.6   $5,063.3  $795.8

As a % of reported net sales

   18.9

1  2021 Proxy Statement


Exhibit A

Twelve Months Ended    
December 31, 2019    
ConsolidatedNet
Sales

Reported

$4,837.4

Pre-tax adjustments:

Operating results attributable to held-for-sale business*

(24.1)

Ranitidine market withdrawal**

9.2

Adjusted

$4,822.5

* Held-for-sale business includes our now divested animal health business.

** Ranitidine market withdrawal includes reversal of recorded returns and inventory write-downs.

   Twelve Months Ended
December 31, 2020
  Twelve Months Ended
December 31, 2019
Consumer Self-Care Americas  Net
Sales
  Net
Sales

Reported

  $2,693.0  $2,487.7

Pre-tax adjustments:

    

Operating results attributable to held-for-sale business**

    (24.1)

Ranitidine market withdrawal*

    7.4
  

 

  

 

Adjusted

  $2,693.0  $2,471.0

* Ranitidine market withdrawal includes reversal of recorded returns and inventory write-downs.

** Held-for-sale business includes our now divested animal health business.

   Twelve Months Ended
December 31, 2020
              Twelve Months Ended
December 31, 2019
Consumer Self-Care International  Net
Sales
              Net
Sales

Reported

  $1,395.2        $1,382.2

Pre-tax adjustments:

          

Ranitidine market withdrawal*

          1.8
  

 

Adjusted

  $1,395.2        $1,384.0

* Ranitidine market withdrawal includes reversal of recorded returns and inventory write-downs.

LOGO2


Exhibit A

PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES

Table I (continued)II

(in millions)

(unaudited)

   Twelve Months Ended   
   December 31, 2018 
   Gross
Profit
      Operating
Income
 

Consumer Healthcare International

     

Reported

  $702.5    $16.5 

As a % of reported net sales

   47.0    1.1

Adjustments:

     

Amortization expense primarily related to acquired intangible assets

  $87.6    $200.1 

Impairment charges

   -     1.8 

Restructuring charges and other termination benefits

               -             17.4 

Unusual litigation

   -     3.2 

Acquisition and integration-related charges and contingent consideration adjustments

   -     (0.3
  

 

 

    

 

 

 

Adjusted

  $790.1    $238.7 

As a % of reported net sales

   52.8    16.0

 

   Twelve Months Ended          
   December 31,
2018
  December 31,
2017
  Total
Change
  FX
Change
  Constant
Currency Change
 

Net sales

      

CHCA

  $  2,411.6  $  2,429.9    

Less: animal health net sales

   (93.9  (141.3   
  

 

 

  

 

 

    
  $2,317.7  $2,288.6   1.3  0.1  1.4
  Twelve Months Ended      
   December 31,
2020
 December 31,
2019
 Total
Change
 FX
Change
 Constant
Currency
Change

Adjusted Net Sales

     

Consolidated net sales as so adjusted

 $5,063.3 $4,822.5 5.0%  

Less: Animal health*

  (19.6)   

Less: Canoderm prescription product

  (13.2)   

Less: Rosemont Pharmaceuticals business

  (27.1)   
 

 

   

Consolidated net sales as so adjusted excluding divested businesses

 $5,063.3 $4,762.6 6.3% 0.1% 6.4%

Less: Ranir***

 (139.1)    

Less: Dr. Fresh**

 (72.3)    

Less: Eastern European Brands Acquisition

 (2.1)    
 

 

   

Organic Consolidated net sales as so adjusted

 $4,849.8 $4,762.6 1.8% 0.1% 1.9%

CSCA net sales as so adjusted

 $2,693.0 $2,471.0 9.0%  

Less: Animal health*

  (19.6)   
 

 

   

CSCA net sales as so adjusted excluding divested businesses

 $2,693.0 $2,451.4 9.9% 0.4% 10.3%

Less: Ranir***

 (100.0)    

Less: Dr. Fresh**

 (68.2)    
 

 

   

Organic CSCA net sales as so adjusted

 $2,524.8 $2,451.4 3.0% 0.4% 3.4%

CSCI net sales as so adjusted

 $1,395.2 $1,384.0 0.8%  

Less: Rosemont Pharmaceuticals business

  (27.1)   

Less: Canoderm prescription product

  (13.2)   
 

 

   

CSCI net sales as so adjusted excluding divested businesses

 $1,395.2 $1,343.7 3.8% (0.2)% 3.6%

Less: Ranir***

 (39.1)    

Less: Dr. Fresh**

 (4.1)    

Less: Eastern European Brands Acquisition

 (2.1)    
 

 

   

Organic CSCI net sales as so adjusted

 $1,349.9 $1,343.7 0.5% (0.3)% 0.2%

RX

 $975.1 $967.5 0.8%  

* This line item excludes the $19.6 million in animal health net sales before the business was classified as held-for-sale for comparative purposes only. This amount is in addition to the $24.1 million of animal health net sales that was excluded from adjusted net sales for the twelve months ended December 31, 2019.

** Dr. Fresh acquisition comprises all oral self-care assets purchased from High Ridge Brands, including the brands Dr. Fresh®, REACH® and Firefly®.

*** Includes Ranir net sales through the second quarter of 2020.

 

   Twelve Months Ended   
   December 31, 2018 

Operating cash flow

  $593.0 

Less: IPR&D Investments

                       50.0 
  

 

 

 

Adjusted operating cash flow

  $643.0 

Adjusted net income

  $628.9 

Cash conversion ratio

   102

LOGO

3  2021 Proxy Statement


ANNEX ALOGO

PERRIGO COMPANY PLC

2019 LONG-TERM INCENTIVE PLAN

SECTION 1.PURPOSE AND HISTORY. Perrigo Company,Perrigo(r) P.O. BOX 8016, CARY, NC 27512-9903 Approved US Proxy Card - Peggy Milbocker - March 16, 2021 at 9:51 a.m. YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: INTERNET Go To: www.proxypush.com/PRGO Cast your vote online Have your Proxy Card ready. Follow the simple instructions to record your vote. PHONE Call 1-866-859-2051 Use days any a Michigan corporation, sponsoredweek. touch-tone telephone, 24 hours a day, 7 Have your Proxy Card ready. Follow the Perrigo Company 2008 Long-Term Incentive Plan (the “2008 Plan”) to encourage employees, directorssimple recorded instructions. MAIL Mark, sign and other persons providing significant services to Perrigo Companydate your Proxy Card. Fold and its subsidiaries and/or Affiliates to acquire a proprietary interestreturn your Proxy Card Form in the growth and performance of Perrigo Company, to generate an increased incentive to contribute to its future success and prosperity, thus enhancing the value of Perrigo Company for the benefit of share owners, and to enhance the ability of Perrigo Company to attract and retain individuals of exceptional talent upon whom, in large measure, the sustained progress, growth and profitability of Perrigo Company depends. Perrigo Company amended and restated the 2008 Plan and renamed the 2008 Plan the Perrigo Company 2013 Long-Term Incentive Plan (the “2013 Plan”) which was approved by the Perrigo Company shareholders on November 18, 2013. Effective December 18, 2013, Perrigo Company became a wholly-owned subsidiary ofpostage-paid envelope provided. Perrigo Company plc a public limited company headquartered in Ireland, and Perrigo Company plc assumed sponsorshipAnnual General Meeting of Shareholders For Shareholders as of March 15, 2021 TIME: Wednesday, May 12, 2021 08:30 AM, Eastern Time (1:30 PM Irish Time) PLACE: Annual General Meeting to be held live via the 2013 Plan. Perrigo Company plc has amended and restated the 2013 Plan, as set forth herein, and has renamed the 2013 Plan the Perrigo Company plc 2019 Long-Term Incentive Plan (the “2019 Plan” or the “Plan”).

SECTION 2.DEFINITIONS. As used in the Plan, the following terms shall have the meanings set forth below:

(a) “Affiliate” and “Associate” have the respective meanings ascribed to such terms in Rule12b-2Internet - please visit www.proxydocs.com/PRGO for more details. CONTROL NUMBER <- Please fold here - Do not separate -> This proxy is being solicited on behalf of the General Rules and Regulations under the Exchange Act.

(b) “Award” means any Option, Stock Appreciation Right, Restricted Share Award, Performance Share, Performance Unit, Restricted Share Unit, or any other right, interest, or option relating to Shares or other securities of Perrigo granted pursuant to the provisions of the Plan.

(c) “Award Agreement” means any written agreement, contract, or other instrument or document evidencing any Award granted hereunder and signed by both Perrigo and the Participant.

(d) “Beneficiary” means the person or persons to whom an Award is transferred by his or her will or by the laws of descent and distribution of the state in which the Participant resided at the time of his or her death.

(e) “Board” means the Board of Directors of Perrigo Company plc.

(f) “Cause” means any of the following events, as determined by the Committee:

(1) The commission of an act which, if proven in a court of law, would constitute a felony violation under applicable criminal laws;

(2) A breach of any material duty or obligation imposed upon the Participant by the Company;

(3) Divulging the Company’s confidential information, or breaching or causing the breach of any confidentiality agreement to which the Participant or the Company is a party;

(4) Engaging or assisting others to engage in business in competition with the Company;

(5) Refusal to follow a lawful order of the Participant’s superior or other conduct which the Board or the Committee determines to represent insubordination on the part of the Participant; or

(6) Other conduct by the Participant which the Board or the Committee, in its discretion, deems to be sufficiently injurious to the interests of the Company to constitute cause.

(g) “CEO” means the Chief Executive Officer of Perrigo.

(h) A “Change in Control” means the occurrence of any of the following:

(1) Any person, entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act or any comparable successor provisions) (other than (A) Perrigo, (B) any employee benefit plan of the Company or any Trustee of or fiduciary with respect to any such plan when acting in such capacity, or (C) any person who, on the Effective Date of the Plan, is an Affiliate of Perrigo and owning in excess of ten percent (10%) of the outstanding Shares of Perrigo and the respective successors, executors, legal representatives, heirs and legal assigns of such person), alone or together with its Affiliates and associates, and other than in a merger or consolidation of the type referred to in subsection (h)(2) below, has acquired or obtained the right to acquire the beneficial ownership of fifty percent (50%) or more of the Shares then outstanding;

(2) The consummation of a merger, consolidation or similar transaction involving Perrigo and, immediately after the consummation of such merger, consolidation or similar transaction, the shareholders of Perrigo immediately prior to such consummation do not beneficially own (within the meaning of Rule13d-3 of the Exchange Act or comparable successor rules), directly or indirectly, either (A) outstanding voting securities representing more than fifty percent (50%) of the combined voting power of the surviving entity in such merger, consolidation or similar transaction, or (B) outstanding voting securities representing more than fifty percent (50%) of the combined voting power of the parent of the surviving entity in such merger, consolidation or similar transaction; or

(3) The Continuing Directors no longer constitute a majority of the Board.

(i) “Code” means the Internal Revenue Code of 1986, as amended from time to time, and any successor thereto.

(j) “Committee” means the Remuneration Committee of the Board, which shall consist of not fewer than three directors, taking into consideration for each such director (i) the rules under Section 16(b) of the Exchange Act regarding“non-employee directors,” (ii) to the extent the administration of an Award relates to a Grandfathered Award, the requirements of Section 162(m) of the Code regarding “outside directors,” and (iii) the rules regarding “independent directors” of the securities exchange on which the Shares are listed, or any successor definition to any of the foregoing. For purposes of the Plan, reference to the Committee shall be deemed to refer to any subcommittee, subcommittees, or other persons or groups of persons to whom the Committee’s authority has been delegated pursuant to Section 3(a) or Section 3(b) of the Plan.

(k) “Company” means Perrigo Company plc, its subsidiaries and/or Affiliates.

(l) “Continuing Director” means any person who was a member of the Board on the Effective Date of the Plan, and any new director thereafter elected by the shareholders or appointed by the

Board, provided such new director’s election or nomination for election by the Perrigo shareholders was approved by a majority of directors who were either directors on the Effective Date or whose election or nomination for election was previously so approved.

(m) “Covered Employee” means a “covered employee” within the meaning of Section 162(m)(3) of the Code as in effect immediately prior to enactment of P.L.115-97.

(n) “Disability” means (i) with respect to an Employee, disability as defined under the Company’s long term disability insurance plan under which such Employee is then covered; (ii) with respect to any Participant who is not covered under a Company long-term disability plan, the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as determined by the Committee in its sole discretion.

(o) “Dividend Equivalent” means a credit made to the bookkeeping account maintained by the Committee on behalf of a Participant, in an amount equal to the dividends paid on one Share for each Share represented by an Award held by such Participant, as described in Section 11 hereof.

(p) “Effective Date” has the meaning set forth in Section 17 hereof.

(q) “Employee” means any employee of the Company.

(r) “Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time, and any successor thereto.

(s) “Fair Market Value” means (i) with respect to a Share, the last reported sale price of a Share on the date of determination, or on the most recent date on which the Share is traded prior to that date, as reported on the securities exchange on which the Shares are listed, and (ii) with respect to any other property, the fair market value of such property determined by such methods or procedures as shall be established from time to time by the Committee.

(t) “Grandfathered Award” means an Award granted to a Covered Employee prior to November 2, 2017, which is (i) intended to constitute “qualified performance-based compensation” within the meaning of Section 162(m) of the Code as in effect immediately prior to enactment of P.L.115-97 and (ii) not modified in any material respect on or after November 2, 2017, within the meaning of Section 13601(e)(2) of P.L.115-97, as may be amended from time to time (including any rules and regulations promulgated thereunder).

(u) “Incentive Stock Option” means an Option that, at the time such Option is granted under Section 6 hereof, qualifies as an incentive stock option within the meaning of Section 422 of the Code or any successor provision thereto. Only Employees may be awarded Incentive Stock Options.

(v) “Involuntary Termination for Economic Reasons” means that the Participant’s Termination Date occurs due to involuntary termination of employment by the Company by reason of a corporate restructuring, a disposition or acquisition of a business or facility, or a downsizing or layoff, as determined by the CEO, in his sole discretion, or by the Committee in the case of a Participant subject to Section 16 of the Exchange Act.

(w) “Nonstatutory Stock Option” means an Option granted under Section 6 hereof that is not intended to be an Incentive Stock Option.

(x) “Option” means an Award of an Incentive Stock Option or a Nonstatutory Stock Option.

(y) “Original Effective Date” means October 28, 2003.

(z) “Participant” means an Employee who has been granted an Award under the Plan.

(aa) “Performance Award” means any Award of Performance Shares or Performance Units pursuant to Section 9 hereof.

(bb) “Performance Period” means the period established by the Committee at the time any Performance Award is granted or at any time thereafter during which the performance goals specified by the Committee with respect to such Award are to be measured.

(cc) “Performance Share” means any grant pursuant to Section 9 hereof of a unit valued by reference to a designated number of Shares, which value may be paid to the Participant by delivery of such property as the Committee shall determine, including, without limitation, cash, Shares, or any combination thereof, upon achievement of such performance goals during the Performance Period as the Committee shall establish at the time of such grant or thereafter.

(dd) “Performance Unit” means any grant pursuant to Section 9 hereof of a unit valued by reference to a designated amount of property other than Shares, which value may be paid to the Participant by delivery of such property as the Committee shall determine, including, without limitation, cash, Shares, or any combination thereof, upon achievement of such performance goals during the Performance Period as the Committee shall establish at the time of such grant or thereafter.

(ee) “Perrigo” means Perrigo Company plc and any successor thereto.

(ff) “Person” means any individual, corporation, partnership, association, joint-stock company, Company, unincorporated organization, limited liability company, other entity or government or political subdivision thereof.

(gg) “Prior Stock Plans” means (i) the Perrigo Company Employee Stock Option Plan, (ii) the Perrigo CompanyNon-Qualified Stock Option Plan for Directors, (iii) the Perrigo Company Restricted Stock Plan for Directors, and (iv) the Perrigo Company Restricted Stock Plan for Directors II.

(hh) “Restricted Share” means any Share issued with the restriction that the holder may not sell, transfer, pledge, or assign such Share and with such other restrictions as the Committee, in its sole discretion, may impose (including, without limitation, any restriction on the right to vote such Share, and the right to receive any cash dividends), which restrictions may lapse separately or in combination at such time or times, in installments or otherwise, as the Committee may deem appropriate.

(ii) “Restricted Share Award” means an award of Restricted Shares under Section 8 hereof.

(jj) “Restricted Share Unit” or “RSU” means restricted share units which entitle the Participant to receive Shares or the value thereof which is determined in whole or in part, or is otherwise based, on Shares pursuant to Section 10 hereof.

(kk) “Retirement” means a Participant’s Termination Date which occurs (i) pursuant to a voluntary early retirement program approved by the Board or the Committee, (ii) after attaining age 65,

or (iii) after attaining age 60 with ten or more years of service with the Company. For this purpose, a year of service shall be a completed12-month period of service beginning on the first day of the Participant’s service with the Company as an Employee or an anniversary of such date.

(ll) “Shares” means ordinary shares, nominal value €0.001 per share, of Perrigo and such other securities of Perrigo as the Committee may from time to time determine.

(mm) “Short-Term Deferral Period” means, with respect to an amount payable pursuant to an Award, the period ending no later than the 15th day of the third month following the later of (i) the end of the Participant’s taxable year in which the amount is no longer subject to a substantial risk of forfeiture, or (ii) the end of Perrigo’s fiscal year in which the amount is no longer subject to a substantial risk of forfeiture. A Participant shall have no discretion over the payment date and shall have no right to interest as a result of payment on a date other than the first day of the Short-Term Deferral Period.

(nn) “Stock Appreciation Right” means any right granted to a Participant pursuant to Section 7 hereof to receive, upon exercise by the Participant, the excess of (i) the Fair Market Value of one Share on the date of exercise over (ii) the grant price of the right on the date of grant, or if granted in connection with an outstanding Option on the date of grant of the related Option, as specified by the Committee in its sole discretion, which shall not be less than the Fair Market Value of one Share on such date of grant of the right or the related Option, as the case may be. Any payment by the Company in respect of such right may be made in cash, Shares, other property, or any combination thereof, as the Committee, in its sole discretion, shall determine.

(oo) “Ten Percent Shareholder” means a person who owns (after taking into account the attribution rules of Section 424(b) of the Code or any successor provision thereto) more than 10% of the combined voting power of all classes of shares beneficial interest of the Company.

(pp) “Termination Date” means the date that a Participant ceases to be an Employee and ceases to perform any material services for the Company, including, but not limited to, advisory or consulting services or services as a member of the Board. Unless otherwise determined by the Committee in its sole discretion, for purposes of the Plan, an Employee shall be considered to have a Termination Date if his or her employer ceases to be an Affiliate, even if he or she continues to be employed by such employer.

SECTION 3. ADMINISTRATION.

(a) AUTHORITY OF COMMITTEE. The Plan shall be administered by the Committee. The Committee shall have full power and authority, subject to such orders or resolutions not inconsistent with the provisions of the Plan as may from time to time be adopted by the Board, to: (i) select the Participants to whom Awards may be granted; (ii) determine the type or types of Awards to be granted to Participants; (iii) determine the number of Shares to be covered by each Award granted hereunder and the term of each such Award; (iv) determine the terms and conditions, not inconsistent with the provisions of the Plan, of any Award granted hereunder (including approval of any form of Award Agreement), which terms and conditions may provide for the forfeiture of Awards, the repayment of cash or Shares or other amounts received with respect to an Award and/or the repayment of any gains or profits on a Participant’s sale of Shares acquired under an Award under specified circumstances; (v) determine whether, to what extent and under what circumstances Awards may be settled in cash, Shares or other property or canceled or suspended; (vi) determine whether, to what extent and under

what circumstances cash, Shares and other property and other amounts payable with respect to an Award under this Plan shall be deferred either automatically or at the election of the Participant; (vii) determine whether, to what extent and under what circumstances, any Award shall be canceled or suspended; (viii)interpret and administer the Plan and any instrument or agreement entered into under the Plan; (ix) establish, amend and rescind rules and regulations relating to the Plan, (x) establish, amend and rescind rules and regulations relating to the Plan (including the adoption of anysub-plan under the Plan) for the purpose of satisfying applicable foreign laws and/or qualifying for preferred tax treatment under applicable foreign laws; (xi) appoint such agents as it shall deem appropriate for the proper administration of the Plan; and (xii) make any other determination and take any other action that the Committee deems necessary or desirable for administration of the Plan. Decisions of the Committee shall be final, conclusive and binding upon all persons, including the Company, any Participant, and shareholder, and any Employee of the Company. Perrigo has adoptedsub-plans governing awards taxable in the State of Israel and the Republic of Ireland, whichsub-plans are attached hereto as Appendix A and Appendix B. Perrigo has also adopted Appendix C as asub-plan governing Awards tonon-employee directors and consultants.

(b) DELEGATION. The CEO has the authority to grant Awards to Participants, other than Participants who are subject to Section 16 of the Exchange Act, and to determine the terms and conditions of such Awards (including approval of any form of Award Agreement), subject to the limitations of the Plan and such other limitations and guidelines as the Committee may deem appropriate. Such delegation of authority includes, but is not limited to, the authority to determine (i) the type or types of Awards to be granted, (ii) the number of Shares to be covered by each such Award, (iii) the expiration date of each such Award, (iv) the period during which an Option shall be exercisable which may be determined at or subsequent to grant, (v) the restriction period applicable to Restricted Share Awards and to RSUs, (vi) the performance criteria and performance period applicable to Performance Awards, (vii) the terms and conditions relating to the effect of a Participant’s Termination Date, and (viii) the effect of a Change in Control on such Awards.

(c)AWARD AGREEMENTS

(1)MINIMUM VESTING. No Award granted under the Plan may vest, in whole or in part, prior to theone-year anniversary of the date of grant of the Award. Notwithstanding the foregoing, a Participant’s Award Agreement may provide for accelerated vesting if the Participant’s Termination Date occurs due to the Participant’s death, Disability or Retirement, upon a Change in Control, or upon the Participant’s termination without “cause” (as defined in the applicable Award Agreement) or separation for “good reason” (as defined in the applicable Award Agreement) within a specified period following a Change in Control. The forgoingone-year minimum vesting period shall not apply to any Award granted in substitution for an Award pursuant to Section 4(f) that does not reduce the vesting period of the Award being substituted.

(2) VESTING DURING DISABILITY. Unless the Committee determines otherwise, the vesting of Awards granted hereunder shall continue during any period of short-term disability. A Participant who is absent from work due to a long-term disability shall continue to vest until the earlier of (i) the six month anniversary of the commencement of the Participant’s long-term disability, or (ii) the Participant’s Termination Date.

(3) PAYMENT FOR AWARDS. Except as otherwise required in any Award Agreement or by the terms of the Plan, recipients of Awards under the Plan shall not be required to make any payment or provide consideration other than the rendering of services.

(4) ACCEPTANCE OF AWARD. The prospective recipient of any Award under the Plan shall not, with respect to such Award, be deemed to have become a Participant, or to have any rights with respect to such Award, until and unless such recipient shall have executed an agreement or other instrument evidencing the Award and delivered a fully executed copy thereof to Perrigo, and otherwise complied with the then applicable terms and conditions.

SECTION 4. DURATION OF, AND SHARES SUBJECT TO PLAN.

(a) TERM. The Plan shall remain in effect until terminated by the Board, provided, however, that no Award may be granted under the Plan more than 10 years after the Effective Date, but any Award theretofore granted may extend beyond that date.

(b) SHARES SUBJECT TO THE PLAN. The maximum number of Shares in respect for which Awards may be granted under the Plan, subject to adjustment as provided in Section 4(f) of the Plan, is (i) 3,000,000, plus (ii) the number of Shares that remained available for issuance under the 2013 Plan as of the Effective Date (including Shares underlying outstanding awards under the 2013 Plan and Prior Stock Plans that are forfeited, terminated, expire unexercised or are otherwise settled without the delivery of Shares on and after the Effective Date). No further awards shall be made under the Prior Stock Plans after the Original Effective Date.

(c) AWARD SHARE LIMITS. No individual Employee may be granted Awards in any one calendar year with respect to more than 400,000 Shares. The maximum amount payable in cash to a Covered Employee for any calendar year with respect to any Award subject to Section 14 shall be $6,000,000.

(d) COMPUTATION OF SHARES. For the purpose of computing the total number of Shares available for Awards under the Plan, there shall be counted against the above limits the number of Shares subject to issuance upon the exercise or settlement of Awards as of the dates on which such Awards are granted. The Shares which were previously subject to Awards shall again be available for Awards under the Plan if any such Awards are forfeited, terminated, expire unexercised, settled in cash or exchanged for other Awards (to the extent of such forfeiture or expiration of such Awards), or if the Shares subject thereto can otherwise no longer be issued. Further, any Shares which are used as full or partial payment to Perrigo by a Participant of the purchase price of Shares or the tax withholding requirement with respect to any Awards granted under the Plan shall again be available for Awards under the Plan. The number of Shares that are forfeited, expire unexercised or are otherwise settled without the delivery of Shares under the Prior Stock Plans on and after the Original Effective Date shall again be available for Awards under this Plan. If a Stock Appreciation Right is settled in Shares, Shares that are in excess of the net Shares delivered on exercise of such Stock Appreciation Right shall be added back to the number of Shares available for future Awards under the Plan.

(e) SOURCE OF SHARES. Shares which may be issued under the Plan may be either authorized and unissued shares or issued shares which have been reacquired by Perrigo. No fractional shares shall be issued under the Plan. The Committee shall determine whether cash, Awards, or other property shall be issued or paid in lieu of fractional Shares or whether such fractional Shares or any rights thereto shall be forfeited or otherwise eliminated. In all cases the Committee shall require that the nominal value of each newly issued Share issued in satisfaction of an Award under the Plan (including anysub-plan) shall be paid up.

(f) CHANGES IN SHARES. In the event of any merger, reorganization, consolidation, recapitalization, stock dividend, stock split, reverse stock split, spin off or similar transaction or other

change in corporate structure affecting the Shares, the Committee shall make equitable adjustments and substitutions with respect to (i) the aggregate number, class and kind of Shares which may be delivered under the Plan, in the aggregate or to any one Participant, (ii) the number, class, kind and option or exercise price of Shares subject to outstanding Options, Stock Appreciation Rights or other Awards granted under the Plan, and (iii) the number, class and kind of Shares subject to, Awards granted under the Plan (including, if the Committee deems appropriate, the substitution of similar options to purchase the shares of, or other awards denominated in the shares of, another company). The Committee shall have the sole discretion to determine the manner of such equitable adjustment or substitution, provided that the number of Shares or other securities subject to any Award shall always be a whole number.

SECTION 5.ELIGIBILITY. Any Employee shall be eligible to be selected as a Participant. Awards may be granted to Employees who are foreign nationals or employed outside the United States, or both, on such terms and conditions different from those specified in the Plan as may, in the judgment of the Committee, be necessary or desirable in order to recognize differences in local law or tax policy. The Committee also may impose conditions on the exercise or vesting of Awards in order to minimize the Company’s obligation with respect to tax equalization for Participants on assignments outside their home country.

SECTION 6.STOCK OPTIONS. Options may be granted hereunder to Participants either alone or in addition to other Awards granted under the Plan. Any Option granted under the Plan shall be evidenced by an Award Agreement in such form as the Committee may from time to time approve. Any such Option shall be subject to the following terms and conditions and to such additional terms and conditions, not inconsistent with the provisions of the Plan, as the Committeeshall deem desirable:

(a) OPTION PRICE. The purchase price per Share purchasable under an Option shall be determined by the Committee in its sole discretion; provided that (i) such purchase price shall not be less than the Fair Market Value of the Share on the date of the grant of the Option, and (ii) such purchase price for an Incentive Stock Option granted to a Ten Percent Shareholder shall be not less than 110% of the Fair Market Value of the Share on the date of grant of the Option.

(b) OPTION PERIOD. The term of each Option shall be fixed by the Committee in its sole discretion; provided that (i) no Option shall be exercisable after the expiration of 10 years from the date the Option is granted, and (ii) no Incentive Stock Option granted to a Ten Percent Shareholder shall be exercisable after the expiration of five years from the date the Option is granted.

(c) EXERCISABILITY. Options shall be exercisable at such time or times as determined by the Committee at or subsequent to grant. Unless otherwise determined by the Committee at or subsequent to grant, no Incentive Stock Option shall be exercisable during the year ending on the day before the first anniversary date of the granting of the Incentive Stock Option.

(d) METHOD OF EXERCISE. Subject to the other provisions of the Plan and any applicable Award Agreement, any Option may be exercised by the Participant in whole or in part at such time or times, and the Participant may make payment of the option price in such form or forms, including, without limitation, payment by delivery of cash, Shares or other consideration (including, where permitted by law and the Committee, Awards) having a Fair Market Value on the exercise date equal to the total option price, or by any combination of cash, Shares and other consideration as the Committee may specify in the applicable Award Agreement.

(e) INCENTIVE STOCK OPTIONS. In accordance with rules and procedures established by the Committee, the aggregate Fair Market Value (determined as of the time of grant) of the Shares with respect to which Incentive Stock Options held by any Participant which are exercisable for the first time by such Participant during any calendar year under the Plan (and under any other benefit plans of Perrigo or of any parent or subsidiary corporation of Perrigo) shall not exceed $100,000 or, if different, the maximum limitation in effect at the time of grant under Section 422 of the Code, or any successor provision, and any regulations promulgated thereunder. The terms of any Incentive Stock Option granted hereunder shall comply in all respects with the provisions of Section 422 of the Code, or any successor provision, and any regulations promulgated thereunder. An Incentive Stock Option must be exercised within three months following the Participant’s Termination Date, or within 12 months if such termination is by reason of death or Disability. If an Option intended to be an Incentive Stock Option fails to satisfy the requirements of Section 422 of the Code, such Option will automatically convert to a Nonstatutory Stock Option.

(f) REPRICING. Except in connection with a corporate transaction involving Perrigo (including, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation,split-up,spin-off, combination, or exchange of shares), the terms of outstanding Awards may not be amended to reduce the exercise price of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price that is less than the exercise price of the original Options or Stock Appreciation Rights, without the approval of Perrigo’s shareholders.

SECTION 7. STOCK APPRECIATION RIGHTS.

(a) GRANT OF AWARDS. Stock Appreciation Rights may be granted hereunder to Participants either alone or in addition to other Awards granted under the Plan and may, but need not, relate to a specific Option granted under Section 6. Each Share subject to a Stock Appreciation Right shall have an exercise price of not less than Fair Market Value of a Share on the date of grant of the Stock Appreciation Right. The term of the Stock Appreciation Right shall be fixed by the Committee in its sole discretion, provided that no Stock Appreciation Right shall be exercisable after the expiration of 10 years from the date the Stock Appreciation Right is granted. The Committee, in its sole discretion, shall establish or impose such other terms and conditions with respect to Stock Appreciation Rights as it shall deem appropriate, which need not be the same with respect to each recipient.

(b) OPTIONS. Any Stock Appreciation Right related to a Nonstatutory Stock Option may be granted at the same time such Option is granted or at any time thereafter before exercise or expiration of such Option. Any Stock Appreciation Right related to an Incentive Stock Option must be granted at the same time such Option is granted, and may be exercised only if and when the Fair Market Value of the Shares subject to the Incentive Stock Option exceeds the aggregate purchase price for the Option. In the case of any Stock Appreciation Right related to any Option, the Stock Appreciation Right or applicable portion thereof shall terminate and no longer be exercisable upon the termination or exercise of the related Option, except that a Stock Appreciation Right granted with respect to less than the full number of Shares covered by a related Option shall not be reduced until the exercise or termination of the related Option exceeds the number of shares not covered by the Stock Appreciation Right. Any Option related to any Stock Appreciation Right shall no longer be exercisable to the extent the related Stock Appreciation Right has been exercised.

SECTION 8. RESTRICTED SHARES.

(a) GRANT OF AWARDS. Restricted Share Awards may be issued hereunder to Participants, for no cash consideration or for such minimum consideration as may be required by applicable law, either alone or in addition to other Awards granted under the Plan. The provisions of Restricted Share Awards need not be the same with respect to each recipient.

(b) REGISTRATION. Any Restricted Shares issued hereunder may be evidenced in such manner as the Committee in its sole discretion shall deem appropriate, including, without limitation, book-entry registration or issuance of a stock certificate or certificates. In the event any stock certificate is issued in respect of Restricted Shares awarded under the Plan, such certificate shall be registered in the name of the Participant, and shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award.

(c) FORFEITURE. Except as set forth in Section 12 or otherwise determined by the Committee at the time of grant, upon a Participant’s Termination Date for any reason during the restriction period, all Restricted Shares still subject to restriction shall be forfeited by the Participant and reacquired by Perrigo; provided that the Committee may, in its sole discretion, when it finds that a waiver would be in the best interests of Perrigo, waive in whole or in part any or all remaining restrictions with respect to such Participant’s Restricted Shares, except for Restricted Share Awards that are intended to comply with the performance-based compensation requirements of Section 14. Unrestricted Shares, evidenced in such manner as the Committee shall deem appropriate, shall be issued to the grantee promptly after the period of forfeiture, as determined or modified by the Committee, shall expire.

SECTION 9. PERFORMANCE AWARDS.

(a) GRANT OF AWARDS. Performance Awards may be issued hereunder to Participants, for no cash consideration or for such minimum consideration as may be required by applicable law, either alone or in addition to other Awards granted under the Plan. The performance criteria to be achieved during any Performance Period, the length of the Performance Period, and the amount of the Award to be distributed shall be determined by the Committee upon the grant of each Performance Award. Subject to the provisions of the Plan, the Committee, in its sole discretion, shall determine the Participants to whom and the time or times at which such Awards shall be made and all conditions of the Awards. The provisions of Performance Awards need not be the same with respect to each recipient.

(b) PAYMENT OF AWARDS. Following the end of each Performance Period, the Committee shall certify the extent to which the performance criteria and other conditions of the Award are achieved. Except as otherwise provided in the Plan, Performance Awards shall be settled following the Committee’s certification after the end of the relevant Performance Period, but in no event shall settlement occur later than the last day of the Short-Term Deferral Period applicable to the Award. Performance Awards may be paid in cash, Shares, other property or any combination of the foregoing, as determined in the sole discretion of the Committee at the time of payment.

SECTION 10. RESTRICTED SHARE UNIT AWARDS.

(a) GRANT OF AWARDS. Restricted Share Unit (“RSU”) Awards may be granted hereunder to Participants either alone or in addition to other Awards granted under the Plan. At the time of grant of an RSU Award, the Committee shall determine the number of RSUs subject to the Award, when such

RSUs shall vest, any conditions (such as continued employment) that must be met in order for the RSUs to vest at the end of the applicable restriction period, and any purchase price applicable to the Award. The Committee shall establish a bookkeeping account in the Participant’s name that reflects the number and type of RSUs standing to the credit of the Participant.

(b) PAYMENT OF AWARDS. Each RSU that vests entitles the Participant to one Share, cash equal to the Fair Market Value of a Share on the date of vesting, or a combination thereof as determined by the Committee and set forth in the Award Agreement. Except as otherwise provided in the Plan or in an Award Agreement, payment in Shares or cash (as applicable) shall be made upon the vesting of an RSU and in no event later than the last day of the Short-Term Deferral Period; provided, however, that a Change in Control (as defined in Section 2) shall not accelerate the payment date of an RSU that is subject to Section 409A of the Code unless such Change in Control is also a “change in control event” as defined in the regulations under Section 409A of the Code.

SECTION 11. DIVIDEND EQUIVALENTS

If the Committee so determines at the time of grant of an Award, Perrigo shall credit to a bookkeeping account maintained on behalf of such Participant an amount equal to the amount of the dividends the Participant would have received, if such Award held by the Participant on the record date for such dividend payment had been a Share. No interest or other earnings shall accrue on such bookkeeping account. Amounts attributable to such dividend equivalents shall be subject to the same terms and conditions as the Awards to which such dividend equivalents relate. Notwithstanding the foregoing, any dividend equivalents granted in connection with unvested Awards shall be payable only if and to the extent the underlying Awards become vested.

SECTION 12. EFFECT OF TERMINATION DATE

(a) AWARDS, GENERALLY. The Committee shall have the discretion to establish terms and conditions relating to the effect of the Participant’s Termination Date on Awards under the Plan.

(b) OPTIONS, STOCK APPRECIATION RIGHTS, AND RESTRICTED SHARES. Unless otherwise determined by the Committee with respect to an Award of Options, Stock Appreciation Rights or Restricted Shares as provided in the applicable Award Agreement, and subject to the terms of the Plan, the following provisions shall apply to Options, Stock Appreciation Rights and Restricted Shares on a Participant’s Termination Date.

(1) DEATH, DISABILITY, RETIREMENT. If the Participant’s Termination Date occurs due to the Participant’s death, Disability or Retirement, (i) the restriction period with respect to any Restricted Shares shall lapse, and (ii) the Participant’s outstanding Options and Stock Appreciation Rights shall immediately vest in full and may thereafter be exercised in whole or in part by the Participant (or the duly appointed fiduciary of the Participant’s estate or Beneficiary in the case of death, or conservator of the Participant’s estate in the case of Disability) at any time prior to the expiration of the respective terms of the Options or Stock Appreciation Rights, as applicable.

(2) INVOLUNTARY TERMINATION FOR ECONOMIC REASONS. If the Participant’s Termination Date occurs by reason of Involuntary Termination for Economic Reasons, the Participant may exercise his or her Options and Stock Appreciation Rights, to the extent vested, at any time prior to the earlier of (i) the date which is 30 days after the date which is 24 months after such Termination Date, or (ii) the expiration of the respective terms of the Options or Stock

Appreciation Rights. Any Options, Stock Appreciation Rights or Restricted Shares that are not vested at such Termination Date, but are scheduled to vest during the24-month period following the Termination Date, shall continue to vest during such24-month period according to the vesting schedule in effect prior to such Termination Date. Any Options, Stock Appreciation Rights and Restricted Shares that are not scheduled to vest during such24-month period will be forfeited on the Termination Date. Notwithstanding the foregoing, if the Participant’s Termination Date occurs for a reason that is both described in this Section 12(b)(2) and in Section 13(a), the special vesting rules described in Section 13(a) shall apply in lieu of the vesting rules described in this Section 12(b)(2).

If the Participant dies after the Termination Date while his or her Options or Stock Appreciation Rights remain exercisable under this paragraph (2), the duly appointed fiduciary of the Participant’s estate or his or her Beneficiary may exercise the Options and Stock Appreciation Rights (to the extent that such Options and Stock Appreciation Rights were vested and exercisable prior to death), at any time prior to the later of the date which is (i) 30 days after the date which is 24 months after the Participant’s Termination Date, or (ii) 12 months after the date of death, but in no event later than the expiration of the respective terms of the Options and Stock Appreciation Rights.

(3) TERMINATION FOR CAUSE. If the Participant’s Termination Date is for Cause, at the time such notice of termination is given by the Company (i) any Restricted Shares subject to a restriction period shall be forfeited, and (ii) the Participant’s right to exercise his or her Options and Stock Appreciation Rights shall terminate. If within 60 days of a Participant’s Termination Date the Company discovers circumstances which would have permitted it to terminate the Participant’s employment or service for Cause, such Termination Date shall be deemed to have occurred for reasons of Cause. Any Shares, cash or other property paid or delivered to the Participant under the Plan within 60 days of such Termination Date shall be forfeited and the Participant shall be required to repay such amount to the Company.

(4) OTHER TERMINATION OF EMPLOYMENT OR SERVICE. If the Participant’s Termination Date occurs for reasons other than as described in this Section 12(b), the Participant shall have the right to exercise his or her Options and Stock Appreciation Rights at any time prior to the earlier of (i) the date which is three months after such Termination Date, or (ii) the expiration date of the respective terms of the Options or Stock Appreciation Rights, as applicable, but only to the extent such Option or Stock Appreciation Right, as applicable, was vested prior to such Termination Date. Any Options or Stock Appreciation Rights which are not vested at such Termination Date shall be forfeited on the Termination Date.

If the Participant dies after the Termination Date while his or her Options or Stock Appreciation Rights remain exercisable under this paragraph (4), the duly appointed fiduciary of the Participant’s estate or his or her Beneficiary may exercise the Options or Stock Appreciation Rights (to the extent that such Options or Stock Appreciation Rights were vested and exercisable prior to death), at any time prior to the earlier of (i) 12 months after the date of death, or (ii) the expiration of the respective terms of the Options or Stock Appreciation Rights, as applicable.

(c) SERVICE-VESTING RSU AWARDS. Unless determined otherwise by the Committee with respect to a service-based vesting RSU Award, the following provisions shall apply.

(1) DEATH, DISABILITY, RETIREMENT. If the Participant’s Termination Date occurs due to the Participant’s death, Disability or Retirement, a service-based vesting RSU shall immediately vest in full, provided that any such Disability is a disability as defined in

Section 409A of the Code and the regulations thereunder. Payment of the Award due to death or Disability shall be made within the Short-Term Deferral Period. Subject to Section 16(f) regarding specified employees, payment of the Award due to Retirement shall be made within the75-day period following the Participant’s separation from service (as defined in Section 409A); provided, however, that the Participant shall not have the right to designate the year of payment if such period spans two calendar years.

(2) INVOLUNTARY TERMINATION FOR ECONOMIC REASONS. If the Participant’s Termination Date occurs by reason of an Involuntary Termination for Economic Reasons that constitutes a separation from service (as defined in Section 409A), (x) any Shares subject to a service-based vesting RSU Award that are scheduled to vest during the24-month period following such Termination Date shall continue to vest during such24-month period according to the vesting schedule in effect prior to such Termination Date, and (y) any Shares that are not scheduled to vest during such period shall be forfeited on the Termination Date. Subject to Section 16(f) regarding specified employees, the Participant shall receive payment with respect to such Award when the scheduled vesting date or dates occur. Notwithstanding the foregoing, if the Participant’s Termination Date occurs for a reason that is both described in this Section 12(c)(2) and in Section 13(a), the special vesting rules described in Section 13(a) shall apply in lieu of the vesting rules described in this Section 12(c)(2).

(3) TERMINATION FOR CAUSE. If the Participant’s Termination Date is for Cause, at the time such notice of termination is given by the Company, the portion of any service-based vesting RSU Award that is not vested shall be forfeited at the time of such notice of termination. If within 60 days of a Participant’s Termination Date the Company discovers circumstances which would have permitted it to terminate the Participant’s employment or service for Cause, such Termination Date shall be deemed to have occurred for reasons of Cause. Any Shares, cash or other property paid or delivered to the Participant under the Plan within 60 days of such Termination Date shall be forfeited and the Participant shall be required to repay such amount to the Company.

(4) OTHER TERMINATION OF EMPLOYMENT OR SERVICE. If the Participant’s Termination Date occurs for reasons other than as described in this Section 12(c), the portion of any service-based vesting RSU Award that is not vested at such Termination Date shall be forfeited on the Termination Date.

(d) PERFORMANCE-VESTING RSU AWARDS (“PSUs”). Unless otherwise determined by the Committee with respect to an RSU Award, the following provisions shall apply.

(1) DEATH, DISABILITY, RETIREMENT. If the Participant’s Termination Date occurs due to the Participant’s death, Disability or Retirement, any Shares subject to the PSU Award shall vest or be forfeited depending on the attainment of performance goals. Subject to Section 16(f) regarding specified employees, the Participant shall receive payment with respect to such PSU Award in accordance with Section 9(b).

(2) INVOLUNTARY TERMINATION FOR ECONOMIC REASONS. If the Participant’s Termination Date occurs by reason of an Involuntary Termination for Economic Reasons that constitutes a separation from service (as defined in Section 409A), (i) any Shares subject to the PSU Award for which the Performance Period is scheduled to end during the24-month period following such Termination Date shall vest or be forfeited depending on the attainment of performance goals, and (ii) any Shares subject to the PSU Award for which the Performance Period is not scheduled to end during such24-month period shall be forfeited on the Termination

Date. Subject to Section 16(f) regarding specified employees, the Participant shall receive payment with respect to such PSU Award in accordance with Section 9(b). Notwithstanding the foregoing, if the Participant’s Termination Date occurs for a reason that is both described in this Section 12(d)(2) and in Section 13(a), the special vesting rules described in Section 13(a) shall apply in lieu of the vesting rules described in this Section 12(d)(2).

(3) TERMINATION FOR CAUSE. If the Participant’s Termination Date is for Cause, at the time such notice of termination is given by the Company, the portion of any PSU Award that is not vested shall be forfeited at the time of such notice of termination. If within 60 days of a Participant’s Termination Date the Company discovers circumstances which would have permitted it to terminate the Participant’s employment or service for Cause, such Termination Date shall be deemed to have occurred for reasons of Cause. Any Shares, cash or other property paid or delivered to the Participant under the Plan within 60 days of such Termination Date shall be forfeited and the Participant shall be required to repay such amount to the Company.

(4) OTHER TERMINATION OF EMPLOYMENT OR SERVICE. If the Participant’s Termination Date occurs for reasons other than as described in this Section 12(d), the portion of any PSU Award that is not vested at such Termination Date shall be forfeited on the Termination Date.

SECTION 13. CHANGE IN CONTROL PROVISIONS

Notwithstanding any other provision of the Plan to the contrary, unless otherwise determined by the Committee with respect to an Award as stipulated in the applicable Award Agreement, in the event of a Change in Control:

(a) If the Participant’s Termination Date occurs by reason of a termination without “cause” (as is defined in the applicable Award Agreement) or a separation for “good reason” (as defined in the applicable Award Agreement) on or after a Change in Control and prior to the two year anniversary of the Change in Control, the following shall apply to Awards held by Participants:

(1) Any Options and Stock Appreciation Rights outstanding as of such Termination Date, and which are not then exercisable and vested, shall become fully exercisable and vested.

(2) The restrictions and deferral limitations and other conditions applicable to any Restricted Shares shall lapse, and such Restricted Shares shall become free of all restrictions and limitations and become fully vested and transferable.

(3) All Performance Awards shall be considered to be earned and payable as if target performance had been obtained for the performance period. In addition, any deferral or other restriction applicable to the Performance Awards shall lapse and such Performance Awards shall be settled as soon as practicable after the Participant’s Termination Date.

(4) The restrictions and deferral limitations and other conditions applicable to any service-based vesting RSU Award shall lapse, and such RSU Awards shall become fully vested and shall be settled as soon as practicable after the Participant’s Termination Date.

(b) In addition to the foregoing, the Committee may take any one or more of the following actions with respect to any or all Awards that were granted on or after February 7, 2007, without the consent of any Participant:

(1) The Committee may require that Participants surrender outstanding Options and Stock Appreciation Rights in exchange for one or more payments by the Company, in cash or Shares as

determined by the Committee, equal to the amount, if any, by which the then Fair Market Value of the Shares subject to the Participant’s unexercised Options and Stock Appreciation Rights exceeds the purchase price. Payment shall be made on such terms as the Committee determines.

(2) After giving Participants an opportunity to exercise their outstanding Options and Stock Appreciation Rights, the Committee may terminate any or all unexercised Options and Stock Appreciation Rights at such time as the Committee deems appropriate.

(3) The Committee may determine that any Awards that remain outstanding after the Change in Control shall be converted to similar grants of the surviving corporation (or a parent or subsidiary of the surviving corporation).

(4) Any such surrender, termination or conversion shall take place as of the date of the Change in Control or such other date as the Committee may specify.

SECTION 14. GRANDFATHERED AWARDS

(a) Notwithstanding any other provision of this Plan, the provisions of this Section 14 shall apply to Grandfathered Awards.

(b) If an Award is subject to this Section 14, then the lapsing of restrictions thereon and the distribution of cash, Shares or other property pursuant thereto, as applicable, shall be subject to the achievement of one or more objective performance goals established by the Committee, which shall be based on the attainment of one or any combination of the following: cash flow; cash flow from operations; net income, total earnings; earnings per share, diluted or basic; earnings per share from continuing operations, diluted or basic; earnings before interest and taxes; earnings before interest, taxes, depreciation, and amortization; earnings from operations; net asset turnover; inventory turnover; capital expenditures; net earnings; operating earnings; gross or operating margin; debt; working capital; return on equity; return on net assets; return on total assets; return on capital; return on invested capital; return on investment; return on sales; net or gross sales; market share; economic value added; cost of capital; change in assets; expense reduction levels; cost control; debt reduction; productivity; delivery performance; safety record; stock price; stock price appreciation; and total stockholder return, of Perrigo or the Affiliate or division of Perrigo for or within which the Participant is primarily employed. Such performance goals also may be based upon the attaining specified levels of Company performance under one or more of the measures described above relative to the performance of other corporations. Such performance goals shall be set by the Committee within the times period prescribed by, and shall otherwise comply with the requirements of, Section 162(m) of the Code and the regulations thereunder as in effect immediately prior to enactment of P.L.115-97.

(c) Notwithstanding any provision of this Plan other than Section 13, with respect to any Award that is subject to this Section 14, the Committee may not adjust upwards the amount payable pursuant to such Award, nor may it waive the achievement of the applicable performance goals except in the case of the death or disability of the Participant.

(d) The Committee shall have the power to impose such other restrictions on Awards subject to this Section 14 as it may deem necessary or appropriate to ensure that such Awards satisfy all requirements for “performance-based compensation” within the meaning of Section 162(m)(4)(B) of the Code as in effect immediately prior to enactment of P.L.115-97.

SECTION 15. AMENDMENT AND TERMINATION.

(a) The Board may amend, alter or discontinue the Plan at any time; provided, however, no amendment, alteration, or discontinuation shall be made that would impair the rights of an optionee or Participant under an Award theretofore granted, without the optionee’s or Participant’s consent; provided, further that, any amendment that would (i) except as is provided in Section 4(f) of the Plan, increase the total number of shares reserved for the purpose of the Plan, (ii) change the employees or class of employees eligible to participate in the Plan, (iii) change the minimum exercise price for any Option or Stock Appreciation Right below the minimum price set forth in Section 6(a) and Section 7 of the Plan, as applicable, or (iv) materially (within the meaning of rules of the securities exchange on which the Shares are then listed) change the terms of the Plan, shall not be effective without the approval of Perrigo’s shareholders.

(b) The Committee may amend the terms of any Award theretofore granted; provided, that no such amendment shall impair the rights of any Participant without his or her consent. In addition, the CEO may amend the terms of any Award theretofore granted to a Participant who is not subject to Section 16 of the Exchange Act; provided, that no such amendment shall impair the rights of any Participant without his or her consent.

(c) Except as provided in Section 14 (regarding Grandfathered Awards), the Committee shall be authorized to make adjustments in Performance Award criteria or in the terms and conditions ofnon-Performance Awards in recognition of unusual or nonrecurring events affecting the Company or its financial statements or changes in applicable laws, regulations or accounting principles. The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem desirable to carry it into effect. In the event the Company shall assume outstanding employee benefit awards or the right or obligation to make future such awards in connection with the acquisition of another corporation or business entity, the Committee may, in its discretion, make such adjustments in the terms of Awards under the Plan as it shall deem appropriate.

SECTION 16. GENERAL PROVISIONS.

(a) TRANSFERS OF AWARDS. Unless otherwise determined by the Committee (or the CEO, as applicable) with respect to an Award other than an Incentive Stock Option, no Award, and no Shares subject to Awards granted under the Plan which have not been issued or as to which any applicable restriction, performance or deferral period has not lapsed, may be sold, assigned, transferred, pledged or otherwise encumbered, except by will or by the laws of descent and distribution or pursuant to a domestic relations order; provided that, if so determined by the Committee (or the CEO, as applicable), a Participant may, in the manner established by the Committee (or the CEO), designate a beneficiary to exercise the rights of the Participant with respect to any Award upon the death of the Participant. Unless otherwise determined by the Committee (or the CEO, as applicable), each Award shall be exercisable, during the Participant’s lifetime, only by the Participant or, if permissible under applicable law, by the Participant’s guardian or legal representative. Notwithstanding the foregoing, subject to such rules as the Committee may establish, a Nonstatutory Stock Option may be transferred by a Participant during his or her lifetime to a trust, partnership or other entity established for the benefit of the Participant and his or her immediate family which, for purposes of the Plan, shall mean those persons who, at the time of such transfer, would be entitled to inherit part or all of the estate of the Participant under the laws of intestate succession then in effect in the state in which the Participant resides if the Participant had died on such transfer date without a will.

(b) NO RIGHT TO BE GRANTED AWARDS. No Employee or Participant shall have any claim to be granted any Award under the Plan nor to remain in the employment or service of the Company and there is no obligation for uniformity of treatment of Employees or Participants under the Plan. The Committee may, in its sole discretion, condition eligibility for an Award on the execution of a noncompete or similar-type agreement.

(c) SHARE CERTIFICATES. All certificates for Shares delivered under the Plan pursuant to any Award shall be subject to such stock-transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of the Securities and Exchange Commission, any securities exchange upon which the Shares are then listed, and any applicable Federal or state securities law, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.

(d) DEFERRAL OF AWARDS. The Committee shall be authorized to establish procedures pursuant to which the payment of any Award may be deferred. Subject to the provisions of this Plan and any Award Agreement, the recipient of an Award (including, without limitation, any deferred Award) may, if so determined by the Committee, be entitled to receive, currently or on a deferred basis, interest or dividends, or interest or dividend equivalents, with respect to the number of shares covered by the Award, as determined by the Committee, in its sole discretion, and the Committee may provide that such amounts (if any) shall be deemed to have been reinvested in additional Shares or otherwise reinvested. Notwithstanding the foregoing, any dividends or dividend equivalents shall be payable only if and to the extent the underlying Awards become vested.

(e) DELIVERY AND EXECUTION OF ELECTRONIC DOCUMENTS. To the extent permitted by applicable law, Perrigo may (i) deliver by email or other electronic means (including posting on a web site maintained by the Company or by a third party under contract with the Company) all documents relating to the Plan or any Award thereunder (including, but not limited to, prospectuses required by the U.S. Securities and Exchange Commission) and all other documents that Perrigo is required to deliver to its shareholders (including, but not limited to, annual reports and proxy statements), and (ii) permit Participants to electronically execute applicable Plan documents (including, but not limited to, Award Agreements) in the manner prescribed by the Committee.

(f) SECTION 409A SPECIFIED EMPLOYEES AND SEPARATE PAYMENTS. Notwithstanding any other provision of the Plan, if and to the extent any portion of any payment of an Award that is subject to Section 409A is payable upon the Participant’s separation from service (as defined in Section 409A) and the Participant is a specified employee (as defined in Section 409A) as determined by Perrigo in accordance with its procedures, such portion of the payment shall be delayed to the first business day following thesix-month anniversary of such separation from service. Each amount payable under an Award that is subject to Section 409A is hereby designated a separate payment for purposes of Section 409A.

(g) WITHHOLDING TAXES. The Company shall be authorized to withhold from any Award granted or payment due under the Plan the amount of any withholding taxes due in respect of an Award or payment hereunder, including withholding from other compensation payable to the Participant by the Company, and shall take all actions as it determines are necessary to satisfy all obligations for the payment of applicable withholding taxes, including, without limitation, any Federal Insurance Contributions Act (“FICA”) taxes due on the vesting of an Award. The Committee shall be authorized to establish procedures for Participants to elect to satisfy such withholding tax obligations by (i) the

delivery of, or directing the Company to retain, Shares, or (ii) tendering payment to the Company in the form of a personal check, a bank order, a money order, or such other form of cash payment as may be approved by the Committee. In no event may the number of Shares withheld exceed the number necessary to satisfy the maximum Federal, state and local income and employment tax withholding requirements.

(h) NO IMPACT ON ADOPTION OF OTHER COMPENSATION PROGRAMS. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to shareholder approval if such approval is otherwise required; and such arrangements may be either generally applicable or applicable only in specific cases.

(i) GOVERNING LAW. The Plan and Awards granted under the Plan shall be governed by the applicable Code provisions to the maximum extent possible. Otherwise, the laws of the State of Michigan (without reference to principles of conflicts of laws) shall govern the operation of, and the rights of Participants under, the Plan and Awards granted hereunder. With respect to Awards granted to Participants who are foreign nationals or who are employed outside the United States, the Plan and any rules and regulations relating to the Plan shall be governed by the applicable Code provisions to the maximum extent possible and otherwise by the laws of the State of Michigan (without reference to principles of conflicts of laws) and, to the extent that applicable foreign law differs from the Code and Michigan law, in accordance with applicable foreign law.

If any provision of this Plan is or becomes or is deemed invalid, illegal or unenforceable in any jurisdiction, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan, it shall be stricken and the remainder of the Plan shall remain in full force and effect.

(j) FORFEITURE OF AWARDS. If Perrigo, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, then (a) if a Participant’s incentive or equity-based compensation is subject to automatic forfeiture due to such misconduct and restatement under Section 304 of the Sarbanes-Oxley Act of 2002, or (b) the Committee determines the Participant either knowingly engaged in or failed to prevent the misconduct, or the Participant’s actions or inactions with respect to the misconduct and restatement constituted gross negligence, the Participant shall (i) be required to reimburse Perrigo for any gain associated with any Option or Stock Appreciation Right exercised during the12-month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement (the“12-Month Window”), (ii) be required to reimburse Perrigo the amount of any payment (whether payment is made in cash, Shares or other property, and including any payment with respect to dividends and/or dividend equivalents) relating to any RSUs, PSUs, Restricted Shares and/or Performance Shares earned, accrued or settled during the12-Month Window, and (iii) all outstanding Awards that have not yet been settled or exercised shall be immediately forfeited. In addition, Shares acquired under the Plan (including Shares acquired through the exercise of Options and/or Stock Appreciation Rights), and any gains or profits on the sale of such Shares, shall be subject to any “clawback” or recoupment policy later adopted by Perrigo.

SECTION 17.EFFECTIVE DATE OF PLAN. This amendment and restatement of the Plan shall be effective on the date that it is approved by Perrigo’s shareholders (the “Effective Date”).

APPENDIX A

2019 LONG-TERM INCENTIVE PLAN

SUB-PLAN GOVERNING AWARDS TAXABLE IN THE STATE OF ISRAEL

1.

GENERAL

1.1.

This Appendix A (the “Appendix”) shall apply only to the grant of Awards to participants who are residents of the state of Israel for Israeli income tax purposes. The provisions specified hereunder shall form an integral part of the Perrigo Company plc 2019 Long-Term Incentive Plan (hereinafter: the “Plan”).

1.2.

This Appendix shall comply with Amendment no. 132 of the Israeli Tax Ordinance, which is effective with respect to Awards granted as of January 1, 2003.

1.3.

This Appendix is to be read as a continuation of the Plan and only modifies grants made to Israeli Participants so that they comply with the requirements set by the Israeli law in general, and in particular with the provisions of Section 102 (as specified herein), as may be amended or replaced from time to time. For the avoidance of doubt, this Appendix does not add to or modify the Plan in respect of any other category of Participants.

1.4.

The Plan and this Appendix are complimentary to each other and shall be deemed as one. In any case of contradiction, whether explicit or implied, between the provisions of this Appendix and the Plan, the provisions set out in the Appendix shall prevail.

1.5.

Awards granted tonon-employee directors and consultants under this Appendix shall also be subject to the “Consultant and NEDSub-Plan” (Appendix C to the Plan).

1.6.

Any capitalized terms not specifically defined in this Appendix shall be construed according to the interpretation given to it in the Plan.

2.

DEFINITIONS

2.1.

Affiliate” means any “employing company” within the meaning of Section 102(a) of the Ordinance.

2.2.

Approved 102 Award” means an Award granted pursuant to Section 102(b) of the Ordinance and held in trust by a Trustee for the benefit of the Participant, or supervised by a Trustee in accordance with the instructions set forth by the ITA.

2.3.

Award”means a Restricted Share Unit, a Restricted Share, a Performance Share, a Performance Unit, a Stock Appreciation Right, and/or an Option granted to Israeli Participants.

2.4.

Capital Gain Award” or “CGA” means an Approved 102 Award elected and designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) of the Ordinance.

2.5.

Controlling Shareholder” shall have the meaning ascribed to it in Section 32(9) of the Ordinance.

2.6.

Employee” means a person who is employed by Perrigo or its Affiliates, including an individual who is serving as a director or an office holder, but excluding any Controlling Shareholder, all as determined in Section 102 of the Ordinance.

2.7.

ITA” means the Israeli Tax Authorities.

2.8.

Non-Employee” means a consultant, adviser, service provider, Controlling Shareholder or any other person who is not an Employee.

2.9.

Ordinary Income Award” or “OIA” means an Approved 102 Award elected and designated by the Company to qualify under the ordinary income tax treatment in accordance with the provisions of Section 102(b)(1) of the Ordinance.

2.10.

102 Award” means any Award granted to Employees pursuant to Section 102 of the Ordinance.

2.11.

3(i) Award”means any Award granted pursuant to Section 3(i) of the Ordinance to any person who is aNon-Employee.

2.12.

Ordinance” means the 1961 Israeli Income Tax Ordinance [New Version] 1961 as now in effect or as hereafter amended.

2.13.

Section 102” means section 102 of the Ordinance and any regulations, rules, orders or procedures promulgated thereunder as now in effect or as hereafter amended.

2.14.

Section 3(i)” means section 3(i) of the Ordinance.

2.15.

Trustee”means any individual appointed by Perrigo to serve as a trustee and approved by the ITA, all in accordance with the provisions of Section 102(a) of the Ordinance.

2.16.

Unapproved 102 Award”means an Award granted pursuant to Section 102(c) of the Ordinance and not held in trust by a Trustee.

3.

ISSUANCE OF AWARDS

3.1.

The persons eligible for participation in the Plan as Participants under this Appendix shall include any Employees and/orNon-Employees; provided, however, that (i) Employees may only be granted 102 Awards; and(ii) Non-Employees may only be granted 3(i) Awards. Each Award Agreement shall state, inter alia, the type of Award granted (whether a CGA, an OIA, Unapproved 102 Award or a 3(i) Award).

3.2.

The Company may designate Awards granted to Employees pursuant to Section 102 as Unapproved 102 Awards or Approved 102 Awards.

3.3.

The grant of Approved 102 Awards shall be made under this Appendix.

3.4.

Approved 102 Awards may either be classified as CGAs or OIAs.

3.5.

Non Approved 102 Awards may be granted under this Appendix to any eligible Employee, unless and until, the Company’s election of the type of Approved 102 Awards as CGA or OIA granted to Employees (the “Election”), is appropriately filed with the ITA. Such Election shall become effective beginning the first date of grant of an Approved 102 Award under this Appendix and shall remain in effect until the end of the year following the year during which the Company first granted Approved 102 Awards. The Election shall obligate the Company to grantonlythe type of Approved 102 Award it has elected, and shall apply to all Participants who were granted Approved 102 Awards during the period indicated herein, all in accordance with the provisions of Section 102(g) of the Ordinance. For the avoidance of doubt, such Election shall not prevent the Company from granting Unapproved 102 Awards simultaneously.

3.6.

All Approved 102 Awards must be held in trust by a Trustee, as described in Section 4 below.

3.7.

For the avoidance of doubt, the designation of Unapproved 102 Awards and Approved 102 Award shall be subject to the terms and conditions set forth in Section 102.

4.

TRUSTEE

4.1.

Approved 102 Awards which shall be granted under this Appendix and/or any Shares allocated or issued upon exercise of such Approved 102 Awards and/or other shares received subsequently following any realization of rights, including without limitation bonus shares, shall be allocated or issued to the Trustee and held for the benefit of the Participants, or shall be supervised by the Trustee in accordance with the instructions set forth by the ITA, for such period of time as required by Section 102 or any regulations, rules or orders or procedures promulgated thereunder (the “Holding Period”). In the case the requirements for Approved 102 Awards are not met, then the Approved 102 Awards may be regarded as Unapproved 102 Awards, all in accordance with the provisions of Section 102.

4.2.

Notwithstanding anything to the contrary, the Trustee shall not release any Shares allocated or issued upon the grant or the exercise of Approved 102 Awards prior to the full payment of the Participant’s tax liabilities arising from Approved 102 Awards which were granted to him and/or any Shares allocated or issued upon the grant and/or exercise of such Approved 102 Awards.

4.3.

With respect to any Approved 102 Awards, subject to the provisions of Section 102 and any rules or regulation or orders or procedures promulgated thereunder, a Participant shall not sell or release from trust any Share received upon the grant and/or exercise of an Approved 102 Award and/or any share received subsequently following any realization of rights, including without limitation, bonus shares, until the lapse of the Holding Period required under Section 102 of the Ordinance. Notwithstanding the above, if any such sale or release occurs during the Holding Period, the sanctions under Section 102 of the Ordinance and under any rules or regulations or orders or procedures promulgated thereunder shall apply to and shall be borne by such Participant only.

4.4.

Upon receipt of Approved 102 Award, the Participant will sign an undertaking to release the Trustee from any liability in respect of any action or decision duly taken and bona fide executed in relation with this Appendix, or any Approved 102 Award or Share granted to him thereunder.

4.5.

In order to ensure the full payment of tax by an Israeli Participant the Company, at its own discretion may deposit the Unapproved 102 Award which shall be granted under this Appendix and/or any Shares allocated or issued upon exercise of such Unapproved 102 Awards and/or other shares received subsequently following any realization of rights, including without limitation bonus shares, with the Trustee which shall hold such Awards, for the benefit of the Participants for such period of time as determined by the Company.

5.

FAIR MARKET VALUE

Without derogating from Section 2(s) of the Plan and solely for the purpose of determining the tax liability pursuant to Section 102(b)(3) of the Ordinance, as long as at the date of grant Perrigo’s shares are listed on any established stock exchange or a national market system, the fair market value of the Shares at the date of grant shall be determined in accordance with the average value of Perrigo’s shares on the thirty (30) trading days preceding the date of grant.

6.

EXERCISE OF OPTIONS OR SARs

Options or SARs shall be exercised by the Participant in accordance with the provisions of the Plan and section 4 above, and with regard to an Approved 102 Award, in accordance with the requirements of Section 102.

7.

VESTING OF AWARDS

Awards shall vest in accordance with the provisions of the Plan and section 4 above, and with regard to an Approved 102 Award, in accordance with the requirements of Section 102.

8.

SETTLEMENT OF 102 AWARDS

Notwithstanding anything to the contrary in the Plan, the settlement of 102 Awards shall be in Shares only.

9.

PERFORMANCE AWARDS

9.1.

Performance Awards granted to Israeli Participants under this Appendix, shall state specifically within the Award Agreement, the maximum amount of Shares to which the Participant may be entitled, subject to achieving the Maximum performance criteria (the “Maximum Amount”). Following the end of each Performance Period, the Committee shall certify the extent to which the performance criteria and other conditions of the Award are achieved, and the number of Shares which shall be delivered to the Participant accordingly.

9.2.

If the number of Shares delivered to the Participant following the achievement of the performance criteria is greater than the Maximum Amount, then such excess amount of Shares shall be treated as a new Award for all intents and purposes, including for the purpose of Sections 4 and 5 of this Appendix.

10.

[RESERVED]

11.

DIVIDEND EQUIVALENTS

As long as 102 Awards are held or supervised by the Trustee, any Dividend Equivalent distributed to the Participant shall be deposited with the Trustee and shall be subject to the terms and conditions of Section 102.

12.

ASSIGNABILITY AND SALE OF AWARDS

All rights of the Participant over the Awards or the Shares issued thereunder are personal, cannot be transferred, assigned, pledged, mortgaged, or given as collateral and no right with respect to them may be given to any third party whatsoever, other than by will or laws of descent and distribution, unless and until actual payment of all taxes required to be paid upon such transfer, assignment, pledge or mortgage has been made to the tax assessor, and the tax assessor confirmed that all taxes required to be paid upon such transfer, assignment, pledge or mortgage have been paid.

13.

INTEGRATION OF SECTION 102 AND TAX ASSESSING OFFICER’S PERMIT

13.1.

With regards to Approved 102 Awards, the provisions of the Plan and/or the Appendix and/or the Award Agreement shall be subject to the provisions of Section 102, the Tax Assessing Officer’s permit, and other instructions set forth by the ITA from time to time.

The said provisions, permit and instructions shall be deemed an integral part of the Plan and of the Appendix and of the Award Agreement.

13.2.

Any provision of Section 102, the said permit, and/or the said instructions which is necessary in order to receive and/or to keep any tax benefit pursuant to Section 102, which is not expressly specified in the Plan or the Appendix or the Award Agreement, shall be considered binding upon the Company and the Participants.

14.

DIVIDEND

Subject to Perrigo’s incorporation documents and the provisions of the Plan and the Award Agreement, with respect to all Restricted Shares and all Shares allocated or issued upon the exercise of Options (but excluding, for avoidance of any doubt, any Restricted Share Units, Performance Shares and unexercised Options) and held by the Participant or by the Trustee as the case may be, the Participant shall be entitled to receive dividends in accordance with the quantity of such shares, and subject to any applicable taxation on distribution of dividends, and when applicable subject to the provisions of Section 102 and the rules, regulations or orders promulgated thereunder.

15.

TAX CONSEQUENCES

15.1.

Any tax consequences arising from the grant of Awards, vesting of Awards or the exercise of any Option, or the disposal of the Shares covered thereby or from any other event or act (of the Company, the Trustee and/or the Participant), hereunder, shall be borne solely by the Participant. The Company and/or the Trustee shall withhold taxes according to the requirements under the applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the Participant shall agree to indemnify the Company and/or the Trustee and hold them harmless against and from any and all liability for all such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Participant.

15.2.

The Company and/or, when applicable, the Trustee shall not be required to release any share certificate to a Participant until all required payments have been fully made.

15.3.

With respect to Unapproved 102 Awards, if the Participant ceases to be employed by the Company, the Participant shall extend to the Company a security or guarantee for the payment of tax due at the time of sale of Shares, all in accordance with the provisions of Section 102 and the rules, regulation or orders promulgated thereunder.

16.

GOVERNING LAW & JURISDICTION

This Appendix shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts made and to be performed therein, without giving effect to the principles of conflict of laws. The competent courts ofTel-Aviv, Israel shall have sole jurisdiction in any matters pertaining to this Appendix.

APPENDIX B

2019 LONG-TERM INCENTIVE PLAN

SUB-PLAN GOVERNING AWARDS TAXABLE IN THE REPUBLIC OF IRELAND

1

GENERAL

1.1

This Appendix B establishes asub-plan (the “IrishSub-Plan”) to the 2019 Long-Term Incentive Plan (the “Plan”) for purposes of employees and directors who are either resident in the Republic of Ireland for tax purposes or who are subject to Irish taxation in relation to their Awards under the Plan and who are granted Restricted Shares that are intended to meet the requirements of a Clog Scheme under Irish tax law.

1.2

All terms that are not otherwise defined herein shall have the same meaning as set forth in the Plan.

2

TERMS OF IRISHSUB-PLAN

2.1

The following definitions shall be inserted into Section 2:

Restricted Share Trust” means the trust established by Perrigo;

Retention Period” in connection with any of a Participant’s Restricted Shares means the period beginning on the date an award of Restricted Shares is made and ending on the 30th day after the fifth anniversary of that date, or such other period (between one year and five years plus 30 days) as the Committee may from time to time determine with respect to an allocation of Restricted Shares provided always that such period shall be set out in the Award Agreement relating to such Restricted Shares;

2.2

The definition of Award Agreement in Section 2 shall be deleted and replaced with the following:

Award Agreement” means a written agreement, contract or other instrument in such form as may from time to time be settled by the Committee which is entered into by Perrigo and a Participant setting out specific contractual terms restricting the Participant’s ability to deal with or realise value in the Restricted Shares during the designated Retention Period and signed by both Perrigo and the Participant;

2.3

The definition of Restricted Share in Section 2 shall be deleted and replaced with the following:

Restricted Share” means an Award of Restricted Shares under this IrishSub-Plan, or (where the context so requires) any other Award under the Plan (including anysub-plan) whereby the Shares subject to that Award to which a Participant becomes entitled at grant, vesting, exercise or settlement (as the case may be) are designated as Restricted Shares for a Retention Period under this IrishSub-Plan within the meaning of Section 128D(3)(a) of the Irish Taxes Consolidation Act 1997, such shares also being forfeitable shares in accordance with Section 8(c) as amended under this IrishSub-Plan.

2.4

Section 5 shall be deleted and replaced with the following:

SECTION 5. ELIGIBILITY. Any Employee or director of the Company shall be eligible to be selected as a Participant under the IrishSub-Plan.

2.5

Section 8 shall be deleted and replaced with the following:

SECTION 8. RESTRICTED SHARES.

(a) GRANT OF AWARDS. Restricted Share Awards may be issued hereunder to Participants, for no cash consideration or for such minimum consideration as may be required by applicable law, either alone or in connection with the vesting, exercise or settlement (as the case may be) of other Awards granted under the Plan. The provisions of Restricted Share Awards need not be the same with respect to each recipient. Restricted Share Awards may be subject to performance criteria in relation to any performance period as the Committee may determine when the Restricted Share Award is granted.

(b) REGISTRATION. Any Restricted Shares issued or awarded hereunder shall be held in the Restricted Share Trust for the duration of the Retention Period and subject to the provisions of the trust deed and Section 128D of the Taxes Consolidation Act 1997.

(c) FORFEITURE. Except as set forth in Section 12 (as amended by the IrishSub-Plan) or otherwise determined by the Committee at the time of grant, upon a Participant’s Termination Date for any reason during the Retention Period, all Restricted Shares still subject to restriction shall be forfeited by the Participant and reacquired by Perrigo whereupon as a result of the forfeiture the Participant will cease to have any beneficial interest in the Restricted Shares so forfeited and will not be entitled to receive, directly or indirectly, consideration in money or money’s worth in respect of the forfeited shares in excess if the consideration given by the Participant for the acquisition of the Restricted Shares. If as a result of any forfeiture of Shares under this Section 8(c) the Participant obtains a refund of any taxes paid in respect of the award of Restricted Shares, the Participant shall be obliged to return such refund to Perrigo immediately upon receipt, unless the Committee determines otherwise in its absolute discretion.

(d) PERFORMANCE CRITERIA. The Committee shall specify in the Award Agreement the extent to which forfeiture applies to a Restricted Share Award at the end of the applicable Retention Period as a result of performance criteria not being achieved, or partially being achieved, in relation to the applicable performance period.

2.6

Section 12(b) shall be deleted and replaced with the following:

(b) OPTIONS AND STOCK APPRECIATION RIGHTS. Unless otherwise determined by the Committee with respect to an Award of Options and Stock Appreciation Rights as provided in the applicable Award Agreement, and subject to the terms of the Plan, the following provisions shall apply to Options and Stock Appreciation Rights on a Participant’s Termination Date.

(1) DEATH, DISABILITY, RETIREMENT. If the Participant’s Termination Date occurs due to the Participant’s death, Disability or Retirement the Participant’s outstanding Options and Stock Appreciation Rights shall immediately vest in full and may thereafter be exercised in whole or in part by the Participant (or the duly appointed fiduciary of the Participant’s estate or Beneficiary in the case of death, or conservator of the Participant’s estate in the case of Disability) at any time prior to the expiration of the respective terms of the Options or Stock Appreciation Rights, as applicable.

(2) INVOLUNTARY TERMINATION FOR ECONOMIC REASONS. If the Participant’s Termination Date occurs by reason of Involuntary Termination for Economic Reasons, the Participant may exercise his or her Options and Stock Appreciation Rights, to the extent vested, at any time prior to the earlier of (i) the date which is 30 days after the date which is 24 months after such Termination Date, or (ii) the expiration of the respective terms

of the Options or Stock Appreciation Rights. Any Options or Stock Appreciation Rights that are not vested at such Termination Date, but are scheduled to vest during the24-month period following the Termination Date, shall continue to vest during such24-month period according to the vesting schedule in effect prior to such Termination Date. Any Options or Stock Appreciation Rights that are not scheduled to vest during such24-month period will be forfeited on the Termination Date. Notwithstanding the foregoing, if the Participant’s Termination Date occurs for a reason that is both described in this Section 12(b)(2) and in Section 13(a), the special vesting rules described in Section 13(a) shall apply in lieu of the vesting rules described in this Section 12(b)(2).

If the Participant dies after the Termination Date while his or her Options or Stock Appreciation Rights remain exercisable under this paragraph (2), the duly appointed fiduciary of the Participant’s estate or his or her Beneficiary may exercise the Options and Stock Appreciation Rights (to the extent that such Options and Stock Appreciation Rights were vested and exercisable prior to death), at any time prior to the later of the date which is (i) 30 days after the date which is 24 months after the Participant’s Termination Date, or (ii) 12 months after the date of death, but in no event later than the expiration of the respective terms of the Options and Stock Appreciation Rights.

(3) TERMINATION FOR CAUSE. If the Participant’s Termination Date is for Cause, at the time such notice of termination is given by the Company the Participant’s right to exercise his or her Options and Stock Appreciation Rights shall terminate. If within 60 days of a Participant’s Termination Date the Company discovers circumstances which would have permitted it to terminate the Participant’s employment or service for Cause, such Termination Date shall be deemed to have occurred for reasons of Cause. Any Shares, cash or other property paid or delivered to the Participant under the Plan within 60 days of such Termination Date shall be forfeited and the Participant shall be required to repay such amount to the Company.

(4) OTHER TERMINATION OF EMPLOYMENT OR SERVICE. If the Participant’s Termination Date occurs for reasons other than as described in this Section 12(b), the Participant shall have the right to exercise his or her Options and Stock Appreciation Rights at any time prior to the earlier of (i) the date which is three months after such Termination Date, or (ii) the expiration date of the respective terms of the Options or Stock Appreciation Rights, as applicable, but only to the extent such Option or Stock Appreciation Right, as applicable, was vested prior to such Termination Date. Any Options or Stock Appreciation Rights which are not vested at such Termination Date shall be forfeited on the Termination Date.

If the Participant dies after the Termination Date while his or her Options or Stock Appreciation Rights remain exercisable under this paragraph (4), the duly appointed fiduciary of the Participant’s estate or his or her Beneficiary may exercise the Options or Stock Appreciation Rights (to the extent that such Options or Stock Appreciation Rights were vested and exercisable prior to death), at any time prior to the earlier of (i) 12 months after the date of death, or (ii) the expiration of the respective terms of the Options or Stock Appreciation Rights, as applicable.

2.7

A new Section 12(e) shall be inserted as follows:

(e) RESTRICTED SHARES. Unless otherwise determined by the Committee with respect to an Award of service-based vesting Restricted Shares as provided in the applicable Award

Agreement, and subject to the terms of the Plan, the following provisions shall apply to service-based vesting Restricted Shares on a Participant’s Termination Date.

(1) DEATH. If the Participant’s Termination Date occurs due to the Participant’s death prior to the end of the Retention Period applicable to his Restricted Shares, the Retention Period with respect to those Restricted Shares shall lapse.

(2) DISABILITY; RETIREMENT. If the Participant’s Termination Date occurs by reason of Disability or Retirement the Participant may continue to hold those Restricted Shares for the remainder of the Retention Period.

(3) INVOLUNTARY TERMINATION FOR ECONOMIC REASONS. If the Participant’s Termination Date occurs by reason of Involuntary Termination for Economic Reasons within 24 months of the end of the Retention Period applicable to his Restricted Shares, the Participant may continue to hold those Restricted Shares for the remainder of the Retention Period. If the Participant’s Termination Date occurs by reason of Involuntary Termination for Economic Reasons more than 24 months before the end of the Retention Period applicable to his Restricted Shares those Restricted Shares will be forfeited on the Termination Date. Notwithstanding the foregoing, if the Participant’s Termination Date occurs for a reason that is both described in this Section 12(e)(3) and in Section 13(a), the special vesting rules described in Section 13(a) shall apply in lieu of the vesting rules described in this Section 12(e)(3).

(4) TERMINATION FOR CAUSE. If the Participant’s Termination Date is for Cause, at the time such notice of termination is given by the Company the Participant’s Restricted Shares will be forfeited. If within 60 days of a Participant’s Termination Date the Company discovers circumstances which would have permitted it to terminate the Participant’s employment or service for Cause, such Termination Date shall be deemed to have occurred for reasons of Cause. Any Shares, cash or other property paid or delivered to the Participant under the Plan within 60 days of such Termination Date shall be forfeited and the Participant shall be required to repay such amount to the Company.

(5) OTHER TERMINATION OF EMPLOYMENT OR SERVICE. If the Participant’s Termination Date occurs for reasons other than as described in this Section 12(d), the Participant’s Restricted Shares will be forfeited on the Termination Date unless the Committee determines that the Participant may continue to hold his Restricted Shares for the remainder of the Retention Period applicable to those Restricted Shares.

APPENDIX C

2019 LONG-TERM INCENTIVE PLAN

CONSULTANT ANDNON-EMPLOYEE DIRECTORSUB-PLAN

1

GENERAL

1.1

This Appendix C establishes asub-plan (the “Consultant and NEDSub-Plan”) to the 2019 Long-Term Incentive Plan (the “Plan”) for awards granted tonon-employee directors and consultants. In order to reflect that Awards granted under the Plan are granted under an “employees’ share scheme” as defined under Irish tax law, (a) references to directors and consultants have been removed from the Plan, and (b) this Appendix C establishes asub-plan for the purpose of granting Awards to Consultants andNon-Employee Directors (as defined below) of Perrigo Company plc and its Affiliates.

1.2

All terms that are not otherwise defined herein shall have the same meaning as set forth in the Plan.

2

Terms of Consultant and NEDSub-Plan

2.1

This Consultant and NEDSub-Plan is hereby established as asub-plan to the Plan. The provisions of the Plan shall apply in their entirety to awards made under this Consultant and NEDSub-Plan save and except only as set out in Rules 2.2 to 2.6 below.

2.2

Definitions

2.2.1

The following definitions shall be inserted for the purposes of the Consultant and NEDSub-Plan:

Consultant” means a consultant, adviser or other person retained by the Company to render significant services to the Company.

Non-Employee Director” means a director of the Company who is not an active employee of the Company.

2.2.2

The following terms as defined in the Plan shall be deleted and replaced with the following for the purposes of the Consultant and NEDSub-Plan:

Participant” means any person who is a Consultant orNon-Employee Director.

Retirement”means a Participant’s Termination Date which occurs (i) pursuant to a voluntary early retirement program approved by the Board or the Committee, (ii) after attaining age 65, or (iii) after attaining age 60 with ten or more years of service with the Company. For this purpose, a year of service shall be a completed12-month period of service beginning on the first day of the Participant’s service with the Company as aNon-Employee Director or Consultant, or an anniversary of such date.

Termination Date” means the date that a Participant both ceases to be aNon-Employee Director or Consultant and ceases to perform any material services for the Company, including, but not limited to, advisory or consulting services or services as a member of the Board.

2.3

Section 3(a) of the Plan is amended by the addition of the following sentence at the end of that clause:

Decisions of the Committee in respect of the Consultant and NEDSub-Plan shall be final, conclusive and binding upon all persons including the Company, any Participant, and shareholder and any Consultant andNon-Employee Director.

2.4

Section 4(c) of the Plan is amended so that the first sentence reads as follows:

No individual Consultant may be granted Awards in any one calendar year with respect to more than 400,000 Shares, and no individualNon-Employee Director may be granted Awards in any one calendar year with respect to more than 25,000 Shares.

2.5

Section 5 of the Plan is amended by replacing it with the following:

SECTION 5. ELIGIBILITY. AnyNon-Employee Director or Consultant shall be eligible to be selected as a Participant. Awards may be grantedNon-Employee Directors or Consultants of the Company or Affiliates who are foreign nationals or who are resident or taxable on the Award outside the United States, or both, on such terms and conditions different from those specified in the Plan as may, in the judgment of the Committee, be necessary or desirable in order to recognize differences in local law or tax policy. The Committee also may impose conditions on the exercise or vesting of Awards in order to minimize the Company’s obligation with respect to tax equalization for Participants on assignments outside their home country.

2.6

Section 6(d) of the Plan is amended by the addition of the following sentence at the end of that clause:

Payment of the option price of any Option granted to a Consultant orNon-Employee Director shall be settled only in accordance with a method that is in compliance with applicable Irish company law.

2.7

Section 16(b) of the Plan is amended by deleting the words “Employee or” and “Employees or” from the first sentence.

2.8

Section 16(g) of the Plan is amended by the addition of the following sentence at the end of that clause:

Withholding taxes applicable to any Awards to a Consultant orNon-Employee Director shall be settled only in accordance with a method that is in compliance with applicable Irish company law.

LOGO


LOGO

PROXY PERRIGO COMPANY PLC THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS ON APRIL 26, 2019. The undersigned, revoking any proxy or voting instructions previously given, appoints Ronald L. WinowieckiRaymond P. Silcock and Todd W. Kingma (the "Named Proxies"), and each of them, as attorneys and proxies with full power of substitution and authorizes them to represent and vote as indicated on the reverse side of this card, with all powers which the undersigned would possess if personally present, all the ordinary shares of Perrigo Company plc beneficially held of record by the undersigned on February 26, 2019March 15, 2021, at the Annual General Meeting of Shareholders to be held virtually at 8:30 a.m. U.S. Eastern Time (1:30 p.m. Irish Time) on April 26, 2019May 12, 2021, via live webcast (with details available at www.proxydocs.com/PRGO) or any adjournment thereof. This Proxy, when properly executed, will be voted in the manner directed herein by the undersigned shareholder. If no direction is made, this proxy will be voted “FOR”"FOR" each director nominee named in Proposal 1, and “FOR”"FOR" Proposals 2 through 7. IMPORTANT -5. If you vote by Internet or telephone, please do not send your proxy by mail. You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE) but you need not mark any box if you wish to vote in accordance with the Board of Directors' recommendation. The Named Proxies cannot vote your shares unless you sign (on the reverse side) and return this card. A proxy submitted by a shareholder of record by mail must be received by May 11, 2021 at 11:59 p.m. U.S. Eastern Time. PLEASE BE SURE TO SIGN AND DATE THIS PROXY MUST BE SIGNEDCARD AND DATEDMARK ON THE REVERSE SIDE PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED. Please sign and date this proxy card and return it promptly, together with an Ownership Certificate from the TASE Clearing House member through which your shares are registered, to Copyright (C) 2021 Mediant Communications Inc. All Rights Reserved


LOGO

Perrigo Company plc P.O. Box 7100, Tel Aviv, Israel 6107002 soAnnual General Meeting of Shareholders Please make your shares may be represented at the Meeting. The proxy card and Ownership Certificate must be received no later than April 22, 2019 to be validly included in the tally of shares voted at the Meeting. The Proxy Materials are available for review at: http://www.viewproxy.com/perrigo/2019


LOGO

marks like this: X Use dark black pencil or pen only THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR PROPOSAL(S) 1, 2, 3, 4, 5. BOARD OF DIRECTORS PROPOSAL YOUR VOTE RECOMMENDS 1. Elect Directors to hold office until the 20202021 Annual General Meeting of Shareholders: FOR AGAINST ABSTAIN 011.01 Bradley A. Alford 02FOR #P2# #P2# #P2# 1.02 Orlando D. Ashford FOR #P3# #P3# #P3# 1.03 Rolf A. Classon 03FOR #P4# #P4# #P4# 1.04 Katherine C. Doyle FOR #P5# #P5# #P5# 1.05 Adriana Karaboutis FOR #P6# #P6# #P6# 1.06 Murray S. Kessler FOR #P7# #P7# #P7# 1.07 Jeffrey B. Kindler FOR #P8# #P8# #P8# 1.08 Erica L. Mann FOR #P9# #P9# #P9# 1.09 Donal O'Connor FOR #P10# #P10# #P10# 1.10 Geoffrey M. Parker FOR #P11# #P11# #P11# 1.11 Theodore R. Samuels FOR #P12# #P12# #P12# FOR AGAINST ABSTAIN 2. Ratify the appointment of Ernst & Young FOR AGAINST ABSTAIN LLP as our independent auditor for the period ending FOR December 31, 2019,2021 and authorize the Board of Directors, acting through the Audit Committee, to #P13# #P13# #P13# fix the remuneration of the auditor: 04 Murray S. Kessler 05 Jeffrey B. Kindler 06 Erica L. Mann 07 Donal O’Connor 08 Geoffrey M. Parker 09 Theodore R. Samuels 10 Jeffrey C. Smith (Except nominee(s) written above.)3. Advisory vote on the Company’sCompany's executive compensation: Renew and restate the Company’s Long-Term Incentive Plan: Approve the creation of distributable reserves by reducing some or all of the Company’s share premium:FOR #P14# #P14# #P14# 4. Renew the Board’sBoard's authority to issue shares under Irish law: FOR #P15# #P15# #P15# 5. Renew the Board’sBoard's authority to opt-out of statutory pre-emption rights under Irish law Please date and sign below. Dated:, 2019. Signature Name (printed) Title Note:law: FOR #P16# #P16# #P16# In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting. You must pre-register to attend the meeting online and/or participate at www.proxydocs.com/PRGO by following the instructions in the Proxy Statement Authorized Signatures - Must be completed for your instructions to be executed. Please sign exactly as nameyour name(s) appears hereon. When shares areon your account. If held byin joint owners, bothtenancy, all persons should sign. WhenTrustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing as attorney, executor, administrator, trustee, guardian, or corporate officer, please give title as such. PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED. PROXY VOTING INSTRUCTIONS Voting cut-off is April 22, 2019 at 11:59 PM Eastern Daylight Time.the Proxy/Vote Form. Signature (and Title if applicable) Date Signature (if held jointly) Date


LOGO

LOGO

ROXY PERRIGO COMPANY PLCTHIS PROXYPerrigo(R) P.O. BOX 8016, CARY, NC 27512-9903 YOUR VOTE IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS FOR THE ANNUALGENERAL MEETING OF SHAREHOLDERS ON APRIL 26, 2019.IMPORTANT! PLEASE VOTE BY: MAIL " Mark, sign and date your Proxy Card. " Fold and return your Proxy Card Form in the postage-paid envelope provided. Approved by Peggy Milbocker 16 March 2021 Perrigo Company plc Annual General Meeting of Stockholders For Stockholders as of March 15, 2021 TIME: Wednesday, May 12, 2021 08:30 AM, Eastern Time PLACE: Annual General Meeting to be held live via the Internet - please visit www.proxydocs.com/PRGO for more details. CONTROL NUMBER <- Please fold here - Do not separate -> This proxy is being solicited on behalf of the Board of Directors The undersigned, revoking any proxy or voting instructions previously given, appoints Ronald L. WinowieckiRaymond P. Silcock and Todd W. Kingma, and each of them, as attorneys and proxies with full power of substitution and authorizes them to represent and vote as indicated on the reverse side of this card, with all powers which the undersigned would possess if personally present, all the ordinary shares of Perrigo Company plc held of record by the undersigned on February 26, 2019March 2021, at 15, www. 2021, proxydocs. at the Annual com/PRGO General or Meeting any adjournment of Shareholders thereof. to be held virtually at 8:30 a.m. U.S. Eastern Time (1:30 p.m. Irish Time) on May 12, be This voted Proxy, "FOR" when each properly director executed, nominee will named be voted in Proposal in the manner 1, and directed "FOR" Proposals herein by 2 the through undersigned 5. If you shareholder. vote by Internet If no or direction telephone, is made, please this do proxy not send will your proxy by mail. which Please your sign shares and date are this registered, proxy card to Perrigo and return Company it promptly, plc, P. together O. Box 7100, with an Tel Ownership Aviv, Israel Certificate 6107002 from so your the TASE shares Clearing may be House represented member at the through Meeting. The proxy card and Ownership Certificate must be received no later than May 9, 2021 at 11:59 p.m. Israel Time, to be validly included in the tally of shares voted at the Meeting. PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE Copyright (C) 2021 Mediant Communications Inc. All Rights Reserved


LOGO

Perrigo Company plc Annual General Meeting of Shareholders to be held on April 26, 2019Stockholders Please make your marks like this: X Use dark black pencil or any adjournment thereof. This Proxy, when properly executed, will be voted in the manner directed herein by the undersigned shareholder. If no direction is made, this proxy will be voted “FOR” each director nominee named in Proposalpen only THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR PROPOSAL(S) 1, and “FOR” Proposals 2, through 7 If you vote by Internet or telephone, please do not send your proxy by mail. IMPORTANT - THIS PROXY MUST BE SIGNED AND DATED ON THE REVERSE SIDE. PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED. Important Notice Regarding the Availability of Proxy Materials for the Annual General Meeting of Shareholders to be held April 26, 2019. The Proxy Materials are available for review at: http://www.viewproxy.com/perrigo/2019


LOGO

3, 4, 5. BOARD OF DIRECTORS PROPOSAL YOUR VOTE RECOMMENDS 1. Elect Directors to hold office until the 20192022 Annual General Meeting of Shareholders: FOR AGAINST ABSTAIN 011.01 Bradley A. Alford 02FOR #P2# #P2# #P2# 1.02 Orlando D. Ashford FOR #P3# #P3# #P3# 1.03 Rolf A. Classon 03 Gary M. Cohen 04FOR #P4# #P4# #P4# 1.04 Katherine C. Doyle FOR #P5# #P5# #P5# 1.05 Adriana Karaboutis 05FOR #P6# #P6# #P6# 1.06 Murray S. Kessler FOR #P7# #P7# #P7# 1.07 Jeffrey B. Kindler 06FOR #P8# #P8# #P8# 1.08 Erica L. Mann FOR #P9# #P9# #P9# 1.09 Donal O’Connor 07O'Connor FOR #P10# #P10# #P10# 1.10 Geoffrey M. Parker 08 Uwe F. Roehrhoff 09FOR #P11# #P11# #P11# 1.11 Theodore R. Samuels 10 Jeffrey C. Smith (Except nominee(s) written above.)FOR #P12# #P12# #P12# FOR AGAINST ABSTAIN 2. Ratify the appointment of Ernst & Young FOR AGAINST ABSTAIN LLP as our independent auditor for the period ending FOR December 31, 2018,2021 and authorize the Board of Directors, acting through the Audit Committee, to #P13# #P13# #P13# fix the remuneration of the auditor: 3. Advisory vote on the Company’sCompany's executive compensation: FOR #P14# #P14# #P14# 4. Renew the Board’sBoard's authority to issue shares under Irish law: FOR #P15# #P15# #P15# 5. Renew the Board’sBoard's authority toopt-out of statutory pre-emption rights under Irish law: 6.FOR #P16# #P16# #P16# In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting. This sectionYou must pre-register to attend the meeting online please visit www.proxydocs.com/PRGO for more details Authorized Signatures - Must be completed for your voteinstructions to be counted. Please date and sign below. Dated: , 2018. Signature Name (printed) Title Note:executed. Please sign exactly as nameyour name(s) appears hereon. When shares areon your account. If held byin joint owners, bothtenancy, all persons should sign. WhenTrustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing as attorney, executor, administrator, trustee, guardian, or corporate officer, please give title as such. CONTROL NUMBER PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED. CONTROL NUMBER PROXY VOTING INSTRUCTIONS Please have your 11 digit control number ready when voting by Internet or telephone A proxy submitted by a shareholder of record by mail must be received by May 3, 2018 at 10:00 AM Irish Standard Time. For participants in the Company’s 401K Plan, Internet and telephone voting is available through April 30, 2018 at 11:59 PM Eastern Daylight Time. For all other holders, Internet and telephone voting is available through May 2, 2018 at 11:59 PM Eastern Daylight Time. INTERNET Proxy/Vote Your Proxy on the Internet: Go to www.AALvote.com/PRGO Have your proxy card available when you access the above -website. Follow the prompts to vote your shares. TELEPHONE MAIL Vote Your Proxy by Phone: Vote Your Proxy by Mail: Call 1 (866)804-9616 Use any touch-tone telephone to Mark, sign, and date your proxy vote your proxy. Have your proxy card, then detach it, and return card available when you call. it in the postage-paid envelope Follow the voting instructions to provided. vote your shares.Form. Signature (and Title if applicable) Date Signature (if held jointly) Date